Compounds and pharmaceutical compositions thereof for the treatment of diseases
Novel ATPase inhibitors targeting SMARCA2 and/or SMARCA4 are developed to treat proliferative diseases by inhibiting these proteins, addressing the need for therapeutic compounds in cancers with mutations in SWI/SNF complexes, thereby reducing cell proliferation and treating conditions like non-small cell lung carcinoma, Burkitt lymphoma, pancreatic adenocarcinoma, ovarian clear cell carcinoma, and melanoma.
Patent Information
- Application Number
- PCT/EP2026/063408
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
There is a need for therapeutic compounds that can inhibit SMARCA2 and/or SMARCA4 to treat or prevent proliferative diseases such as cancer, as these proteins are frequently mutated in various cancers and play a critical role in chromatin remodeling and cell proliferation.
Development of novel compounds, particularly ATPase inhibitors targeting SMARCA2 and/or SMARCA4, which are used in pharmaceutical compositions to inhibit these proteins and treat proliferative diseases.
The compounds effectively inhibit SMARCA2 and/or SMARCA4, offering potential therapeutic benefits for SMARCA4-deleted or deficient cancers by targeting chromatin remodeling, thereby reducing cell proliferation and potentially treating conditions like non-small cell lung carcinoma, Burkitt lymphoma, pancreatic adenocarcinoma, ovarian clear cell carcinoma, and melanoma.
Smart Images

Figure EP2026063408_12112026_PF_FP_ABST
Abstract
Description
COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASESFIELD OF THE INVENTION
[0001] The present invention relates to compounds, methods for the production of the compounds of the invention, pharmaceutical compositions comprising the compounds of the invention, uses and methods for the prophylaxis and / or treatment of proliferative diseases by administering the compounds of the invention. In particular, the compounds of the invention may inhibit SMARCA2 and / or SMARCA4.BACKGROUND OF THE INVENTION
[0002] The mammalian SWItch / Sucrose Non-Fermentable (SWI / SNF) complexes are large, ATP dependent chromatin remodelers with vital roles in various cellular processes, including transcription, DNA repair, and replication, achieved by regulating DNA accessibility.
[0003] Approximately 20% of all human cancers exhibit mutations in the genes encoding the nearly 20 canonical SWI / SNF subunits (Kadoch et al. 2013). These mutations are most frequently found in rhabdoid tumors, female-specific cancers (such as ovarian, uterine, cervical, and endometrial cancers), lung adenocarcinoma, gastric adenocarcinoma, melanoma, esophageal cancer, and renal clear cell carcinoma.
[0004] Within these SWI / SNF complexes, SWI / SNF-related, Matrix-associated, Actin-dependent Regulator of Chromatin, subfamily A member 2 (SMARCA2, Brahma, or BRM) and SWI / SNF-related, Matrix-associated, Actin-dependent Regulator of Chromatin, subfamily A, member 4 (SMARCA4 or BRG1) stand out as subunits that contain catalytic ATPase domains, essential for the SWI / SNF complex function. They perturb histone-DNA contacts, thereby providing access points fortranscription factors and DNA elements that regulate gene activation and repression.
[0005] SMARCA2 and SMARCA4 share a high degree of similarity, up to 75%, and both contain a DNA-stimulated, conserved ATPase domain driving chromatin-remodeling activity. In primary tumors, SMARCA4 is frequently mutated, particularly in lung, melanoma, liver, and pancreatic cancers. In SMARCA4-deleted cancer cells, SMARCA2's ATPase activity becomes critical for chromatin remodeling, which is essential for functions like cell proliferation, survival, and growth. Consequently, targeting SMARCA2 may hold promise as a therapeutic approach for SMARCA4-deleted or deficient cancers, e.g. non-small cell lung carcinoma, Burkitt lymphoma, childhood medulloblastoma, pancreatic adenocarcinoma, ovarian clear cell carcinoma, and melanoma (Wilson et al. 2014). Conversely, inhibition of SMARCA4 represents a therapeutic strategy for the treatment of SMARCA2-deficient cancers (Ehrenhbfer-Wblfer et al. 2019).
[0006] Hence, there is a need for therapeutic compounds that can inhibit SMARCA2 and / or SMARCA4 for the prophylaxis and / or treatment of the above mentioned diseases.SUMMARY OF THE INVENTION
[0007] The present invention is based on the identification of novel compounds, and their use in the prophylaxis and / or treatment of proliferative diseases. In particular, the compounds of the invention may be ATPase inhibitors, and more particularly SMARCA2 and / or SMARCA4 inhibitors. The present invention also provides methods for the production of these compounds, pharmaceutical compositions comprising these compounds and methods for the prophylaxis and / or treatment of proliferative diseases by administering the compounds of the invention.
[0008] Accordingly, in a first aspect of the invention, the compounds of the invention are provided having a Formula I:O R4a p4b Cy2Iwherein,A is 6-10 membered monocyclic or bicyclic aryl, or 5-10 membered monocyclic or bicyclic heteroaryl comprising one, two or three heteroatoms independently selected from N, O, and S;R* NO O OA' Y^VY is independently selected from' ' , ' ' andRyand Rzare each independently hydrogen or C1-3 alkyl;X is N or CH;R1is C1-6 alkyl, C1-3 alkoxy(Ci-3)alkyl, 3-6 membered monocyclic cycloalkyl, 4-6 membered monocyclic heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S, -NH2, -NH(Ci.3 alkyl), -N(CI-3alkyl)2, -NHC(=O)(Ci.3alkyl), -N(CI-3alkyl)C(=O)(Ci-3alkyl), or hydroxy(Ci.4)alkyl, wherein said cycloalkyl, heterocycloalkyl, alkyl and alkoxy groups are optionally substituted with one or more halogen, C1-6 alkoxy, -NH2, -NH(CI-3 alkyl), -N(CI-3 alkyl)2;n is 0, 1, or 2;each R2is independently selected from halogen and C1-6 alkyl, which alkyl is optionally substituted with halo or C1.4 alkoxy;or R1and one R2together with the atoms onto which they are attached form a fused 5-8 membered monocyclic cycloalkyl, or a fused 5-8 membered monocyclic heterocycloalkyl comprising Y in formula I and zero, one, or two additional heteroatoms independently selected from N, O, and S, wherein the cycloalkyl or heterocycloalkyl is optionally substituted with one or more independently selected halogens (preferably fluoro) or C1-4 alkyl;R3is hydrogen or C1-6 alkyl;R4aand R4bare each independently hydrogen or Ci-6 alkyl optionally substituted with one or more independently selected halo or C1-4 alkoxy;or R4aand R4b, together with the carbon to which they are attached, form a C3-6 cycloalkyl or 4-6 membered heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S, which cycloalkyl or heterocycloalkyl is optionally substituted with one or more halo or C1-4 alkoxy;Li is a bond or C1-4 alkyl;B is phenyl or 5-6 membered monocyclic heteroaryl comprising one, two, three or four heteroatoms independently selected from N, O, and S;Cyi is phenyl or 5-6 membered monocyclic heteroaryl comprising one, two, three or four heteroatoms independently selected from N, O, and S, each of which is optionally substituted with one or more independently selected halo,Cy2 is a 5-6-membered monocyclic heteroaryl comprising one, two, three or four heteroatoms independently selected from N, O, and S, which heteroaryl is optionally substituted with one or more independently selected -L2-R5groups;L2 is a bond or Ci-e alkyl;Each R5is independently selected from- -OH,- -CN,- -P(O)(Ci.4alkyl)2,- halo,- -S(=O)2-Ci.4 alkyl,- -NR8aR8b,- -CONR9aR9b,- -CO2R9a,- C1-4 alkyl optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9aor Ci -4 alkoxy,- C1-4 alkoxy optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9a, C1-4 alkoxy, or C3-6 cycloalkyl, and- C3-6 cycloalkyl, which cycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1.4 alkyl, C1.4 alkoxy, , -S(=O)2Ci.4alkyl, -C(=O)Ci.4alkyl, or -CO2R9a,- 4-8 membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, C1-4 alkoxy, -S(=O)2Ci-4 alkyl, -C(=O)Ci-4 alkyl, or -CO2R9a;R6is hydrogen, halo, or C1-6 alkyl;The subscript m is 0, 1 or 2;Each R7is independently selected from- -OH,- -CN,- -P(O)(Ci.4alkyl)2,- halo,- -S(=O)2-Ci.4 alkyl,- -NR8aR8b,- -CONR9aR9b,- -CO2R9a,- C1-4 alkyl optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9aor Ci -4 alkoxy,- C1-4 alkoxy optionally substituted with one or more independently selected halo, -OH, -CN, or C1-4 alkoxy,- C3-6 cycloalkyl, which cycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy, and- 4-8 membered monocyclic or spirocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy;each R8ais independently hydrogen or C1-4 alkyl;each R8bis independently hydrogen, C1-4 alkyl or -C(O)Ci.2alkyl;each R9ais independently selected from hydrogen and C1-4 alkyl;R9bis hydrogen, C1-4 alkyl or C1-4 alkoxy, orR9aand R9btogether with the atoms onto which they are attached form a 4-7 membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, whichheterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, Ci -4 alkyl.
[0009] In a particular aspect, the compounds of the invention are provided for use in the prophylaxis and / or treatment of proliferative diseases.
[0010] Certain compounds according to the invention may also exhibit one or more benefits including, inter alia, advantageous levels of biological activity which may be useful in the prophylaxis and / or treatment of one or more disease, improved safety characteristics (e.g. relating to hERG inhibition, drugdrug interaction (DDI) or CYP-interaction characteristics, etc), improved selectivity for one or more disease-associated biological target (e.g. reduced off-target effects, etc), improved pharmacokinetic properties (e.g. relating to dosing, solubility, absorption, etc), improved pharmacodynamic properties (e.g. relating to permeability, efflux, etc) or superior properties for use as pharmaceutical active ingredients alone or in pharmaceutical compositions (e.g. stability), or advantageous physico-chemical properties useful in the manufacturability of such aforementioned pharmaceutical compositions.
[0011] In a further aspect, the present invention provides pharmaceutical compositions comprising a compound of the invention, and a pharmaceutical carrier, excipient or diluent. In a particular aspect, the pharmaceutical composition may additionally comprise further therapeutically active ingredients suitable for use in combination with the compounds of the invention. In a more particular aspect, the further therapeutically active ingredient is an agent for the treatment of proliferative diseases.
[0012] Moreover, the compounds of the invention, useful in the pharmaceutical compositions and treatment methods disclosed herein, are pharmaceutically acceptable as prepared and used.
[0013] In a further aspect of the invention, this invention provides a method of treating a mammal, in particular humans, afflicted with a condition selected from among those listed herein, and particularly proliferative diseases, which method comprises administering an effective amount of the pharmaceutical composition or compounds of the invention as described herein.
[0014] The present invention also provides pharmaceutical compositions comprising a compound of the invention, and a suitable pharmaceutical carrier, excipient or diluent for use in medicine. In a particular aspect, the pharmaceutical composition is for use in the prophylaxis and / or treatment of proliferative diseases.
[0015] In additional aspects, this invention provides methods for synthesizing the compounds of the invention, with representative synthetic protocols and pathways disclosed later on herein.
[0016] Certain compounds according to the invention may exhibit one or more benefits including, inter alia, advantageous levels of biological activity which may be useful in the prophylaxis and / or treatment of one or more disease, improved safety characteristics (e.g. relating to hERG inhibition, drug-drug interaction (DDI) or CYP-interaction characteristics, etc), improved selectivity for one or more disease-associated biological target (e.g. reduced off-target effects, etc), improved pharmacokinetic properties (e.g. relating to dosing, solubility, absorption, etc), improved pharmacodynamic properties (e.g. relating to permeability, efflux, etc) or superior properties for use as pharmaceutical active ingredients alone or in pharmaceuticalcompositions (e.g. stability), or advantageous physico-chemical properties useful in the manufacturability of such aforementioned pharmaceutical compositions.
[0017] Other objects and advantages will become apparent to those skilled in the art from a consideration of the ensuing detailed description.
[0018] It will be appreciated that compounds of the invention may be metabolized to yield biologically active metabolites.DETAILED DESCRIPTION OF THE INVENTIONDefinitions
[0019] The following terms are intended to have the meanings presented therewith below and are useful in understanding the description and intended scope of the present invention.
[0020] When describing the invention, which may include compounds, pharmaceutical compositions containing such compounds and methods of using such compounds and compositions, the following terms, if present, have the following meanings unless otherwise indicated. It should also be understood that when described herein any of the moieties defined forth below may be substituted with a variety of substituents, and that the respective definitions are intended to include such substituted moieties within their scope as set out below. Unless otherwise stated, the term “substituted” is to be defined as set out below. It should be further understood that the terms “groups” and “radicals” can be considered interchangeable when used herein.
[0021] The articles ‘a’ and ‘an’ may be used herein to refer to one or to more than one (i.e. at least one) of the grammatical objects of the article. By way of example ‘an analogue’ means one analogue or more than one analogue.
[0022] A dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -CONH2 is attached through the carbon atom. A dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning.
[0023] A wavy line drawn through a line in a structure indicates a point of attachment of a group. Similarly, a squiggly line on a chemical group as shown, for example, indicates a point of attachment, i.e., it shows the broken bond by which the group is connected to another described group.
[0024] The prefix “Cu-v” indicates that the following group has from u to v carbon atoms. For example, “C1-8 alkyl” indicates that the alkyl group has from 1 to 8 carbon atoms.
[0025] Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. In certain embodiments, the term “about” includes the indicated amount ± 10%. In other embodiments, the term “about” includes the indicated amount ± 5%. In certain other embodiments, the term “about” includes the indicated amount ± 1%. Also, to the term “about X” includes description of “X”. Also, the singular forms "a" and "the" include plural references unless thecontext clearly dictates otherwise. Thus, e.g., reference to "the compound" includes a plurality of such compounds and reference to "the assay" includes reference to one or more assays and equivalents thereof known to those skilled in the art.
[0026] Unless indicated explicitly otherwise, where combinations of groups are referred to herein as one moiety, e.g. arylalkyl, the last mentioned group contains the atom by which the moiety is attached to the rest of the molecule.
[0027] ‘Alkyl’ means straight or branched aliphatic hydrocarbon having the specified number of carbon atoms. Particular alkyl groups have 1 to 6 carbon atoms or 1 to 4 carbon atoms. Branched means that one or more alkyl groups such as methyl, ethyl or propyl is attached to a linear alkyl chain. Particular alkyl groups are methyl (-CH3), ethyl (-CH2-CH3), w-propyl (-CH2-CH2-CH3), isopropyl (-CH(CH3)2), w-butyl (-CH2-CH2-CH2-CH3), tert-butyl (-C(CH3)3), sec-butyl (-CH(CH3)-CH2CH3), isobutyl (-CH2-CH(CH3)2), w-pcntyl (-CH2-CH2-CH2-CH2-CH3), w-hcx l (-CH2-CH2-CH2-CH2-CH2-CH3), and 1,2-dimethylbutyl (-CH(CH3)-CH(CH3)-CH2-CH3). Particular alkyl groups have between 1 and 4 carbon atoms.
[0028] ‘hydroxyalkyl’ refers to an alkyl group with the number of carbon atoms specified, substituted with an -OH group. For example, hydroxy(Ci-4)alkyl refers to carbon chain straight or branched wherein one carbon atom is substituted with an -OH group. Examples of such hydroxyalkyl include without limitation -CH2-OH, -CH(CH3)-OH, -CH2-CH2CH2-OH, or -C(CH3)2-OH.
[0029] ‘Alkylene’ refers to divalent alkene radical groups having the number of carbon atoms specified, in particular having 1 to 6 carbon atoms and more particularly 1 to 4 carbon atoms which can be straight-chained or branched. This term is exemplified by groups such as methylene (-CH2-), ethylene (-CH2-CH2-), or -CH(CH3)- and the like.
[0030] ‘Alkoxy’ refers to the group O-alkyl, where the alkyl group has the number of carbon atoms specified. In particular the term refers to the group -O-Ci e alkyl. Particular alkoxy groups are methoxy, ethoxy, w-propoxy. isopropoxy, w-butoxy. tert-butoxy, scc-butoxy. w-pcntoxy. w-hcxoxy. and 1,2-dimethylbutoxy. Particular alkoxy groups are lower alkoxy, i.e. with between 1 and 6 carbon atoms. Further particular alkoxy groups have between 1 and 4 carbon atoms.
[0031] ‘ Amino’ refers to the radical -NH2.
[0032] ‘Aryl’ refers to a monovalent aromatic hydrocarbon group derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. In particular aryl refers to an aromatic ring structure, monocyclic or fused polycyclic, with the number of ring atoms specified. Specifically, the term includes groups that include from 6 to 10 ring members. Particular aryl groups include phenyl, and naphthyl.
[0033] “Aryl” also covers partially aromatic bi- or polycyclic ring systems wherein at least one ring is an aromatic ring and one or more of the other ring(s) is a non-aromatic, saturated or partially saturated ring. Partially aromatic aryl bicyclic ring systems can be vicinally fused, i.e., where the rings are linked to each other through two adjacent carbon atoms. Examples of partially aromatic heteroaryl groups include for example:
[0034] ‘Cycloalkyl’ refers to a non-aromatic hydrocarbyl ring structure, monocyclic, fused polycyclic, bridged polycyclic, or spirocyclic, with the number of ring atoms specified. A cycloalkyl may have from 3 to 12 carbon atoms, in particular from 3 to 10, and more particularly from 3 to 7 carbon atoms. Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
[0035] ‘Cyano’ refers to the radical -CN.
[0036] ‘Halo’ or ‘halogen’ refers to fluoro (F), chloro (Cl), bromo (Br) and iodo (I). Particular halo groups are either fluoro or chloro.
[0037] As used herein, term ‘polycyclic’ refers to chemical groups featuring several closed rings of atoms. In particular it refers to groups featuring two, three or four rings of atoms, more particularly two or three rings of atoms, most particularly two rings of atoms.
[0038] ‘Hetero’ when used to describe a compound or a group present on a compound means that one or more carbon atoms in the compound or group have been replaced by a nitrogen, oxygen, or sulfur heteroatom. Hetero may be applied to any of the hydrocarbyl groups described previously such as alkyl, e.g. heteroalkyl, cycloalkyl, e.g. heterocycloalkyl, aryl, e.g. heteroaryl, and the like having from 1 to 4, and particularly from 1 to 3 heteroatoms, more typically 1 or 2 heteroatoms, for example a single heteroatom.
[0039] ‘Heteroaryl’ means an aromatic ring structure, monocyclic or fused polycyclic, that includes one or more heteroatoms independently selected from O, N and S and the number of ring atoms specified. In particular, the aromatic ring structure may have from 5 to 9 ring members. The heteroaryl group can be, for example, a five membered or six membered monocyclic ring or a fused bicyclic structure formed from fused five and six membered rings or two fused six membered rings or, by way of a further example, two fused five membered rings. Each ring may contain up to four heteroatoms typically selected from nitrogen, sulfur and oxygen. Typically the heteroaryl ring will contain up to 4 heteroatoms, more typically up to 3 heteroatoms, more usually up to 2, for example a single heteroatom. In one embodiment, the heteroaryl ring contains at least one ring nitrogen atom. The nitrogen atoms in the heteroaryl rings can be basic, as in the case of an imidazole or pyridine, or essentially non-basic as in the case of an indole or pyrrole nitrogen. In general the number of basic nitrogen atoms present in the heteroaryl group, including any amino group substituents of the ring, will be less than five.
[0040] Examples of five membered monocyclic heteroaryl groups include but are not limited to pyrrolyl, furanyl, thiophenyl, imidazolyl, furazanyl, oxazolyl, oxadiazolyl, oxatriazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl and tetrazolyl groups.
[0041] “Heteroaryl” also covers partially aromatic bi- or polycyclic ring systems wherein at least one ring is an aromatic ring and one or more of the other ring(s) is a non-aromatic, saturated or partially saturated ring, provided at least one ring contains one or more heteroatoms selected from nitrogen, oxygen or sulfur. Partially aromatic heteroaryl bicyclic ring systems can be vicinally fused, i.e., where the rings are linked toeach other through two adjacent carbon and / or nitrogen atoms. Examples of partially aromatic heteroaryl groups include for example, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 2-oxo-l, 2,3,4-tetrahydroquinolinyl, dihydrobenzthienyl, dihydrobenzfuranyl, 1,3-dihydroisobenzofuran, 2,3-dihydro-benzo[l,4]dioxinyl, benzo[l,3]dioxolyl, 2,2-dioxo-l,3-dihydro-2-benzothienyl, 4, 5,6,7-tetrahydrobenzofuranyl, indolinyl, l,2,3,4-tetrahydro-l,8-naphthyridinyl, l.2.3.4-tctrahydropyrido|2.3- / ?|pyrazinyl and 3.4-dihydro-2 / / -pyrido|3.2- / ?|| l,4]oxazinyl.
[0042] Examples of five membered monocyclic heteroaryl groups include but are not limited to pyrrolyl, furanyl, thiophenyl, imidazolyl, furazanyl, oxazolyl, oxadiazolyl, oxatriazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl and tetrazolyl groups.
[0043] Examples of six membered monocyclic heteroaryl groups include but are not limited to pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl and triazinyl.
[0044] Particular examples of bicyclic heteroaryl groups containing a five membered ring fused to another five-membered ring include but are not limited to imidazothiazolyl and imidazoimidazolyl.
[0045] Particular examples of bicyclic heteroaryl groups containing a six membered ring fused to a five membered ring include but are not limited to benzofuranyl, benzothiophenyl, benzoimidazolyl, benzoxazolyl, isobenzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoisothiazolyl, isobenzofuranyl, indolyl, isoindolyl, indolizinyl, purinyl (e.g. adenine, guanine), indazolyl, pyrazolopyrimidinyl, triazolopyrimidinyl, and pyrazolopyridinyl groups.
[0046] Particular examples of bicyclic heteroaryl groups containing two fused six membered rings include but are not limited to quinolinyl, isoquinolinyl, pyridopyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, naphthyridinyl, and pteridinyl groups. Particular heteroaryl groups are those derived from thiophenyl, pyrrolyl, benzothiophenyl, benzofuranyl, indolyl, pyridinyl, quinolinyl, imidazolyl, oxazolyl and pyrazinyl.
[0047] Examples of representative heteroaryls include the following:wherein each Y is selected from >C=O, NH, O and S.
[0048] ‘Heterocycloalkyl’ means a non-aromatic fully saturated ring structure, monocyclic, fused polycyclic, spirocyclic, or bridged polycyclic, that includes one or more heteroatoms independently selected from O, N and S and the number of ring atoms specified. The heterocycloalkyl ring structure may have from 4 to 12 ring members, in particular from 4 to 10 ring members and more particularly from 4 to 7 ring members. Each ring may contain up to four heteroatoms typically selected from nitrogen, sulfur and oxygen. Typically the heterocycloalkyl ring will contain up to 4 heteroatoms, more typically up to 3 heteroatoms, more usually up to 2, for example a single heteroatom. Examples of heterocyclic rings include,but are not limited to azetidinyl, oxetanyl, thietanyl, pyrrolidinyl (e.g. 1-pyrrolidinyl, 2-pyrrolidinyl and 3-pyrrolidinyl), tetrahydrofuranyl (e.g. 1 -tetrahydrofuranyl, 2 -tetrahydrofuranyl and 3 -tetrahydrofuranyl), tetrahydrothiophenyl (e.g. 1 -tetrahydrothiophenyl, 2-tetrahydrothiophenyl and 3 -tetrahydrothiophenyl), piperidinyl (e.g. 1-piperidinyl, 2-piperidinyl, 3-piperidinyl and 4-piperidinyl), tetrahydropyranyl (e.g. 4-tetrahydropyranyl), tetrahydrothiopyranyl (e.g. 4-tetrahydrothiopyranyl), morpholinyl, thiomorpholinyl, dioxanyl, or piperazinyl.
[0049] Particular examples of monocyclic rings are shown in the following illustrative examples:wherein each W and Y is independently selected from -CH2-, -NH-, -O- and -S-.
[0050] Particular examples of fused bicyclic rings are shown in the following illustrative examples:Y W Ywherein each W and Y is independently selected from -CH2-, -NH-, -O- and -S-.
[0051] Particular examples of bridged bicyclic rings are shown in the following illustrative examples:wherein each W and Y is independently selected from -CH2-, -NH-, -O- and -S- and each Z is selected from N or CH.
[0052] Particular examples of spirocyclic rings are shown in the following illustrative examples:wherein each Y is selected from -CH2-, -NH-, -O- and -S-.
[0053] ‘Hydroxyl’ refers to the radical -OH.
[0054] ‘Oxo’ refers to the radical =0.
[0055] ‘ Substituted’ refers to a group in which one or more hydrogen atoms are each independently replaced with the same or different substituent(s).
[0056] As used herein, term ‘substituted with one or more’ refers to one to four substituents. In particular, it refers to one to three substituents. More particularly, it refers to one or two substituents. Most particularly, it refers to one substituent.
[0057] One having ordinary skill in the art of organic synthesis will recognize that the maximum number of heteroatoms in a stable, chemically feasible heterocyclic ring, whether it is aromatic or non-aromatic, is determined by the size of the ring, the degree of unsaturation and the valence of theheteroatoms. In general, a heterocyclic ring may have one to four heteroatoms so long as the heteroaromatic ring is chemically feasible and stable.
[0058] ‘Pharmaceutically acceptable’ means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly, in humans.
[0059] ‘Pharmaceutically acceptable salt’ refers to a salt of a compound of the invention that is pharmaceutically acceptable and that retains the biological activity of the given compound, and which are is not biologically or otherwise undesirable. In particular, such salts may be inorganic or organic acid addition salts and base addition salts. For example, pharmaceutically acceptable salts are described in Handbook of Pharmaceutical Salts: Properties, Selection, and Use (Stahl & Wermuth 2011). The salts can be prepared in situ during the final isolation and purification of the compounds described herein or separately, e.g., by reacting the free base group with a suitable inorganic or organic acid. The compounds of the invention may have ionizable groups so as to be capable of preparation as pharmaceutically acceptable salts. These salts may be acid addition salts involving inorganic or organic acids or the salts may, in the case of acidic forms of the compounds of the invention be prepared from inorganic or organic bases. Frequently, the compounds are prepared or used as pharmaceutically acceptable salts prepared as addition products of pharmaceutically acceptable acids or bases. Suitable pharmaceutically acceptable acids and bases are well known in the art, such as, e.g., hydrochloric acid for forming acid addition salts, and such as, e.g., sodium hydroxide for forming basic salts. The term ‘pharmaceutically acceptable cation’ refers to an acceptable cationic counter-ion of an acidic functional group. Such cations are exemplified by sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium cations, and the like.
[0060] ‘Pharmaceutically acceptable vehicle’ refers to a diluent, adjuvant, excipient or carrier with which a compound of the invention is administered.
[0061] ‘Prodrugs’ refers to compounds, including derivatives of the compounds of the invention, which have cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention which are pharmaceutically active in vivo. Such examples include, but are not limited to, choline ester derivatives and the like, N-alkylmorpholine esters and the like.
[0062] ‘ Solvate’ refers to forms of the compound that are associated with a solvent, usually by a solvolysis reaction. This physical association includes hydrogen bonding. Conventional solvents include water, EtOH, acetic acid and the like. The compounds of the invention may be prepared e.g. in crystalline form and may be solvated or hydrated. Suitable solvates include pharmaceutically acceptable solvates, such as hydrates, and further include both stoichiometric solvates and non-stoichiometric solvates. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. ‘Solvate’ encompasses both solution-phase and isolable solvates. Representative solvates include hydrates, ethanolates and methanolates.
[0063] ‘Subject’ includes humans. The terms ‘human’, ‘patient’ and ‘subject’ are used interchangeably herein.
[0064] ‘ Effective amount’ means the amount of a compound of the invention that, when administered to a subject for treating a disease, is sufficient to effect such treatment for the disease. The “effective amount” can vary depending on the compound, the disease and its severity, and the age, weight, etc., of the subject to be treated.
[0065] ‘Preventing’ or ‘prevention’ refers to a reduction in risk of acquiring or developing a disease or disorder (i.e. causing at least one of the clinical symptoms of the disease not to develop in a subject that may be exposed to a disease-causing agent, or predisposed to the disease in advance of disease onset.
[0066] The term ‘prophylaxis’ is related to ‘prevention’, and refers to a measure or procedure the purpose of which is to prevent, rather than to treat or cure a disease. Non-limiting examples of prophylactic measures may include the administration of vaccines; the administration of low molecular weight heparin to hospital patients at risk for thrombosis due, for example, to immobilization; and the administration of an anti-malarial agent such as chloroquine, in advance of a visit to a geographical region where malaria is endemic or the risk of contracting malaria is high.
[0067] ‘Treating’ or ‘treatment’ of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (z. e. arresting the disease or reducing the manifestation, extent or severity of at least one of the clinical symptoms thereof). In another embodiment ‘treating’ or ‘treatment’ refers to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, ‘treating’ or ‘treatment’ refers to modulating the disease or disorder, either physically, (e.g. stabilization of a discernible symptom), physiologically, (e.g. stabilization of a physical parameter), or both. In a further embodiment, “treating” or “treatment” relates to slowing the progression of the disease.
[0068] As used herein the term ‘proliferative disease(s)’ refers to diseases associated with excessive proliferation of cells and turnover of cellular matrix. In particular, the term refers to conditions such as cancer (e.g. uterine leiomyosarcoma or prostate cancer), myeloproliferative disorders (e.g. polycythemia vera, essential thrombocytosis and myelofibrosis), leukemia (e.g. acute myeloid leukemia, acute and chronic lymphoblastic leukemia), multiple myeloma, psoriasis, restenosis, scleroderma or fibrosis. In particular, the term refers to cancer, leukemia, and multiple myeloma.
[0069] Certain compounds of formula (I), or a pharmaceutically acceptable salt thereof, selectively target SMARCA2. For example, certain compounds of formula (I), or a pharmaceutically acceptable salt thereof, selectively target SMARCA2 over SMARCA4. For example, certain compounds of formula (I), or a pharmaceutically acceptable salt thereof, are at least about 3 fold (e.g. at least about 4-, 5- , 6-, 7-, 8-, 9-, 10-, 15-, 20-, 30-, 40-, 50-fold, or more) more selective for SMARCA2 than for SMARCA4.
[0070] As used herein, the term "selectivity" of a compound refers to the compound having more potent activity at the first target than the second target. A fold selectivity can be calculated by any method known in the art. For example, a fold selectivity can be calculated by dividing the IC50 value of a compound for the second target (e.g., SMARCA4) by the IC50 value of the same compound for the first target (e.g.,SMARCA2). An IC50 value can be determined by any method known in the art. For example, an IC50 value can be determined as described in the assays below.
[0071] As used herein, the term ‘cancer’ refers to a malignant or benign growth of cells in skin or in body organs, for example but without limitation, breast, prostate, lung, kidney, pancreas, stomach or bowel. A cancer tends to infdtrate into adjacent tissue and spread (metastasize) to distant organs, for example to bone, liver, lung or the brain. As used herein the term cancer includes both metastatic tumour cell types (such as but not limited to, melanoma, lymphoma, leukemia, fibrosarcoma, rhabdomyosarcoma, and mastocytoma) and types of tissue carcinoma (such as but not limited to, colorectal cancer, prostate cancer, small cell lung cancer and non-small cell lung cancer, breast cancer, pancreatic cancer, bladder cancer, renal cancer, gastric cancer, glioblastoma, primary liver cancer, ovarian cancer, and uterine leiomyosarcoma). In particular, the term ‘cancer’ refers to acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, anal cancer, appendix cancer, astrocytomas, atypical teratoid / rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer (osteosarcoma and malignant fibrous histiocytoma), brain stem glioma, brain tumors, brain and spinal cord tumors, breast cancer, bronchial tumors, Burkitt lymphoma, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, embryonal tumors, endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, Ewing sarcoma family of tumors, eye cancer, retinoblastoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), gastrointestinal stromal cell tumor, germ cell tumor, glioma, hairy cell leukemia, head and neck cancer, hepatocellular (liver) cancer, hypopharyngeal cancer, intraocular melanoma, islet cell tumors (endocrine pancreas), Kaposi’s sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, hairy cell leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, lymphoma, Waldenstrom macroglobulinemia, medulloblastoma, medulloepithelioma, melanoma, mesothelioma, mouth cancer, myeloid leukemia, multiple myeloma, nasopharyngeal cancer, neuroblastoma, oral cancer, oropharyngeal cancer, osteosarcoma, malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, papillomatosis, parathyroid cancer, penile cancer, pharyngeal cancer, pineal parenchymal tumors of intermediate differentiation, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm / multiple myeloma, pleuropulmonary blastoma, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell (kidney) cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, Ewing sarcoma family of tumors, sarcoma, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach (gastric) cancer, supratentorial primitive neuroectodermal tumors, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, vulvar cancer, and Wilms tumor.
[0072] As used herein the term ‘leukemia’ refers to neoplastic diseases of the blood and blood forming organs. Such diseases can cause bone marrow and immune system dysfunction, which renders the host highly susceptible to infection and bleeding. In particular the term leukemia refers to acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) and chronic lymphoblastic leukemia (CLL).
[0073] ‘Compound(s) of the invention’, and equivalent expressions, are meant to embrace compounds of the Formula(e) as herein described, which expression includes the pharmaceutically acceptable salts, and the solvates, e.g. hydrates, and the solvates of the pharmaceutically acceptable salts where the context so permits. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to embrace their salts, and solvates, where the context so permits.
[0074] When ranges are referred to herein, for example but without limitation, Ci-s alkyl, the citation of a range should be considered a representation of each member of said range.
[0075] Other derivatives of the compounds of this invention have activity in both their acid and acid derivative forms, but in the acid sensitive form often offers advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (Bundgaard 1985). Prodrugs include acid derivatives well know to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides. Simple aliphatic or aromatic esters, amides and anhydrides derived from acidic groups pendant on the compounds of this invention are particularly useful prodrugs. In some cases it is desirable to prepare double ester type prodrugs such as (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkylesters. Particular such prodrugs are the Ci-s alkyl, C2-8 alkenyl, Ce-io optionally substituted aryl, and (C6-ioaryl)-(Ci-4 alkyl) esters of the compounds of the invention.
[0076] The present disclosure includes all isotopic forms of the compounds of the invention provided herein, whether in a form (i) wherein all atoms of a given atomic number have a mass number (or mixture of mass numbers) which predominates in nature (referred to herein as the “natural isotopic form”) or (ii) wherein one or more atoms are replaced by atoms having the same atomic number, but a mass number different from the mass number of atoms which predominates in nature (referred to herein as an “unnatural variant isotopic form”). It is understood that an atom may naturally exists as a mixture of mass numbers. The term “unnatural variant isotopic form” also includes embodiments in which the proportion of an atom of given atomic number having a mass number found less commonly in nature (referred to herein as an “uncommon isotope”) has been increased relative to that which is naturally occurring e.g. to the level of >20%, >50%, >75%, >90%, >95% or> 99% by number of the atoms of that atomic number (the latter embodiment referred to as an "isotopically enriched variant form"). The term “unnatural variant isotopic form” also includes embodiments in which the proportion of an uncommon isotope has been reduced relative to that which is naturally occurring. Isotopic forms may include radioactive forms (i.e. they incorporate radioisotopes) and non-radioactive forms. Radioactive forms will typically be isotopically enriched variant forms.
[0077] An unnatural variant isotopic form of a compound may thus contain one or more artificial or uncommon isotopes such as deuterium (2H or D), carbon-11 (nC), carbon-13 (13C), carbon-14 (14C), nitrogen-13 (13N), nitrogen-15 (15N), oxygen-15 (15O), oxygen-17 (17O), oxygen-18 (18O), phosphorus-32 (32P), sulfur-35 (35S), chlorine-36 (36C1), chlorine-37 (37C1), fluorine-18 (18F) iodine-123 (123I), iodine-125 (125I) in one or more atoms or may contain an increased proportion of said isotopes as compared with the proportion that predominates in nature in one or more atoms.
[0078] Unnatural variant isotopic forms comprising radioisotopes may, for example, be used for drug and / or substrate tissue distribution studies. The radioactive isotopes tritium, i.e.3H, and carbon- 14, i.e.14C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Unnatural variant isotopic forms which incorporate deuterium i.e2H or D may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances. Further, unnatural variant isotopic forms may be prepared which incorporate positron emitting isotopes, such asnC,18F,15O and13N, and would be useful in Positron Emission Tomography (PET) studies for examining substrate receptor occupancy.
[0079] The selective replacement of hydrogen with deuterium in a compound may modulate the metabolism of the compound, the PK / PD properties of the compound and / or the toxicity of the compound. For example, deuteration may increase the half-life or reduce the clearance of the compound in vivo. Deuteration may also inhibit the formation of toxic metabolites, thereby improving safety and tolerability. It is to be understood that the invention encompasses deuterated derivatives of compounds of any of formulae I-XVIII. As used herein, the term deuterated derivative refers to compounds of the invention where in a particular position at least one hydrogen atom is replaced by deuterium. Accordingly, in a compound of the invention one or more hydrogen atom is optionally replaced by deuterium. For example, one or more hydrogen atoms in a Ci-4-alkyl group may be replaced by deuterium to form a deuterated C1-4-alkyl group. By way of example, if any of Ry, Rz, R1, R2, R3, R4a, R4b, R5, R6, R7, R8a, R8b, R9a, R9b, R10, R10a, R10b, Rlla, Rllb, R12a, or R12b, is methyl, the invention also encompasses -CD3, -CHD2and -CH2D. Similarly Ry, Rz, R3, R4a, R4b, R5, R6, R8a, R8b, R9a, R9b, Rlla, Rllb, R12a, or R12bmay be D.
[0080] It is also to be understood that compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed ‘isomers’. Isomers that differ in the arrangement of their atoms in space are termed ‘stereoisomers’.
[0081] Stereoisomers that are not mirror images of one another are termed ‘diastereomers’ and those that are non-superimposable mirror images of each other are termed ‘enantiomers’. When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn, Ingold and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e. as (+) or (-)-isomersrespectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a ‘racemic mixture’.
[0082] ‘ Tautomers’ refer to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of 71 electrons and an atom (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Another example of tautomerism is the aci- and nitro- forms of phenylnitromethane that are likewise formed by treatment with acid or base.
[0083] Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound of interest.
[0084] The compounds of the invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)- stereoisomers or as mixtures thereof.
[0085] An optical isomer with unknown absolute configuration may be depicted with an asterix (*) at thechiral center, e.g.,and / or and / or '''' and / or Likewise, when a chemical structure possessing one or more asymmetric centers is described using its chemical name, stereocenters with unknown absolute configuration may be depicted with an asterix (*), e.g. R* and / or S*. Alternatively, if stereochemistry has been depicted but the phrase “stereochemistry arbitrary assigned”, or something to that effect, is present then this indicates an optical isomer with unknown absolute configuration.
[0086] Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art.
[0087] It will be appreciated that compounds of the invention may be metabolized to yield biologically active metabolites.THE INVENTION
[0088] The present invention is based on the identification of novel compounds, and their use in the prophylaxis and / or treatment of proliferative diseases. In particular, the compounds of the invention may be SMARCA2 and / or SMARCA4 inhibitors, and more particularly SMARCA2 inhibitors.
[0089] The present invention also provides methods for the production of these compounds, pharmaceutical compositions comprising these compounds and methods for the prophylaxis and / or treatment of proliferative diseases by administering the compounds of the invention.
[0090] Accordingly, in a first aspect of the invention, the compounds of the invention are provided having a Formula I:O R4a p4b Cy2Iwherein,A is 6-10 membered monocyclic or bicyclic aryl, or 5-10 membered monocyclic or bicyclic heteroaryl comprising one, two or three heteroatoms independently selected from N, O, and S;R* N0 0 OY is independently selected from' ' , ' ' andRyand Rzare each independently hydrogen or C1-3 alkyl;X is N or CH;R1is Ci -e alkyl, C1-3 alkoxy(Ci-3)alkyl, 3-6 membered monocyclic cycloalkyl, 4-6 membered monocyclic heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S, -NH2, -NH(CI.3 alkyl), -N(CI-3alkyl)2, -NHC(=0)(CI.3alkyl), -N(CI-3alkyl)C(=O)(Ci-3alkyl), or hydroxy(Ci.4)alkyl, wherein said cycloalkyl, heterocycloalkyl, alkyl and alkoxy groups are optionally substituted with one or more halogen, C1-6 alkoxy, -NH2, -NH(CI-3 alkyl), -N(CI-3 alkyl)2;n is 0, 1, or 2;each R2is independently selected from halogen and Ci-e alkyl, which alkyl is optionally substituted with halo or C1-4 alkoxy;or R1and one R2together with the atoms onto which they are attached form a fused 5-8 membered monocyclic cycloalkyl, or a fused 5-8 membered monocyclic heterocycloalkyl comprising Y in formula I and zero, one, or two additional heteroatoms independently selected from N, O, and S, wherein the cycloalkyl or heterocycloalkyl is optionally substituted with one or more independently selected halogens (preferably fluoro) or C1-4 alkyl;R3is hydrogen or C1-6 alkyl;R4aand R4bare each independently hydrogen or C1-6 alkyl optionally substituted with one or more independently selected halo or C1-4 alkoxy;or R4aand R4b, together with the carbon to which they are attached, form a C3-6 cycloalkyl or 4-6 membered heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S, which cycloalkyl or heterocycloalkyl is optionally substituted with one or more halo or C1-4 alkoxy;Li is a bond or C1-4 alkyl;B is phenyl or 5-6 membered monocyclic heteroaryl comprising one, two, three or four heteroatoms independently selected from N, O, and S;Cyi is phenyl or 5-6 membered monocyclic heteroaryl comprising one, two, three or four heteroatoms independently selected from N, O, and S, each of which is optionally substituted with one or more independently selected halo,Cy2 is a 5-6-membered monocyclic heteroaryl comprising one, two, three or four heteroatoms independently selected from N, O, and S, which heteroaryl is optionally substituted with one or more independently selected -L2-R5groups;L2 is a bond or Ci-e alkyl;Each R5is independently selected from- -OH,- -CN,- -P(O)(Ci.4alkyl)2,- halo,- -S(=O)2-Ci.4 alkyl,- -NR8aR8b,- -CONR9aR9b,- -CO2R9a,- C1-4 alkyl optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9aor Ci -4 alkoxy,- C1-4 alkoxy optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9a, C1-4 alkoxy, or C3-6 cycloalkyl, and- C3-6 cycloalkyl, which cycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1.4 alkyl, C1.4 alkoxy, , -S(=O)2Ci.4alkyl, -C(=O)Ci.4alkyl, or -CO2R9a, - 4-8 membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, C1-4 alkoxy, -S(=O)2Ci-4 alkyl, -C(=O)Ci-4 alkyl, or -CO2R9a;R6is hydrogen, halo, or C1-6 alkyl;The subscript m is 0, 1 or 2;Each R7is independently selected from- -OH,- -CN,- -P(O)(Ci.4alkyl)2,- halo,- -S(=O)2-Ci.4 alkyl,- -NR8aR8b,- -CONR9aR9b,- -CO2R9a,- Ci-4 alkyl optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9aor Ci -4 alkoxy,- Ci-4 alkoxy optionally substituted with one or more independently selected halo, -OH, -CN, or C1-4 alkoxy,- C3-6 cycloalkyl, which cycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy, and- 4-8 membered monocyclic or spirocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy;each R8ais independently hydrogen or C1-4 alkyl;each R8bis independently hydrogen, C1-4 alkyl or -C(O)Ci.2alkyl;each R9ais independently selected from hydrogen and C1-4 alkyl;R9bis hydrogen, C1-4 alkyl or C1-4 alkoxy, orR9aand R9btogether with the atoms onto which they are attached form a 4-7 membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, Ci -4 alkyl.
[0091] Certain compounds according to the invention may exhibit one or more benefits including, inter alia, advantageous levels of biological activity which may be useful in the prophylaxis and / or treatment of one or more disease, improved safety characteristics (e.g. relating to hERG inhibition, drug-drug interaction (DDI) or CYP -interaction characteristics, etc), improved selectivity for one or more disease-associated biological target (e.g. reduced off-target effects, etc), improved pharmacokinetic properties (e.g. relating to dosing, solubility, absorption, etc), improved pharmacodynamic properties (e.g. relating to permeability, efflux, etc) or superior properties for use as pharmaceutical active ingredients alone or in pharmaceutical compositions (e.g. stability), or advantageous physico-chemical properties useful in the manufacturability of such aforementioned pharmaceutical compositions.
[0092] In certain embodiments, the compound of the formula (I) is a compound of the formula (II):o R4aR4b Cy2(II)wherein A, Y, B, Cyi, Cy2, R1, R2, R3, R4a, R4b, R6, R7, Li, m and n are as defined for formula (I).
[0093] In certain embodiments, the compound of the formula (I) is a compound of the formula (III):(HI)wherein A, Y, B, Cyi, Cy2, R1, R2, R3, R4a, R4b, R6, R7, m and n are as defined for formula (I).
[0094] In certain embodiments, the compound of the formula (I) is a compound of the formula (IVa) orwherein A, Y, B, Cyi, Cy2, R1, R2, R3, R4a, R4b, R6, R7, m and n are as defined for formula (I).
[0095] In certain embodiments, the compound of the formula (I) is a compound of the formula (V):wherein A, Y, B, Cyi, Cy2, R1, R2, R3, R4a, R4b, R6, R7, and n are as defined for formula (I).
[0096] In certain embodiments, the compound of the formula (I) is a compound of the formula (VI):(VI)wherein A, Y, B, Cyi, Cy2, R1, R2, R3, R4a, R4b, R6, and n are as defined for formula (I).
[0097] In certain embodiments, the compound of the formula (I) is a compound of the formula (VII):(VII)wherein A, B, Cyi, Cy2, R1, R2, R3, R4a, R4b, R6, m and n are as defined for formula (I).
[0098] In certain embodiments, the compound of the formula (I) is a compound of the formula (VIII):(VIII)wherein A, B, Cyi, Cy2, R1, R2, R3, R4a, R4b, R6, Li, m and n are as defined for formula (I).
[0099] In certain embodiments, the compound of the formula (I) is a compound of the formula (VIII):(VIII)wherein A, B, Cyi, Cy2, R1, R2, R3, R4a, R4b, R6, Li, m and n are as defined for formula (I).
[0100] In certain embodiments, the compound of the formula (I) is a compound of the formula (IXa):whereinnl is 0 or 1;n2 is 0, 1, 2, 3, or 4;R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl; andwherein B, Cyi, Cy2, R2, R3, R4a, R4b, R6, Li, m and n are as defined for formula (I).
[0101] In certain embodiments, the compound of the formula (I) is a compound of the formula (IX):(IXb) whereinnl is 0 or 1;n2 is 0, 1, 2, 3, or 4;R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl; andwherein B, Cyi, Cy2, R2, R3, R4a, R4b, R6, Li, m and n are as defined for formula (I).
[0102] In certain embodiments, the compound of the formula (I) is a compound of the formula (X):wherein A, B, Cyi, Cy2, R1, R2, R3, R4a, R4b, R5, R6, Rz, Li, mand n are as defined for formula (I).
[0103] In certain embodiments, the compound of the formula (I) is a compound of the formula (XI):N(XI)whereinn3 is 0 or 1;n4 is 0, 1, 2, 3, or 4;R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl; andCyi, Cy2, Rz, R2, R3, R4a, R4b, R5, R6, R7, m and Li, are as defined for formula (I).
[0104] In certain embodiments, the compound of the formula (I) is a compound of the formula (XII):wherein Cyi, Cy2, R1, R2, R3, R4a, R4b, R6, R7, and n are as defined for formula (I).
[0105] In certain embodiments, the compound of the formula (I) is a compound of the formula (XIII):(XIII)wherein Cyi, Cy2, R1, R2, R3, R4a, R4b, R6, R7, and n are as defined for formula (I).
[0106] In certain embodiments, the compound of the formula (I) is a compound of the formula (XlVa):whereinnl is 0 or 1;n2 is 0, 1, 2, 3, or 4;R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl; andCyi, Cy2, R2, R3, R4a, R4b, R6, and R7, are as defined for formula (I).
[0107] In certain embodiments, the compound of the formula (I) is a compound of the formula (XlVb):(XlVb)whereinnl is 0 or 1;n2 is 0, 1, 2, 3, or 4;R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl; andCyi, Cy2, R2, R3, R4a, R4b, R6, and R7, are as defined for formula (I).
[0108] In certain embodiments, the compound of the formula (I) is a compound of the formula (XV):(XV)wherein Cyi, Cy2, R1, R2, R3, R4a, R4b, R6, R7, Rz, and n are as defined for formula (I).
[0109] In certain embodiments, the compound of the formula (I) is a compound of the formula (XVI):whereinn3 is 0 or 1;n4 is 0, 1, 2, 3, or 4;R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl; andCyi, Cy2, R2, R3, R4a, R4b, R6, R7, and Rz, are as defined for formula (I).
[0110] The following embodiments apply to compounds of any of Formulae I-XVI. These embodiments are independent and interchangeable. Any one embodiment may be combined with any other embodiment, where chemically allowed. In other words, any of the features described in the following embodiments may (where chemically allowable) may be combined with the features described in one or more other embodiments. In particular, where a compound is exemplified or illustrated in this specification, any two or more of the embodiments listed below, expressed at any level of generality, which encompass that compound may be combined to provide a further embodiment which forms part of the present disclosure.[oni] In some embodiments, the compound is according to any one of Formulae I-XVI, wherein R3is hydrogen.
[0112] In some embodiments, the compound is according to any one of Formulae I-XVI, wherein R4aand R4bare hydrogen.
[0113] In some embodiments, the compound is according to any one of Formulae I-XVI, wherein R3, R4aand R4bare hydrogen.
[0114] In some embodiments, the compound is according to any one of Formulae I-XVI, wherein R6is hydrogen.
[0115] In some embodiments, the compound is according to any one of Formulae I-XVI, wherein R3, R4a, R4b, and R6are hydrogen.
[0116] In some embodiments, A is 6-10 membered monocyclic or bicyclic aryl. In some embodiments, A is phenyl. In some embodiments, A is 9-10 membered bicyclic aryl.is selected from:
[0118] In some embodiments, is selected from:
[0119] In some embodiments, A is 5-10 membered monocyclic or bicyclic heteroaryl comprising one, two or three heteroatoms independently selected from N, O, and S.
[0120] In some embodiments, A is 5 -membered monocyclic heteroaryl. In some embodiments, A is 6-membered monocyclic heteroaryl. In some embodiments, A is 9-membered bicyclic heteroaryl. In some embodiments, A is 10-membered bicyclic heteroaryl.o o
[0123] In some embodiments, Y is independently selected from'7andO OS
[0124] In some embodiments,Y is
[0125] In some embodiments, Y is' ' In some embodiments, Ryis hydrogen. In some embodiments, Ryis methyl. In some embodiments, Ryis ethyl.NRz
[0126] In some embodiments, Y isIn some embodiments, Rzis hydrogen. In some embodiments, Rzis methyl. In some embodiments, Rzis ethyl.
[0127] In some embodiments, R1is C1-3 alkyl, C1-3 alkoxy(Ci-3)alkyl, -N(CI-3 alkyl)2 or hydroxy(Ci-3)alkyl, wherein said alkyl and alkoxy groups are optionally substituted with one or more halogen.
[0128] In some embodiments, R1is C1-3 alkyl, C1-3 alkoxy(Ci-3)alkyl, or hydroxy(Ci-3)alkyl, wherein said alkyl and alkoxy groups are optionally substituted with one or more halogen.
[0129] In some embodiments, R1is C1-3 alkyl or C1-3 alkoxy(Ci-3)alkyl, wherein said alkyl and alkoxy groups are optionally substituted with one or more halogen.
[0130] In some embodiments, R1is C1-3 alkyl, wherein said alkyl group is optionally substituted with one or more halogen. In some embodiments, R1is C1-3 alkyl, wherein said alkyl group is optionally substituted with one or more fluoro.
[0131] In some embodiments, R1is methyl.
[0132] In some embodiments, R1is C1-3 alkoxy(Ci-3)alkyl, wherein said alkyl and alkoxy groups are optionally substituted with one or more halogen. In some embodiments, R1is C1-3 alkoxy(Ci-3)alkyl, wherein said alkyl and alkoxy groups are optionally substituted with one or more fluoro.
[0133] In some embodiments, R1is -NH2.
[0134] In some embodiments, R1is -NH(CI-3 alkyl).
[0135] In some embodiments, R1is -N(CI-3 alkyl)2.
[0136] In some embodiments, R1is hydroxy(Ci-3)alkyl.
[0137] In some embodiments, R1is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl.
[0138] In some embodiments, R1is -N(CH3)C(=O)(CI-3 alkyl).
[0139] In some embodiments,is selected from:and
[0145] In some embodiments,R1
[0147] In some embodiments,R1
[0148] In some embodiments,
[0149] R1
[0150] In some embodiments,R1
[0151] In some embodiments,
[0152] In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2.
[0153] In some embodiments, R2is independently selected from halogen and C1-3 alkyl, which alkyl is optionally substituted with halo or C1-4 alkoxy.
[0154] In some embodiments, R2is halogen. In some embodiments, R2is fluoro. In some embodiments, R2is chloro.
[0155] In some embodiments, R2is C1-3 alkyl, which alkyl is optionally substituted with halo or C1.4 alkoxy.
[0156] In some embodiments, R2is C1-3 alkyl, which alkyl is optionally substituted with halo. In some embodiments, R2is C1-3 alkyl, which alkyl is optionally substituted with fluoro.
[0157] In some embodiments, R2is methyl, which methyl is optionally substituted with halo. In some embodiments, R2is methyl, which alkyl is optionally substituted with fluoro.
[0158] In some embodiments, R2is methyl.
[0159] In some embodiments, R1and one R2together with the atoms onto which they are attached form a fused 5-8 membered monocyclic cycloalkyl, or a fused 5-8 membered monocyclic heterocycloalkyl comprising Y in formula I and zero, one, or two additional heteroatoms independently selected from N, O, and S, wherein the cycloalkyl or heterocycloalkyl is optionally substituted with one or more independently selected halogens (preferably fluoro) or C1.4 alkyl.
[0160] In some embodiments, Y isand R1and one R2together with the atoms onto which they are attached form a fused 5-8 membered monocyclic cycloalkyl, or a fused 5-8 membered monocyclic heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S, wherein the cycloalkyl or heterocycloalkyl is optionally substituted with one or more independently selected halogens (preferably fluoro-) or C1-4 alkyl.
[0161] In some embodiments, Y isand R1and one R2together with the atoms onto which they are attached form a fused 5-8 membered monocyclic heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S, wherein the heterocycloalkyl is optionally substituted with one or more independently selected halogens (preferably fluoro-) or C1-4 alkyl.R1
[0162] In some embodiments,; wherein n3 is 0 or 1, n4 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.R1
[0163] In some embodiments,; wherein n3 is 0 or 1, n4 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.R1
[0164] In some embodiments,; wherein n3 is 0 or 1, n4 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.R1
[0165] In some embodiments,; wherein n3 is 0 or 1, n4 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.R1
[0166] In some embodiments,; wherein n3 is 0 or 1, n4 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.R1
[0167] In some embodiments,; wherein n3 is 0 or 1, n4 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.
[0168] In some embodiments,Y is and R1and one R2together with the atoms onto which they are attached form a fused 5-8 membered monocyclic heterocycloalkyl comprising the S atom of Y and zero, one, or two additional heteroatoms independently selected from N, O, and S, wherein the heterocycloalkyl is optionally substituted with one or more independently selected halogens (preferably fluoro-) or C1-4 alkyl.O O|0169| In some embodiments, Y is Y 'SY ' and R1and one R2together with the atoms onto which they are attached form a fused 5-8 membered monocyclic heterocycloalkyl comprising the S atom ofY and zero, one, or two additional heteroatoms independently selected from N, O, and S, wherein the heterocycloalkyl is optionally substituted with one or more independently selected halogens (preferably fluoro-) or C1-4 alkyl.0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and C1-4 alkyl.is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and C1-4 alkyl.0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and C1-4 alkyl.is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and C1-4 alkyl.R1
[0174] In some embodiments,1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.
[0175] In some embodiments,; wherein nl is 0 or 1, n5 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.R1
[0176] In some embodiments,; wherein nl is 0 or 1, n6 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and C1-4 alkyl.R1
[0177] In some embodiments,; wherein nl is 0 or 1, n6 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and C1.4 alkyl.R1
[0178] In some embodiments,; wherein nl is 0 or 1, n7 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl,o oR1
[0179] In some embodiments,; wherein nl is 0 or 1, n7 is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.is 0, 1, 2, 3, or 4 and R2ais selected from halogen (preferably fluoro) and Ci-4 alkyl.
[0182] In some embodiments nl is 0. In some embodiments nl is 1.
[0183] In some embodiments n2 is 0. In some embodiments n2 is 1.
[0184] In some embodiments n3 is 0. In some embodiments n3 is 1.
[0185] In some embodiments n4 is 0. In some embodiments n4 is 1.
[0186] In some embodiments n5 is 0. In some embodiments n5 is 1.
[0187] In some embodiments n6 is 0. In some embodiments n6 is 1.
[0188] In some embodiments n7 is 0. In some embodiments n7 is 1.
[0189] In some embodiments n8 is 0. In some embodiments n8 is 1.
[0190] In some embodiments, R2ais fluoro.
[0191] In some embodiments, R2ais methyl. In such embodiments, R2amay be a substituent on nitrogenwithin the ring, e.g., where , the -N(H)- may be -N(R2a)-.
[0192] In some embodiments,lR2l is selected from:
[0193] R
[0194] In some embodiments,R
[0195] In some embodiments,R
[0196] In some embodiments, is selected from:
[0197] In some embodiments, R3is hydrogen.
[0198] In some embodiments, R3is Ci-6 alkyl. In some embodiments, R3is methyl. In some embodiments, R3is ethyl.
[0199] In some embodiments, R4ais hydrogen.
[0200] In some embodiments, R4ais C1-6 alkyl. In another embodiment, R4ais -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -CH2CH2CH3, -CH2CH(CH3)2, -CH(CH3)CH2CH3, -CH2C(CH3)3, -CH(CH3)CH(CH3)2, -C(CH3)2CH2CH3, -CH(CH3)C(CH3)3, or -C(CH3)2C(CH3)2.
[0201] In some embodiments, R4ais -CH3, -CH2CH3, -CH(CH3)2, -CH2CH2CH3, -CH2CH(CH3)2, or -CH(CH3)CH2CH3. In a most particular embodiment, R4ais -CH3.
[0202] In some embodiments, R4bis hydrogen.
[0203] In some embodiments, R4bis C1-6 alkyl. In another embodiment, R4bis -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -CH2CH2CH3, -CH2CH(CH3)2, -CH(CH3)CH2CH3, -CH2C(CH3)3, -CH(CH3)CH(CH3)2, -C(CH3)2CH2CH3, -CH(CH3)C(CH3)3, or -C(CH3)2C(CH3)2.
[0204] In some embodiments, R4bis -CH3, -CH2CH3, -CH(CH3)2, -CH2CH2CH3, -CH2CH(CH3)2, or -CH(CH3)CH2CH3. In a most particular embodiment, R4bis -CH3.
[0205] In some embodiments, R4aand R4bare each hydrogen.
[0206] In some embodiments, R4aand R4btogether with the carbon to which they are attached, form a C3-e cycloalkyl or 4-6 membered heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S, which cycloalkyl or heterocycloalkyl is optionally substituted with one or more halo or C1.4 alkoxy.
[0207] In some embodiments, R4aand R4btogether with the carbon to which they are attached, form the structure:R4cl J p; wherein C is a C3-6 cycloalkyl or 4-6 membered heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S; p is 0, 1, or 2; and R4cis independently selected from halo or C1.4 alkoxy .
[0208] In some embodiments, C is C3-6 cycloalkyl. In some embodiments, C is cyclopropyl. In some embodiments, C is cyclobutyl. In some embodiments, C is cyclopentyl.
[0209] In some embodiments, C is 4-6 membered heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S. In some embodiments, C is 4-membered heterocycloalkyl comprising one heteroatom independently selected from N, O, and S. In some embodiments, C is 5-membered heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S.
[0210] In some embodiments, C is selected from:
[0211] In some embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p is 0.
[0212] In some embodiments, R4cis halo. In some embodiments, R4cis fluoro.
[0213] In some embodiments, R4cis Ci-4 alkoxy. In some embodiments, R4cis -O-methyl. In some embodiments, R4cis -O-ethyl.
[0214] In some embodiments, C is selected from:
[0215] In some embodiments, C is
[0216] In some embodiments, X is N. In some embodiments, X is CH.
[0217] In some embodiments, R6is hydrogen.
[0218] In some embodiments, R6is halo. In some embodiments, R6is fluoro.
[0219] In some embodiments, R6is Ci-6 alkyl. In some embodiments, R6is C1-3 alkyl. In some embodiments, R6is methyl.
[0220] In some embodiments, Li is a bond.''S'*Sf‘R71
[0221] In some embodiments, Bism, wherein m is 0, 1, 2, 3, or 4.^X^R7
[0222] In some embodiments,B is ' * .
[0223] In some embodiments, B is 5-6 membered monocyclic or bicyclic heteroaryl comprising one, two, three or four heteroatoms independently selected from N, O, and S. In some embodiments, Li is a bond and B is 5-10 membered monocyclic or bicyclic heteroaryl comprising one, two, three or four heteroatoms independently selected from N, O, and S.
[0224] In some embodiments, B is imidazolyl, pyrazolyl, oxazolyl, pyridyl, pyridinyl, or pyrazinyl. In a particular embodiment, B is pyridinyl.
[0225] In some embodiments, B is selected from:
[0226] In some embodiments, m is 0.
[0227] In some embodiments, m is 2.
[0228] In some embodiments, m is 3.
[0229] In some embodiments, m is 4.
[0230] In some embodiments, m is 1.
[0231] In some embodiments,B is
[0232] In some embodiments, R7is selected from:- -OH,- -CN,- -P(O)(Ci.4alkyl)2,halo,- -S(=O)2-Ci.4 alkyl,- -NR8aR8b,- -CONR9aR9b,- -CO2R9a,Ci-4 alkyl optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9aor Ci -4 alkoxy,Ci-4 alkoxy optionally substituted with one or more independently selected halo, -OH, -CN, or Cn 4 alkoxy,C3-6 cycloalkyl, which cycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy, and4-8 membered monocyclic or spirocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy;
[0233] In some embodiments, R7is selected from:- -OH,- -CN,halo,C1-4 alkyl optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9aor Ci -4 alkoxy,Ci-4 alkoxy optionally substituted with one or more independently selected halo, -OH, -CN, or Ci- 4 alkoxy,C3-6 cycloalkyl, which cycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy, and4-8 membered monocyclic or spirocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy;
[0234] In some embodiments, R7is selected from:- -CN,halo,C1-4 alkoxy optionally substituted with one or more independently selected halo, -OH, -CN, or Ci- 4 alkoxy, and4-8 membered monocyclic or spirocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy.
[0235] In some embodiments, R7is -CN.
[0236] In some embodiments, R7is halo. In some embodiments, R7is fluoro. In some embodiments, R7is chloro.
[0237] In some embodiments, R7is C1-4 alkoxy optionally substituted with one or more independently selected halo, -OH, -CN, or C1.4 alkoxy.
[0238] In some embodiments, R7is C1-4 alkoxy optionally substituted with one or more independently selected -OH or C 1.4 alkoxy.
[0239] In some embodiments, R7is C1-4 alkoxy optionally substituted with one or more independently selected -OH or C 1.2 alkoxy.
[0240] In some embodiments, R7is C1-2 alkoxy optionally substituted with one or more independently selected -OH or C 1.2 alkoxy.
[0241] In some embodiments, R7is -OCH3. In some embodiments, R7is -OCH2CH3. In some embodiments, R7is -OCH2CH2OH. In some embodiments, R7is -OCH2CH2OCH3.
[0242] In some embodiments,is selected from:Cyi— Cy2and'-V[ [R 7]m1SCyi — Oy20243] In some embodiments,
[0244] In some embodiments, R7is 4-8 membered monocyclic or spirocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, Ci-4 alkyl, or Ci-4 alkoxy.
[0245] In some embodiments, R7is 4-membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1.4 alkyl, or C1.4 alkoxy.
[0246] In some embodiments, R7is 5 -membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1.4 alkyl, or C1.4 alkoxy.
[0247] In some embodiments, R7is 6-membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1.4 alkyl, or C1.4 alkoxy.
[0248] In some embodiments, R7is 4-membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected halo, -OH, -CN, or C 1.2 alkyl.
[0249] In some embodiments, R7is 5 -membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected halo, -OH, -CN, or C 1.2 alkyl.
[0250] In some embodiments, R7is 6-membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected halo, -OH, -CN, or C 1.2 alkyl.
[0251] In some embodiments, R7is selected from:Nwherein R7is optionally substituted with one or more independently selected halo, -OH, -CN, or C1-2 alkyl.
[0252] In some embodiments, Cyi is phenyl optionally substituted with one or more independently selected halo.
[0253] In some embodiments, Cyi is phenyl.
[0254] In some embodiments, Cyi is pyridinyl optionally substituted with one or more independently selected halo.
[0255] In some embodiments, Cyi is pyridinyl.
[0256] In some embodiments, Cyi is:
[0257] In some embodiments, Cy2 is a 5-membered monocyclic heteroaryl comprising one, two, or three heteroatoms independently selected from N, O, and S, which heteroaryl is optionally substituted with one or more independently selected R5groups. In a particular embodiment, Cy2 is imidazolyl, oxazolyl, pyrazolyl, pyridinyl, pyrazinyl, or pyridazinyl, each of which is optionally substituted with one or more independently selected R5groups. In a more particular embodiment, Cy2 is oxazolyl or pyridinyl, each of which is optionally substituted with one or more independently selected R5groups. In a more particular embodiment, Cy2 is oxazolyl optionally substituted with one or more independently selected R5groups.Cy2
[0260] In some embodiment, Cy2 is p5b p5bwherein each R5aand R5bis as defined for R5in formula (I).
[0261] In some embodiment, Cy2 isR5bor wherein each R5aand R5bis as defined for R5in formula (I).
[0262] In some embodiment, Cy2 isR5bwherein each R5aand R5bis as defined for R5in formula (I).
[0263] In some embodiments, each R5, R5aand R5bis independently selected from- Ci-4 alkyl optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9aor Ci .4 alkoxy,- Cs-e cycloalkyl, which cycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy, and- 4-8 membered monocyclic or spirocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, C1-4 alkoxy, or -CO2R9a;
[0264] In some embodiments, one or more independently selected R5, R5aand R5bis selected from C1-4 alkyl optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9aor C1-4 alkoxy.
[0265] In some embodiments, one or more independently selected R5, R5aand R5bis selected from C1-4 alkyl optionally substituted with one or more independently selected halo, -OH, or -CN.
[0266] In some embodiments, one or more independently selected R5, R5aand R5bis selected from C1-4 alkyl optionally substituted with one or more -OH.
[0267] In some embodiments, one or more independently selected R5, R5aand R5bis selected from 4-8 membered monocyclic or spirocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1.4 alkyl, C1-4 alkoxy, or -CO2R9a.
[0268] In some embodiments, one or more independently selected R5, R5aand R5bis selected from 4-6 membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1.4 alkyl, C1-4 alkoxy, or -CO2R9a.
[0269] In some embodiments, R8ais hydrogen. In some embodiments, R8ais C1-4 alkyl. In some embodiments, R8ais methyl. In some embodiments, R8ais ethyl.
[0270] In some embodiments, R8bis hydrogen. In some embodiments, R8bis -C(O)Ci-2 alkyl. In some embodiments, R8bis C1.4 alkyl. In some embodiments, R8bis methyl. In some embodiments, R8bis ethyl.
[0271] In some embodiments, R9ais hydrogen. In some embodiments, R9ais C1-4 alkyl. In some embodiments, R9ais methyl. In some embodiments, R9ais ethyl.
[0272] In some embodiments, R9bis hydrogen. In some embodiments, R9bis C1-4 alkyl. In some embodiments, R9bis methyl. In some embodiments, R9bis ethyl. In some embodiments, R9bis C1-4 alkoxy. In some embodiments, R9bis C1-2 alkoxy. In some embodiments, R9bis -OCH3. In some embodiments, R9bis -OCH2CH3.
[0273] In some embodiments, Cy2 is selected from:
[0274] In one embodiment, a compound of the invention is provided in a natural isotopic form.
[0275] In one embodiment, a compound of the invention is provided in an unnatural variant isotopic form. In a specific embodiment, the unnatural variant isotopic form is a form in which deuterium (z. e.2H or D) is incorporated where hydrogen is specified in the chemical structure in one or more atoms of a compound of the invention. In one embodiment, the atoms of the compounds of the invention are in an isotopic form which is not radioactive. In one embodiment, one or more atoms of the compounds of the invention are in an isotopic form which is radioactive. Suitably radioactive isotopes are stable isotopes. Suitably, the unnatural variant isotopic form is a pharmaceutically acceptable form.
[0276] In one embodiment, a compound of the invention is provided whereby a single atom of the compound exists in an unnatural variant isotopic form. In another embodiment, a compound of the invention is provided whereby two or more atoms exist in an unnatural variant isotopic form.
[0277] Unnatural isotopic variant forms can generally be prepared by conventional techniques known to those skilled in the art or by processes described herein e.g. processes analogous to those described in the accompanying Examples for preparing natural isotopic forms. Thus, unnatural isotopic variant forms could be prepared by using appropriate isotopically variant (or labelled) reagents in place of the normal reagents employed in the illustrative example as examples.
[0278] In one aspect a compound of the invention according to any one of the embodiments herein described is present as the free base.
[0279] In one aspect a compound of the invention according to any one of the embodiments herein described is a pharmaceutically acceptable salt of the compound.
[0280] In one aspect a compound of the invention according to any one of the embodiments herein described is a solvate of the compound.
[0281] In one aspect a compound of the invention according to any one of the embodiments herein described is a solvate of a pharmaceutically acceptable salt of the compound.
[0282] While specified groups for each embodiment have generally been listed above separately, a compound of the invention includes one in which several or each embodiment in the above Formula, as well as other formulae presented herein, is selected from one or more of particular members or groups designated respectively, for each variable. Therefore, this invention is intended to include all combinations of such embodiments within its scope.
[0283] While specified groups for each embodiment have generally been listed above separately, a compound of the invention may be one for which one or more variables (for example, R groups) is selected from one or more embodiments according to any of the Formula(e) listed above. Therefore, the presentinvention is intended to include all combinations of variables from any of the disclosed embodiments within its scope.
[0284] Alternatively, the exclusion of one or more of the specified variables from a group or an embodiment, or combinations thereof is also contemplated by the present invention.
[0285] In certain aspects, the present invention provides prodrugs and derivatives of the compounds according to the formulae above. Prodrugs are derivatives of the compounds of the invention, which have metabolically cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention, which are pharmaceutically active, in vivo. Such examples include, but are not limited to, choline ester derivatives and the like, A-alkylmorpholine esters and the like.
[0286] Other derivatives of the compounds of this invention have activity in both their acid and acid derivative forms, but the acid sensitive form often offers advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (Bundgaard 1985). Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides. Simple aliphatic or aromatic esters, amides and anhydrides derived from acidic groups pendant on the compounds of this invention are preferred prodrugs. In some cases it is desirable to prepare double ester type prodrugs such as (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkylesters. Particularly useful are the Ci to Cs alkyl, C2-C8 alkenyl, aryl, C7-C12 substituted aryl, and C7-C12 arylalkyl esters of the compounds of the invention.PHARMACEUTICAL COMPOSITIONS
[0287] When employed as a pharmaceutical, a compound of the invention is typically administered in the form of a pharmaceutical composition. Such compositions can be prepared in a manner well known in the pharmaceutical art and comprise at least one active compound of the invention according to Formula I. Generally, a compound of the invention is administered in a pharmaceutically effective amount. The amount of compound of the invention actually administered will typically be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound of the invention administered, the age, weight, and response of the individual patient, the severity of the patient’s symptoms, and the like.
[0288] In one embodiment, the present invention provides pharmaceutical compositions comprising a compound of the invention and another therapeutic agent.
[0289] In one embodiment, the present invention provides pharmaceutical compositions comprising a compound of the invention and another therapeutic agent, which other therapeutic agent is a proliferative diseases treatment agent. In particular, the term proliferative diseases refers to cancer, myeloproliferative disorders, leukemia, multiple myeloma, psoriasis, restenosis, scleroderma or fibrosis. More particularly, the term refers to cancer, leukemia, and multiple myeloma.
[0290] In a particular embodiment, the present invention provides pharmaceutical compositions comprising a compound of the invention and another therapeutic agent, which other therapeutic agent is a cancer treatment agent. In particular, the term refers to both metastatic tumour cell types (such as but not limited to, melanoma, lymphoma, leukemia, fibrosarcoma, rhabdomyosarcoma, and mastocytoma) and types of tissue carcinoma (such as but not limited to, colorectal cancer, prostate cancer, small cell lung cancer and non-small cell lung cancer, breast cancer, pancreatic cancer, bladder cancer, renal cancer, gastric cancer, glioblastoma, primary liver cancer, ovarian cancer, and uterine leiomyosarcoma). More particularly, the term refers to acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, anal cancer, appendix cancer, astrocytomas, atypical teratoid / rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer (osteosarcoma and malignant fibrous histiocytoma), brain stem glioma, brain tumors, brain and spinal cord tumors, breast cancer, bronchial tumors, Burkitt lymphoma, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, embryonal tumors, endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, Ewing sarcoma family of tumors, eye cancer, retinoblastoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), gastrointestinal stromal cell tumor, germ cell tumor, glioma, hairy cell leukemia, head and neck cancer, hepatocellular (liver) cancer, hypopharyngeal cancer, intraocular melanoma, islet cell tumors (endocrine pancreas), Kaposi’s sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, hairy cell leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, lymphoma, Waldenstrom macroglobulinemia, medulloblastoma, medulloepithelioma, melanoma, mesothelioma, mouth cancer, myeloid leukemia, multiple myeloma, nasopharyngeal cancer, neuroblastoma, oral cancer, oropharyngeal cancer, osteosarcoma, malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, papillomatosis, parathyroid cancer, penile cancer, pharyngeal cancer, pineal parenchymal tumors of intermediate differentiation, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm / multiple myeloma, pleuropulmonary blastoma, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell (kidney) cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, Ewing sarcoma family of tumors, sarcoma, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach (gastric) cancer, supratentorial primitive neuroectodermal tumors, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, vulvar cancer, and Wilms tumor. Most particularly, the term refers to non-small cell lung cancer, Burkitt lymphoma, medulloblastoma, pancreatic cancer, ovarian cancer, and melanoma
[0291] In a further particular embodiment, the present invention provides pharmaceutical compositions comprising a compound of the invention and another therapeutic agent, which other therapeutic agent is a leukemia treatment agent. In particular, the term refers to neoplastic diseases of the blood and blood formingorgans. More particularly, the term refers to acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) and chronic lymphoblastic leukemia (CLL).
[0292] The pharmaceutical compositions of this invention can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intra-articular, intravenous, intramuscular, and intranasal. Depending on the intended route of delivery, a compound of the invention is preferably formulated as either injectable or oral compositions or as salves, as lotions or as patches all for transdermal administration.
[0293] The compositions for oral administration can take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, the compositions are presented in unit dosage forms to facilitate accurate dosing. The term ‘unit dosage forms’ refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient, vehicle or carrier. Typical unit dosage forms include prefdled, premeasured ampules or syringes of the liquid compositions or pills, tablets, capsules or the like in the case of solid compositions. In such compositions, the compound of the invention according to Formula I is usually a minor component (from about 0.1 to about 50% by weight or preferably from about 1 to about 40% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.
[0294] Liquid forms suitable for oral administration may include a suitable aqueous or non-aqueous vehicle with buffers, suspending and dispensing agents, colorants, flavors and the like. Solid forms may include, for example, any of the following ingredients, or compound of the inventions of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or com starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint or orange flavoring.
[0295] Injectable compositions are typically based upon injectable sterile saline or phosphate-buffered saline or other injectable carriers known in the art. As before, the active compound of the invention according to Formula I in such compositions is typically a minor component, often being from about 0.05 to 10% by weight with the remainder being the injectable carrier and the like.
[0296] Transdermal compositions are typically formulated as a topical ointment or cream containing the active ingredient(s), generally in an amount ranging from about 0.01 to about 20% by weight, preferably from about 0.1 to about 20% by weight, preferably from about 0.1 to about 10% by weight, and more preferably from about 0.5 to about 15% by weight. When formulated as an ointment, the active ingredients will typically be combined with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with, for example an oil-in-water cream base. Such transdermal formulations are well-known in the art and generally include additional ingredients to enhance the dermal penetration or stability of the active ingredients or the formulation. All such known transdermal formulations and ingredients are included within the scope of this invention.
[0297] A compound of the invention can also be administered by a transdermal device. Accordingly, transdermal administration can be accomplished using a patch either of the reservoir or porous membrane type, or of a solid matrix variety.
[0298] The above-described components for orally administrable, injectable or topically administrable compositions are merely representative. Other materials as well as processing techniques and the like are set forth in Part 8 of Remington’s Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pennsylvania, which is incorporated herein by reference.
[0299] A compound of the invention can also be administered in sustained release forms or from sustained release drug delivery systems. A description of representative sustained release materials can be found in Remington’s Pharmaceutical Sciences (Remington & Gennaro 1985).
[0300] The following formulation examples illustrate representative pharmaceutical compositions that may be prepared in accordance with this invention. The present invention, however, is not limited to the following pharmaceutical compositions.Formulation 1 - Tablets
[0301] A compound of the invention according to Formula I may be admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio. A minor amount of magnesium stearate may be added as a lubricant. The mixture may be formed into 240-270 mg tablets (80-90 mg of active compound of the invention according to Formula I per tablet) in a tablet press.Formulation 2 - Capsules
[0302] A compound of the invention according to Formula I may be admixed as a dry powder with a starch diluent in an approximate 1:1 weight ratio. The mixture may be fdled into 250 mg capsules (125 mg of active compound of the invention according to Formula I per capsule).Formulation 3 - Liquid
[0303] A compound of the invention according to Formula I (125 mg), maybe admixed with sucrose (1.75 g) and xanthan gum (4 mg) and the resultant mixture may be blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of microcrystalline cellulose and sodium carboxymethyl cellulose (11:89, 50 mg) in water. Sodium benzoate (10 mg), flavor, and color may be diluted with water and added with stirring. Sufficient water may then be added with stirring. Further sufficient water may be then added to produce a total volume of 5 mL.Formulation 4 - Tablets
[0304] A compound of the invention according to Formula I may be admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio. A minor amount of magnesium stearate may be added as a lubricant. The mixture may be formed into 450-900 mg tablets (150-300 mg of active compound of the invention according to Formula I) in a tablet press.Formulation 5 - Injection
[0305] A compound of the invention according to Formula I may be dissolved or suspended in a buffered sterile saline injectable aqueous medium to a concentration of approximately 5 mg / mL.Formulation 6 - Topical
[0306] Stearyl alcohol (250 g) and a white petrolatum (250 g) may be melted at about 75 °C and then a mixture of a compound of the invention according to Formula I (50 g) methylparaben (0.25 g), propylparaben (0.15 g), sodium lauryl sulfate (10 g), and propylene glycol (120 g) dissolved in water (about 370 g) may be added and the resulting mixture may be stirred until it congeals.METHODS OF TREATMENT
[0307] In one embodiment, the present invention provides compounds of the invention, or pharmaceutical compositions comprising a compound of the invention, for use in medicine.
[0308] In one embodiment, the present invention provides compounds of the invention or pharmaceutical compositions comprising a compound of the invention, for use in the prophylaxis and / or treatment of proliferative diseases. In particular, the term proliferative diseases refers to cancer, myeloproliferative disorders, leukemia, multiple myeloma, psoriasis, restenosis, scleroderma or fibrosis. More particularly, the term refers to cancer, leukemia, and multiple myeloma.
[0309] In another embodiment, the present invention provides the use of compounds of the invention or pharmaceutical compositions comprising a compound of the invention in the manufacture of a medicament for the prophylaxis and / or treatment of proliferative diseases. In particular, the term proliferative diseases refers to cancer, myeloproliferative disorders, leukemia, multiple myeloma, psoriasis, restenosis, scleroderma or fibrosis. More particularly, the term refers to cancer, leukemia, and multiple myeloma.
[0310] In additional methods of treatment aspects, this invention provides methods of prophylaxis and / or treatment of a mammal afflicted with proliferative diseases, which methods comprise the administration of an effective amount of a compound of the invention or one or more of the pharmaceutical compositions herein described for the treatment or prophylaxis of said condition. In particular, the term proliferative diseases refers to cancer, myeloproliferative disorders, leukemia, multiple myeloma, psoriasis, restenosis, scleroderma or fibrosis. More particularly, the term refers to cancer, leukemia, and multiple myeloma.
[0311] In a particular embodiment, the present invention provides compounds of the invention or pharmaceutical compositions comprising a compound of the invention, for use in the prophylaxis and / or treatment of cancer. In particular, the term refers to both metastatic tumour cell types (such as but not limited to, melanoma, lymphoma, leukemia, fibrosarcoma, rhabdomyosarcoma, and mastocytoma) and types of tissue carcinoma (such as but not limited to, colorectal cancer, prostate cancer, small cell lung cancer and non-small cell lung cancer, breast cancer, pancreatic cancer, bladder cancer, renal cancer, gastric cancer, glioblastoma, primary liver cancer, ovarian cancer, and uterine leiomyosarcoma). More particularly, the term refers to acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, analcancer, appendix cancer, astrocytomas, atypical teratoid / rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer (osteosarcoma and malignant fibrous histiocytoma), brain stem glioma, brain tumors, brain and spinal cord tumors, breast cancer, bronchial tumors, Burkitt lymphoma, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, embryonal tumors, endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, Ewing sarcoma family of tumors, eye cancer, retinoblastoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), gastrointestinal stromal cell tumor, germ cell tumor, glioma, hairy cell leukemia, head and neck cancer, hepatocellular (liver) cancer, hypopharyngeal cancer, intraocular melanoma, islet cell tumors (endocrine pancreas), Kaposi’s sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, hairy cell leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, lymphoma, Waldenstrom macroglobulinemia, medulloblastoma, medulloepithelioma, melanoma, mesothelioma, mouth cancer, myeloid leukemia, multiple myeloma, nasopharyngeal cancer, neuroblastoma, oral cancer, oropharyngeal cancer, osteosarcoma, malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, papillomatosis, parathyroid cancer, penile cancer, pharyngeal cancer, pineal parenchymal tumors of intermediate differentiation, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm / multiple myeloma, pleuropulmonary blastoma, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell (kidney) cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, Ewing sarcoma family of tumors, sarcoma, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach (gastric) cancer, supratentorial primitive neuroectodermal tumors, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, vulvar cancer, and Wilms tumor. Most particularly, the term refers to non-small cell lung cancer, Burkitt lymphoma, medulloblastoma, pancreatic cancer, ovarian cancer, and melanoma.
[0312] In another embodiment, the present invention provides the use of compounds of the invention or pharmaceutical compositions comprising a compound of the invention in the manufacture of a medicament for the prophylaxis and / or treatment of cancer. In particular, the term refers to both metastatic tumour cell types (such as but not limited to, melanoma, lymphoma, leukemia, fibrosarcoma, rhabdomyosarcoma, and mastocytoma) and types of tissue carcinoma (such as but not limited to, colorectal cancer, prostate cancer, small cell lung cancer and non-small cell lung cancer, breast cancer, pancreatic cancer, bladder cancer, renal cancer, gastric cancer, glioblastoma, primary liver cancer, ovarian cancer, and uterine leiomyosarcoma). More particularly, the term refers to acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, anal cancer, appendix cancer, astrocytomas, atypical teratoid / rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer (osteosarcoma and malignant fibrous histiocytoma), brain stem glioma, brain tumors, brain and spinal cord tumors, breast cancer,bronchial tumors, Burkitt lymphoma, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, embryonal tumors, endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, Ewing sarcoma family of tumors, eye cancer, retinoblastoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), gastrointestinal stromal cell tumor, germ cell tumor, glioma, hairy cell leukemia, head and neck cancer, hepatocellular (liver) cancer, hypopharyngeal cancer, intraocular melanoma, islet cell tumors (endocrine pancreas), Kaposi’s sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, hairy cell leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, lymphoma, Waldenstrom macroglobulinemia, medulloblastoma, medulloepithelioma, melanoma, mesothelioma, mouth cancer, myeloid leukemia, multiple myeloma, nasopharyngeal cancer, neuroblastoma, oral cancer, oropharyngeal cancer, osteosarcoma, malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, papillomatosis, parathyroid cancer, penile cancer, pharyngeal cancer, pineal parenchymal tumors of intermediate differentiation, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm / multiple myeloma, pleuropulmonary blastoma, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell (kidney) cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, Ewing sarcoma family of tumors, sarcoma, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach (gastric) cancer, supratentorial primitive neuroectodermal tumors, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, vulvar cancer, and Wilms tumor. Most particularly, the term refers to non-small cell lung cancer, Burkitt lymphoma, medulloblastoma, pancreatic cancer, ovarian cancer, and melanoma.
[0313] In additional method of treatment aspects, this invention provides methods of prophylaxis and / or treatment of a mammal afflicted with cancer, which methods comprise the administration of an effective amount of a compound of the invention or one or more of the pharmaceutical compositions herein described for the treatment or prophylaxis of said condition. In particular, the term refers to both metastatic tumour cell types (such as but not limited to, melanoma, lymphoma, leukemia, fibrosarcoma, rhabdomyosarcoma, and mastocytoma) and types of tissue carcinoma (such as but not limited to, colorectal cancer, prostate cancer, small cell lung cancer and non-small cell lung cancer, breast cancer, pancreatic cancer, bladder cancer, renal cancer, gastric cancer, glioblastoma, primary liver cancer, ovarian cancer, and uterine leiomyosarcoma). More particularly, the term refers to acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, anal cancer, appendix cancer, astrocytomas, atypical teratoid / rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer (osteosarcoma and malignant fibrous histiocytoma), brain stem glioma, brain tumors, brain and spinal cord tumors, breast cancer, bronchial tumors, Burkitt lymphoma, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, embryonaltumors, endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, Ewing sarcoma family of tumors, eye cancer, retinoblastoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), gastrointestinal stromal cell tumor, germ cell tumor, glioma, hairy cell leukemia, head and neck cancer, hepatocellular (liver) cancer, hypopharyngeal cancer, intraocular melanoma, islet cell tumors (endocrine pancreas), Kaposi’s sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, hairy cell leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, lymphoma, Waldenstrom macroglobulinemia, medulloblastoma, medulloepithelioma, melanoma, mesothelioma, mouth cancer, myeloid leukemia, multiple myeloma, nasopharyngeal cancer, neuroblastoma, oral cancer, oropharyngeal cancer, osteosarcoma, malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, papillomatosis, parathyroid cancer, penile cancer, pharyngeal cancer, pineal parenchymal tumors of intermediate differentiation, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm / multiple myeloma, pleuropulmonary blastoma, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell (kidney) cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, Ewing sarcoma family of tumors, sarcoma, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach (gastric) cancer, supratentorial primitive neuroectodermal tumors, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, vulvar cancer, and Wilms tumor. Most particularly, the term refers to non-small cell lung cancer, Burkitt lymphoma, medulloblastoma, pancreatic cancer, ovarian cancer, and melanoma.
[0314] In a particular embodiment, the present invention provides compounds of the invention or pharmaceutical compositions comprising a compound of the invention, for use in the prophylaxis and / or treatment of leukemia. In particular, the term refers to neoplastic diseases of the blood and blood forming organs. More particularly, the term refers to acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) and chronic lymphoblastic leukemia (CLL).
[0315] In another embodiment, the present invention provides the use of compounds of the invention or pharmaceutical compositions comprising a compound of the invention in the manufacture of a medicament for the prophylaxis and / or treatment of leukemia. In particular, the term refers to neoplastic diseases of the blood and blood forming organs. More particularly, the term refers to acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) and chronic lymphoblastic leukemia (CLL).
[0316] In additional method of treatment aspects, this invention provides methods of prophylaxis and / or treatment of a mammal afflicted with leukemia, which methods comprise the administration of an effective amount of a compound of the invention or one or more of the pharmaceutical compositions herein described for the treatment or prophylaxis of said condition. In particular, the term refers to neoplastic diseases of the blood and blood forming organs. More particularly, the term refers to acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) and chronic lymphoblastic leukemia (CLL).
[0317] Injection dose levels range from about 0.1 mg / kg / h to at least 10 mg / kg / h, all for from about 1 to about 120 h and especially 24 to 96 h. A preloading bolus of from about 0.1 mg / kg to about 10 mg / kg or more may also be administered to achieve adequate steady state levels. The maximum total dose is not expected to exceed about 1 g / day for a 40 to 80 kg human patient.
[0318] For the prophylaxis and / or treatment of long-term conditions, such as degenerative conditions, the regimen for treatment usually stretches over many months or years so oral dosing is preferred for patient convenience and tolerance. With oral dosing, one to four (1-4) regular doses daily, especially one to three (1-3) regular doses daily, typically one to two (1-2) regular doses daily, and most typically one (1) regular dose daily are representative regimens. Alternatively for long lasting effect drugs, with oral dosing, once every other week, once weekly, and once a day are representative regimens. In particular, dosage regimen can be every 1-14 days, more particularly 1-10 days, even more particularly 1-7 days, and most particularly 1-3 days.
[0319] Using these dosing patterns, each dose provides from about 1 to about 1000 mg of a compound of the invention, with particular doses each providing from about 10 to about 500 mg and especially about 30 to about 250 mg.
[0320] Transdermal doses are generally selected to provide similar or lower blood levels than are achieved using injection doses.
[0321] When used to prevent the onset of a condition, a compound of the invention will be administered to a patient at risk for developing the condition, typically on the advice and under the supervision of a physician, at the dosage levels described above. Patients at risk for developing a particular condition generally include those that have a family history of the condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the condition.
[0322] A compound of the invention can be administered as the sole active agent or it can be administered in combination with other therapeutic agents, including other compound of the inventions that demonstrate the same or a similar therapeutic activity and that are determined to be safe and efficacious for such combined administration. In a specific embodiment, co-administration of two (or more) agents allows for significantly lower doses of each to be used, thereby reducing the side effects seen.
[0323] In one embodiment, a compound of the invention or a pharmaceutical composition comprising a compound of the invention is administered as a medicament. In a specific embodiment, said pharmaceutical composition additionally comprises a further active ingredient.
[0324] In one embodiment, a compound of the invention is co-administered with another therapeutic agent for the treatment and / or prophylaxis of proliferative disorders, particular agents include but are not limited to: methotrexate, leucovorin, adriamycin, prednisone, bleomycin, cyclophosphamide, 5 -fluorouracil, paclitaxel, docetaxel, vincristine, vinblastine, vinorelbine, doxorubicin, tamoxifen, toremifene, megestrol acetate, anastrozole, goserelin, anti-HER2 monoclonal antibody (e.g. Herceptin®), capecitabine, raloxifene hydrochloride, EGFR inhibitors (e.g. Iressa®, Tarceva®, Erbitux®), VEGF inhibitors (e.g. Avastin®), proteasome inhibitors (e.g. Velcade®), Glivec® and hsp90 inhibitors (e.g. 17-AAG). Additionally, thecompound of the invention according to Formula I may be administered in combination with other therapies including, but not limited to, radiotherapy or surgery. In a specific embodiment the proliferative disorder is selected from cancer, myeloproliferative disease or leukemia.
[0325] By co-administration is included any means of delivering two or more therapeutic agents to the patient as part of the same treatment regime, as will be apparent to the skilled person. Whilst the two or more agents may be administered simultaneously in a single formulation, i. e. as a single pharmaceutical composition, this is not essential. The agents may be administered in different formulations and at different times.CHEMICAL SYNTHETIC PROCEDURESGeneral
[0326] The compound of the invention can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e. reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
[0327] Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. The choice of a suitable protecting group for a particular functional group as well as suitable conditions for protection and deprotection are well known in the art (Wuts & Greene 2006).
[0328] The following methods are presented with details as to the preparation of a compound of the invention as defined hereinabove and the comparative examples. A compound of the invention may be prepared from known or commercially available starting materials and reagents by one skilled in the art of organic synthesis.
[0329] All reagents are of commercial grade and are used as received without further purification, unless otherwise stated. Commercially available anhydrous solvents are used for reactions conducted under inert atmosphere. Reagent grade solvents are used in all other cases, unless otherwise specified. Column chromatography is performed on silica gel 60 (35-70 pm) or with Biotage® Sfar KP -Amino D, Biotage® Sfar HC D, or Interchim® PuriFlash® Si HC flash chromatography cartridges. Thin layer chromatography is carried out using pre-coated silica gel F-254 plates (thickness 0.25 mm). Biotage® ISOLUTE® phase separators (e.g. , Cat# 120-1907-E) are used for aqueous phase separation. ’H NMR spectra are recorded on a Bruker Avance NEO 400 NMR spectrometer (400 MHz), a Bruker Avance 400 NMR spectrometer (400 MHz), a Bruker Avance III HD NMR spectrometer (400 MHz), or a Bruker Avance DRX 500 spectrometer (500 MHz). Chemical shifts (5) for ’H NMR spectra are reported in parts per million (ppm) relative to tetramethylsilane (50.00) or the appropriate residual solvent peak, e.g. CHCls (57.26), MeOH (53.31), or DMSO (5 2.50 ppm), as internal reference. Multiplicities are given as singlet (s), doublet (d), triplet (t),multiplet (m) and broad (br). LCMS : Electrospray MS spectra are obtained on a Waters Acquity H-Class UPLC system coupled to a UV PDA detector and to a Waters SQD or SQD2 mass spectrometer. Columns used: Waters Acquity UPLC BEH C18 1.7 pm, 2.1 mm ID x 30 / 50 mm L; Waters Acquity UPLC CSH C18 1.7 pm, 2.1 mm ID x 50 / 100 mm L; Waters Acquity UPLC CSH PhenylHexyl 1.7 pm, 2.1 mm ID x 100 mm L; Waters Acquity UPLC HSS PPP 1.8 pm, 2.1 mm ID x 100 mm L. The methods are using ACN / water or MeOH / water gradients with either 0.1% formic acid in both mobile phases, 0.05% NH4OH in both mobile phases, or 10 mM NH4HCO3 in water (adjusted to pH 10 with ammonia). Preparative HPLC is performed on a Waters AutoPurification system with UV and MS detection using Waters XBridge BEH C18 OBD 30 mm ID x 100 / 150 mm L columns and ACN / water gradients with either 0.1% formic acid in both mobile phases, 0.1% diethylamine in both mobile phases, 0.1% formic acid in water, or 10 mM NH4HCO3 in water (adjusted to pH 10 with ammonia), or on a Buchi® Pure C-850 Flash with UV and ESDL detection using Buchi® C18 AQ 100 A 250 x 20 mm column and using ACN / water gradients with either 0.1% formic acid in both mobile phases or 0.05% NH4OH in both mobile phases. Chiral SFC : Electrospray MS spectra are obtained on a Waters Acquity UPC2 system coupled to a UV PDA detector and to a Waters QDA mass spectrometer. Columns used: Daicel CHIRALPAK AD-3 3 pm, 4.6 mm ID x 100 mm L ; Daicel CHIRALPAK AS-3 3 pm, 4.6 mm ID x 100 mm L ; Daicel CHIRALPAK IC-3 3 pm, 4.6 mm ID x 100 mm L ; Daicel CHIRALPAK IH-3 3 pm, 4.6 mm ID x 100 mm L ; Daicel CHIRALCEL OD-3 3 pm, 4.6 mm ID x 100 mm L ; Daicel CHIRALCEL OD-3 3 pm, 4.6 mm ID x 100 mm L ; Daicel CHIRALPAK IG-3 3 pm, 4.6 mm ID x 100 mm L ; Daicel CHIRALPAK IA-3 3 pm, 4.6 mm ID x 100 mm L ; Daicel CHIRALPAK IBN-3 3 pm, 4.6 mm ID x 100 mm L ; Phenomenex Lux Cellulose-2 3 pm, 4.6 mm ID x 100 mm L ; Phenomenex Lux Cellulose-43 pm, 4.6 mm ID x 100 mm L ; Phenomenex Lux Amylose-23 pm, 4.6 mm ID x 100 mm L. The methods are using CCL / MeOH or CCL / EtOH or CCL / iPrOH gradients or isocratics with sometimes 0.3% iPrNH2 in alcohol. Preparative SFC is performed on a PIC SOLUTIION PREP200 or PREP 100 systems with UV detection using same stationary phases as the analytical scale (listing above) but with 2 different dimensions 5 pm, 20 mm ID ; 250 mm L or 5 pm, 30 mm ID ; 250 mm L and CCL / MeOH or CCL / EtOH or CO2 / iPrOH gradients or isocratics with sometimes 0.3% iPrNH2 in alcohol. Achiral SFC ; Electrospray MS spectra are obtained on a Waters Acquity UPC2 system coupled to a UV PDA detector and to a Waters QDA mass spectrometer. Columns used PrincetonSFC 2-Ethylpyridine 3 pm, 4.6 mm ID x 100 mm L ; PrincetonSFC Cyano 3 pm, 4.6 mm ID x 100 mm L ; PrincetonSFC Amino 3 pm, 4.6 mm ID x 100 mm L ; PrincetonSFC Diethylaminopropyl 3 pm, 4.6 mm ID x 100 mm L ; PrincetonSFC Diol 3 pm, 4.6 mm ID x 100 mm L . The methods are using CCL / MeOH gradients or isocratics with sometimes 0.3% iPrNH2 in alcohol. Preparative SFC is performed on a PIC SOLUTIION PREP200 or PREP 100 systems with UV detection using same stationary phases as the analytical scale (listing above) but with a different dimensions 5 pm, 20 mm ID ; 250 mm L and CO2 / MeOH gradients or isocratics with sometimes 0.3% iPrNH2 in alcohol.Table I. List of abbreviations used in the experimental section:Abbreviation Definition Abbreviation Definition ACN acetonitrile high-performance liquid HPLCchromatography AcOH acetic acidInt intermediate AcOK potassium acetatem multiplet aq. aqueousMeOH methanol atm atmospheremin minuteBoc tert-butyloxy-carbonylmmol millimole Cpd compoundMS mass spectrometry d doubletMtd method DCM dichloromethaneMW molecular weight dd doublet of doubletsMW (calcd) molecular weight calculated N, A'-diisopropylcthylamincDIPEA(CAS# 7087-68-5) MW (obsd) molecular weight observed DMAc N, A'-di m ethyl acetam i de NA not available DMF N, A'-di m ethyl form am ide NBS N-bromosuccinimide DMSO dimethylsulfoxide P(Cy)3Tricyclohexylphosphine 1 , 1 '-bis(diphenylphosphino) [1,1 '-bis(diphenylphosphino) dppf ferrocene ferrocene]dichloropalladium(I Pd(dppf)Cl2- (CAS# 12150-46-8) I) complex with dichloro DCMdt doublet of triplets methane (CAS# 95464-05-4) eq- equivalentPd(OAc)2Palladium(II) acetate EtOAc ethyl acetateTetrakis(triphenylphosphine) Et2O diethyl ether Pd(PPh3)4palladium(O) EtOH ethanol Bis(triphenylphosphine)palla Pd(PPh3)2Cl2h hour dium(II) dichloride 1- PPm parts-per-million [bis(dimethylamino)methylen Zsopropylaminc / 2- iPrNH2e]-lH-l,2,3-triazolo[4,5- propanamine HATEb]pyridinium 3-oxidzPrOH Zsopropanol / 2-propanol hexafluorophosphateq quartet (CAS# 148893-10-1)RT room temperatureAbbreviation Definition Abbreviation Definitions singlet 4,5-Bis(diphenylphos XantPhos phino)-9,9-dimethylxanthene t triplet(CAS# 161265-03-8) td triplet of doublets(2-Dicyclohexylphosphino- TEA triethylamine 2',4',6'-triisopropyl-l,l'- TFA trifluoroacetic acid biphenyl) [2-(2'-amino- 1,1'- THF tetrahydrofuran Xphos Pd G3 biphenyl)]palladium(II) methanesulfonate TBAF Tetrabutylammonium fluoride2,4,6-tripropyl-l,3,5,2,4,6- (CAS# 1445085-55-1) trioxatriphosphorinane-2,4,6- T3P DMAc N, / V-dimethylacetamide trioxyde(CAS# 68957-94-8) DMF N, / V-dimethylformamide / BuXPhos-Pd-G3. [(2-Di-tert- DMSO dimethylsulfoxide butylphosphino-2',4',6'- 1 , 1 '-bis(diphenylphosphino) triisopropyl- 1 , 1 '-biphenyl)-2- dppf ferrocene tBuXPhos Pd(2'-amino- 1 , 1 '-biphenyl)] (CAS# 12150-46-8) G3palladium (II)methanesulfonate(CAS# 1447963-75-8)SYNTHETIC PREPARATION OF THE COMPOUNDS OF THE INVENTIONExample 1. General synthetic methodsGeneral method Al : Suzuki couplingR1R4-X R26 R R4— R1'O' "O'3
[0330] A stirred solution of the halogenated derivative (1.0 to 1.5 eq.) and the boronic ester derivative (1.0 to 1.5 eq.) and base (CS2CO3 or K2CO3: 2.0 to 3.0 eq.) in a mix of l,4-dioxane / H2O (ratio : 9 / 1 to 10 / 1 ; cone. = 0.05 to 0.13 M) was degassed either with argon or nitrogen for 5 min. Catalyst (Pd(dppf)C12'DCM or XPhosPdG3: 0.025 to 0.1 eq.) was then added, and the reaction was stirred at 90 °C for 1 to 32 hours. SiliaMetS thiol silica (Silicycle, 40-63 urn) could be added and the resulting suspension was stirred at rt for 1 h and the mixture was fdtered over celite The reaction mixture could also be either directly evaporated or fdtrated over celite before evaporation to dryness. Then the mixture was purified or poured onto H2O, extracted EtOAc, dried over MgSCE, filtered and the solvent was evaporated then purified by column chromatography on silica gel and / or if needed, by preparative HPLC to afford the desired compound.
[0331] Illustrative synthesis of Int-24
[0332] In a vial, to a stirred solution of 2-bromo-l-fluoro-4-iodobenzene (CAS# : 811842-30-5 ; 1.1 eq., 347.67 mg, 0.15 mb, 1.16 mmol) and Int-25 (1 eq., 410 mg, 1.05 mmol) in dioxane (9.12 mb) and water (1.013 mb) was added CS2CO3 (2 eq., 684.48 mg, 2.101 mmol). The reaction mixture was backfdled 3 times with N2 and then Pd(dppf)C12 • DCM (0.05 eq., 42.89 mg, 0.053 mmol) was added, then the reaction was backfdled 3 times with N2 and stirred at 90 °C for 2 h. The mixture was poured into water and extracted with EtOAc (3 x). The combined organic layers were combined, washed with NaCl (sat.), dried over MgSO4, fdtered and evaporated under vacuum to give a crude which was purified by normal phase LC (irregular SiOH 40-60 pm, 20 g, Agela, liquid loading (DCM), mobile phase : DCM / MeOH from 100 / 0 to 95 / 5 for 20 CV). Fractions containing product were combined and evaporated to dryness to give a mixture which was purified by reverse phase LC (Column YMC 40 g, Focused gradient MeCN / aq.NFLHCCE 0.2% Focused gradient from 0 / 100 to 45 / 55 for 15CV). The fractions containing the desired product were evaporated, leading to Int-24 (208 mg, 0.55 mmol, 52%) as a yellow oil.General method A2 : Suzuki couplingR1R4-X R26 R R4— R1'O' "O'3
[0333] A stirred solution of the halogenated derivative (1.0 to 1.2 eq.) and the boronic ester derivative (1.0 to 1.1 eq.) and Base (CS2CO3 or aqueous solution of K2CO3 2M: 2.0 to 3.0 eq.) in a either 1,4-dioxane or a mix of l,4-dioxane / H2O (ratio : 6 / 1 to 10 / 1) (cone. = 0.07 to 0.16 M) was degassed either with argon or nitrogen for 5 min. Catalyst (Pd(dppf)C12-DCM orXPhosPdG3 orPd(Ph3)4: 0.05 to 0.2 eq.) was then added, and the reaction was heated to 120 °C using one single mode microwave (Anton-Paar) with a power output ranging from 0 to 850 W for 30 min to 2 hours. SiliaMetS thiol silica (Silicycle, 40-63 um) could be added and the resulting suspension was stirred at rt for 1 h and the mixture was fdtered over celite The reaction mixture could also be either directly evaporated or fdtrated over celite before evaporation to dryness. Then the mixture was purified or poured onto H2O, extracted EtOAc, dried over MgSCL, filtered and the solvent was evaporated then purified by column chromatography on silica gel and / or if needed, by preparative HPLC to afford the desired compound.Illustrative synthesis ofInt-7
[0334] In a sealed tube, to amixture ofInt-3 (1 eq., 350 mg, 0.72 mmol), 2-bromo-l-fluoro-4-iodobenzene (CAS# : 811842-30-5 ; 1.1 eq., 238.15 mg, 0.79 mmol), CS2CO3 (2 eq., 468.87 mg, 1.44 mmol) andPd(dppf)C12'DCM (0.1 eq., 58.76 mg, 0.072 mmol) were added 1,4-dioxane (5.87 mL) and water (0.59 mL). The resulting mixture was heated at 120 °C using one single mode microwave (Anton Paar) with a power output ranging from 0 to 850 W for 30 min. SiliaMetS thiol silica (Silicycle, 40-63 um) (150 mg, ) was added. The resulting suspension was stirred at rt for 1 h and the mixture was filtered over celite and then concentrated under reduced pressure to give a crude which was purified by preparative LC (irregular SiOH, 40-60 pm, 12 g Agela, liquid injection (DCM), mobile phase gradient : DCM / MeOH from 100 / 0 to 96 / 4). Fractions containing product were combined and evaporated to dryness to give Int-7 (278 mg, 0.58 mmol, 81%) as a brown gum.General method B : Miyaura borylation - Suzuki cross coupling(Bpin)2. KOAc, R4-XCatacXiumPdG3, Base, Catalyst,1 ,4-dioxane R1waterR1— X R26 R R4— R1'O' "O'3
[0335] A stirred solution of halogenated derivative 1 (1.0 eq.) in 1,4-dioxane (cone. 0.12 M) was added bis(pinacolato)diboron (1.3 to 2.0 eq.) and KOAc (3.0 eq.). The resulting mixture was degassed with N2 and catacxium A Pd G3 (0.1 eq. to 0.2 eq.) was added. The resulting mixture was heated either using one single mode microwave (Anton Paar) with a power output ranging from 0 to 850 W or by traditional heating plate at 80 to 150 °C for 30 min to 8 hours.
[0336] The reaction mixture was cooled down to rt then halogenated derivative 2 (1.0 to 1.1 eq.), Base (CS2CO3 or K2CO3 3.0 eq.), Catalyst (Pd(dppf)C12-DCM or catacxium A Pd G3 or none (0.1 eq.) and water (10 to 25 %Vi,4-dioxane) were added, the mixture was refded with N2 gas then heated either using one single mode micro wave (Anton Paar) with a power output ranging from 0 to 850 W or by traditional heating plate at 80 to 150 °C for 30 min to 14 hours. The reaction mixture is either directly or, after filtration over celite, evaporated to dryness and purified or poured onto H2O, extracted EtOAc, dried over MgSCfi. filtered and the solvent was evaporated then purified by column chromatography on silica gel and / or if needed, by preparative HPLC to afford the desired compound.Illustrative synthesis of Int-23
[0337] In a MW tube, to Int-24 (1 eq., 191 mg, 0.501 mmol) in 1,4-dioxane (4.063 mL) was added bis(pinacolato)diboron (CAS# : 73183-34-3 ; 2 eq., 254.44 mg, 1.002 mmol) and KOAc (3 eq., 147.505 mg, 1.503 mmol). The resulting mixture was degassed with N2 and catacxium A Pd G3 (0.1 eq., 36.49 mg, 0.0501 mmol) was added. The resulting mixture was heated at 150 °C using one single mode microwave (Anton Paar) with a power output ranging from 0 to 850 W for 30 min. The reaction mixture was cooled down to rt then 2-(3-iodophenyl)-5-methyl-l,3-oxazole (CAS# 1092114-39-0 ; 1.1 eq., 157.107 mg, 0.55 mmol), CS2CO3 (3 eq., 489.7 mg, 1.503 mmol), Pd(dppf)C12'DCM (0.1 eq., 40.91 mg, 0.0501 mmol) andwater (0.61 mL) were added, the mixture was refiled with N2 gas then heated at 150 °C using one single mode microwave (Anton Paar) with a power output ranging from 0 to 850 W for 30 min. The mixture was fdtered over celite and then concentrated under reduced pressure to give a crude which was purified by preparative LC (irregular SiOH, 40-60 pm, 12 g Agela, liquid injection (DCM), mobile phase, isocratic flow 100% DCM for 3 CV gradient : DCM / MeOH from 100 / 0 to 98 / 2 for 25 CV and gradient DCM / MeOH from 98 / 2 to 95 / 5 for 5CV ). The fractions containing product were combined and evaporated to dryness to give Int-23 (121 mg, 0.26 mmol, 53%) as a yellow oil.General method C : Miyaura borylationR1"'
[0338] To a stirred solution of the halogenated derivative (1.0 eq.) and either 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2- dioxaborolane or 4,4,5,5-tetraethyl-2-(4,4,5,5-tetraethyl-l,3,2-dioxaborolan-2-yl)-l,3,2- dioxaborolane (1.4 to 2.0 eq.) in 1,4-dioxane (cone. 0.08 to 0.2 M) was added AcOK (3.0 eq.). The mixture was degassed with argon or N2 for 5 min. Then catalyst (Pd(dppf)C12-DCM or CatacXiumDpG3 : 0.05 to 0.1 eq.) was added and the reaction was heated either using one single mode micro wave (Anton Paar) with a power output ranging from 0 to 850 W or by traditional heating plate at 80 to 150 °C for 30 min to 18 hours. The reaction mixture is either directly or, after filtration over celite, evaporated to dryness and use as it or purified or poured onto H2O, extracted EtOAc, dried over MgSCfi. filtered and the solvent was evaporated then purified by column chromatography on silica gel and / or if needed, by preparative HPLC to afford the desired compound. Illustrative synthesis of Int-3O-
[0339] To a stirred mixture of Int-4 (1 eq., 4.8 g, 12.52 mmol), 4,4,5,5-tetraethyl-2-(4,4,5,5-tetraethyl- l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (CAS# : 2247367-07-1 ; 1.6 eq., 7.34 g, 20.039 mmol), KOAc (3 eq., 3.69 g, 37.57 mmol) and Pd(dppf)C12 • DCM (0.1 eq., 1.023 g, 1.25 mmol) in 1,4-dioxane (96.045 mL) was purged with N2 for 5 min then stirred at 100 °C for 16 h. The reaction mixture was filtered over Celite, the cake was washed with EtOAc and the filtrate was concentrated in vacuo to obtain which was purified by preparative LC (irregular SiOH, 40-60 pm, 220 g Agela, liquid injection (DCM), mobile phase gradient : DCM / MeOH from 100 / 0 to 96 / 4). Fractions containing product were combined and evaporated to dryness then coevaporated with heptane to give Int-3 (4.26 g, 8.77 mmol, 70%) as a brown foam.General method D : Amide couplingH2N'
[0340] Coupling reagent (T3P 50% in EtOAc or HATU : 1.3 to 1.9 eq.) was added portionwise to a solution of carboxylic acid (1.0 to 1.1 eq.), amine (1.0 to 1.4 eq.) and DiPEA (3.0 to 10.0 eq.) in solvent (DCM or DMAc : cone. 0.08 to 0.35 M) then the reaction mixture was stirred at 20 °C for 1 to 4 hours. The reaction mixture was diluted with DCM and either water or a mixture of brine and water 1 / 1, the organic layer was dried over Na2SC>4 or MgSCE, filtered and the solvent was evaporated then purified by column chromatography on silica gel and / or if needed, by preparative HPLC to afford the desired compound Illustrative synthesis of Int-4
[0341] T3P 50% in EtOAc (1.3 eq., 11.58 g, 10.84 mL, 18.204 mmol) was added dropwise to a solution of 3-methanesulfonyl-4-methylbenzoic acid (CAS# : 51522-22-6 ; 1 eq., 3 g, 14.003 mmol), l-(4-bromopyridin-2-yl)methanamine (CAS# : 865156-50-9 ; 1.1 eq., 2.88 g, 15.403 mmol) and DIEA (5 eq., 9.049 g, 12.2 mL, 70.015 mmol) in DCM (65 mL) then the reaction mixture was stirred at rt for 1 h. Water and DCM were added. The organic layer was separated (Chromabond) and concentrated in vacuo to give a crude which was purified by flash chromatography (irregular SiOH 40-60 pm, 12 g, Agela, liquid loading (DCM), mobile phase : DCM / MeOH from 100 / 0 to 96 / 4). Fractions containing product were combined and evaporated to dryness to give Int-4 (4.8 g, 89%).General methode E : Oxazole formationNH
[0342] To a solution of propargyl amide (1.0 eq.) in DMSO (cone. 0.25 to 0.35 M) was added CS2CO3 (2.0 eq.). The mixture was stirred at 100 °C for 3 to 8 h. The reaction mixture was quenched with water and extracted with EtOAc. The combined organic extracts were washed with water twice, then with brine, dried over Na2SO4, filtered and the solvent was evaporated then purified by column chromatography on silica gel and / or if needed, by preparative HPLC to afford the desired compound.Illustrative synthesis of Int-8
[0343] To a solution of 2-chloro-N-(prop-2-yn-l-yl)pyridine-4-carboxamide (CAS# 131418-12-7 ; 1 eq., 2.15 g, 11.047 mmol) in DMSO (43 mL) was added CS2CO3 (2 eq., 7.2 g, 22.094 mmol). The mixture was stirred at 100 °C for 4 h. The reaction mixture was quenched with water and extracted with EtOAc (3 x 100 mL). The combined organic extracts were washed with water twice, then with sat brine, dried over Na2SO4,filtered and concentrated under pressure to give a crude which was purified by normal phase preparative LC (Stationary phase : irregular SiOH, Agela, 80 g, liquid loading (DCM) Mobile phase Gradient from Heptane / EtOAc 100:0 to 50:50 over 15 CV) to give Int-8 (1.033 g, 5.308 mmol, 48.047%) as a white solid.General method F : Acidic deprotection"HCIX= NH or O X = NH or O
[0344] To a solution of protected compound (1.0 eq.) in DCM (cone. 0.055 to 0.08 M) was added HC14N in 1,4-dioxane (6.0 to 10.0 eq.) and the solution was allowed to stir at 20 °C for 1 to 16 hours. The resulting suspension was filtered. The cake was washed with either DCM or heptane twice. The solid was collected and dried under high vacuum to afford the desired compound.Illustrative synthesis of Int-22HCI
[0345] To a solution of Int-23 (1 eq., 109 mg, 0.24 mmol) in dichloromethane (3.71 mb) was added HC1 4N in 1,4-dioxane (9.4 eq., 0.56 mb, 2.23 mmol). The mixture was stirred at rt for 2 h. The resulting suspension was filtered. The cake was washed with DCM twice. The solid was collected and dried under high vacuum at 25 °C to give, without further purification, Int-22 (111 mg, 0.24 mmol, 99.8%) as a light orange solid.Preparation of the compounds of the inventionInt-17
[0346] To a degassed mixture of Int-18 (1.0 eq., 131 mg, 0.37 mmol) and PdC12(dppf).DCM (0.1 eq., 30.57 mg, 0.037 mmol) in THF (3.82 mb) was added bromo(cyclopropyl)zinc (1.1 eq., 0.82 mb, 0.41 mmol) under nitrogen. The resulting mixture was stirred at rt for 18 h. Bromo(cyclopropyl)zinc (CAS#: 126403-68-7 ; 1.1 eq., 0.82 mb, 0.41 mmol) was added and the reaction mixture was stirred at 65 °C for 5 h. Water and EtOAc were added to the mixture. The aqueous layer was extracted with EtOAc, then the combined organic layers were washed with brine, dried over Na2SO4, filtered and evaporated to give a crude which was purified by normal phase preparative LC (irregular SiOH, 40-60 pm, 20 g Agela, liquid injection (DCM), mobile phase gradient : heptane / EtOAc from 100:0 to 50:50 over 12 CV). The fractions containing product were combined and evaporated to give Int-17 (74 mg, 0.28 mmol, 75%) as a colorless oil.Int-18
[0347] To a mixture of 2-(3-bromophenyl)-l,3-oxazole (CAS# 885274-35-1 ; 1 eq., 347 mg, 1.55 mmol) and NIS (CAS# 516-12-1 ; 2.2 eq., 766.56 mg, 3.407 mmol) in CHCls (15.27 mL) was added TFA (0.1 eq., 17.66 mg, 0.012 mL, 0.15 mmol) then the resulting mixture was stirred at 65 °C for 16 h. The heating was carried on for 8 h. The mixture was stirred at 75 °C for 16 h. An extra amount of TFA (0.1 eq., 17.66 mg, 0.012 mL, 0.15 mmol) was added and the heating was carried on at 75 °C for 8 h. The mixture was stirred at the same temperature for 16 h. An extra amount of NIS (0.5 eq., 174.22 mg, 0.77 mmol) was added and the heating was carried on for 3 h. The reaction was cooled down to rt. The reaction was added to a mixture of 10% aq. Na2S20s and 10% aq. NaHCCf. The layers were separated, and the aqueous layer was extracted once again with DCM. The combined organic layers were dried over MgSO4, fdtered and the solvent was removed in vacuo to give the crude which was directly purified by normal phase preparative LC (irregular SiOH, 40-60 pm, Agela 80 g, liquid loading (DCM), mobile phase gradient: from heptane / EtOAc 100 / 0 to 60 / 40). The fractions containing product were combined and evaporated to dryness to give Int-18 (387 mg).Int-19
[0348] A 40 mL reaction vial equipped with a magnetic stirring bar was charged with Int-20 (1 eq., 264 mg, 1.063 mmol), MeOH (7.16 mL), water (3.56 mL) & oxone (6 eq., 1941.84 mg, 6.38 mmol). The reaction mixture was stirred at rt for 60 h. The reaction mixture was heated to 50 °C for 7 h. Heating at 50 °C was prolonged for 16 h. More oxone (2 eq., 323.64 mg, 2.13 mmol) was added and heating at 50 °C was prolonged for 7 h. More oxone (2 eq., 323.64 mg, 2.13 mmol) was added and heating at 50 °C was prolonged for 16 h. The reaction mixture was diluted with water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed successively with sat brine, dried over sodium sulfate, fdtered and concentrated in vacuo to give a mixture of Int-19 as a white sticky solid (292 mg, 92%). Int-20
[0349] A 40 mL reaction vial was charged with Int-21 (1 eq., 300 mg, 1.033 mmol) & EtOH (10.3 mL) The reaction mixture was cooled to 0 °C and NaBFL (2 eq., 78.2 mg, 2.067 mmol) was added. The reaction mixture was warmed to rt and stirred for 2 h. The reaction mixture was cooled to 0 °C, quenched with 0.5 M aq HC1 (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed satbrine (25 mL), dried over sodium sulfate, fdtered and concentrated in vacuo to give Int-20 (256.6 mg, 1.03 mmol, 100%) as a white solid.Int-21o
[0350] A 40 mL reaction vial equipped with a magnetic stirring bar was charged with 4-methyl-3-sulfanylbenzoic acid (CAS# : 200720-35-0 ; 1 eq., 250 mg, 1.49 mmol) & DMF (10 mL). The reaction mixture was cooled to 0 °C and EtsN (3 eq., 451.19 mg, 0.62 mL, 4.46 mmol) & ethyl bromodifluoroacetate (CAS# : 667-27-6 ; 1.5 eq., 452.52 mg, 0.29 mL, 2.23 mmol) were added dropwise successively. The reaction mixture was warmed to rt and stirred for 1 h. The reaction mixture was quenched with 0.2 M aq HC1 (50 mL) and extracted with EtOAc (100 mL). The aqueous layer was washed with 0.2 M aq HC1 (2 x 50 mL) and sat brine (50 mL), dried over sodium sulfate, fdtered and concentrated in vacuo to give a crude which was purified by normal phase flash chromatography (irregular SiOH, 20 g Agela, liquid injection (DCM), mobile phase gradient: DCM / MeOH 100:0 to 90:10 over 15 CV. Pure fractions were combined and concentrated in vacuo to give Int-21 (379 mg, 1.306 mmol, 88%) as a white solid.Int-26
[0351] In a sealed bomb were added 2-(5-bromo-2-methylbenzenesulfonyl)ethan-l-ol (CAS# 1895543-43-7 ; 1 eq., 2.22 g, 7.95 mmol) and TEA (6 eq., 4.88 g, 6.7 mL, 47.72 mmol) in H2O (13.16 mL) and Dioxane (82 mL) then [l,T-bis(diphenylphosphino)ferrocene]dichloropalladium(ii) complex with dichloromethane 95+% (0.1 eq., 0.65 g, 0.8 mmol). The sealed bomb was filled with CO (5 bar). The mixture was heated at 120 °C for 18 h. The mixture was filtered over a pad of celite. The pad was eluted with EtOAc. The filtrate was concentrated in vacuo to give Int-26 (4.6 g, 99.9%) as a brown solid.Int-30
[0352] In a presure vessel reactor were added Int_31 (1 eq., 200 mg, 0.67 mmol) and K2CO3 (1.5 eq., 139.46 mg, 1.009 mmol) in DMSO (9.56 mL) and H2O (0.93 mL) then Palladium acetate (0.1 eq., 11.14 mg, 0.067 mmol) and l,3-bis(dicyclohexylphosphino)propane bis(tetrafluoroborate) (0.2 eq., 82.15 mg, 0.13 mmol) were added. The reaction mixture was stirred under 5 bars of CO () at 100 °C for 18 h. The mixture was diluted with H2O and brine and fdtered over a pad of celite. EtOAc was added to the fdtrate and the layers were separated. The aqueous layer was extracted once with EtOAc and the organic layer was discarded. The aqueous layer was acidified until pH ~3 with IM HC1, then extracted 3 times with DCM,dried over Na2SC>4, filtered and concentrated under vacuum to give Int-30 (145 mg, 0.55 mmol, 82%) as a pale yellow oil.Int-31
[0353] A reaction vial was charged with Int-32 (1 eq., 905 mg, 2.67 mmol) & isopropanol (34 mL). The reaction mixture was cooled to 0 °C and NaBH (2 eq., 201.88 mg, 5.34 mmol) was added. The reaction mixture was warmed to rt and stirred for 2 h. Aq. HC1 IN and EtOAc were added to the mixture then the layers were separated. The aqueous layer was extracted with EtOAc then the combined organic layers were washed with brine, dried over Na2SO4, filtered and evaporated to give Int-31 (768 mg, 2.58 mmol, 97%) as a pale yellow oil.Int-32
[0354] At 0 °C, ruthenium trichloride (0.05 eq., 28.7 mg, 0.14 mmol) was added to a solution of Int-33 (1 eq., 966 mg, 2.77 mmol), NalC (3.3 eq., 1953 mg, 9.13 mmol) in DCE (5.1mL), CHsCN (4.1 mL) and water (3.27 mL). The reaction mixture was stirred at rt for 18 h. The reaction was diluted with DCM. The salts were filtered over a pad of celite and the filtrate was washed with HC1 IM. The organics layers were combined, dried over Na2SC>4, filtered and the solvent was evaporated under vacuo to give Int-32 (905 mg, 2.67 mmol, 96%) as a pale brown oil.Int-33
[0355] A reaction vial equipped with a magnetic stirring bar was charged with 5-bromo-2-methylbenzene- 1 -thiol (CAS# : 69321-55-7 ; 1 eq., 500 mg, 2.46 mmol) & DMF (16 mL) then the reaction mixture was cooled to 0 °C. EtsN (3 eq., 747.36 mg, 1.03 mL, 7.39 mmol) & ethyl bromofluoroacetate (CAS# : 401-55-8 ; 1.5 eq., 683.13 mg, 0.44 mL, 3.69 mmol) were added dropwise successively. The reaction mixture was warmed to rt and stirred for 2 h. EtOAc and water were added. The aqueous layer was extracted with EtOAc then the combined organic layers were washed with water, dried over Na2SO4, filtered and evaporated to give Int-33 (752 mg, 2.45 mmol, 99%) as an orange oil.Int-37
[0356] A mixture of l-bromo-3-(isocyanomethyl)benzene (CAS# : 31938-07-5 ; 1 eq., 430 mg, 2.19 mmol), 2-cyclopropylacetyl chloride (CAS# : 54322-65-5 ; 1.3 eq., 338.057 mg, 2.85 mmol), 2,6-dimethylpyridine (1 eq., 235 mg, 0.26 mL, 2.19 mmol) in toluene (21.5 mL) was stirred at 80 °C overnight. The reaction mixture was poured into water and extracted with EtOAc (3 x). The combined organic layers were acidified with HC1 IM, dried over Na2SC>4 and filtered to a crude which was directly purified by normal phase flash chromatography (irregular SiOH, 12 g Agela, liquid injection (DCM), mobile phase gradient: heptane / EtOAc 100 / 0 to 50 / 50 over 15 CV). Pure fractions were combined and concentrated in vacuum to Int-37 (20 mg, 0.072 mmol, 3.3%) as white powder.Int-42
[0357] To a stirred solution of Int-43 (1 eq., 220 mg, 0.56 mmol) in DCM (5.4 mL) at rt was added in one quick fraction TBDMSC1 (CAS# : 18162-48-6 ; 2 eq., 168.62 mg, 0.19 mL, 1.12 mmol) and IH-imidazol (4 eq., 152.3 mg, 2.24 mmol). The solution was allowed to stir at this temperature 2 hours. The solution was diluted in DCM and washed successively by an aq. sol. of 10% NH4CI, the an aq. sol. of sat. NaHCOs and brine. The organic layer was dried over MgSO4, filtered and evaporated to dryness to afford a crude which was o p"urified by normal phase LC (irregular SiOH 40-60 pm, 24 g, Agela, liquid loading (DCM), mobile phase : Heptane / EtOAc from 90 / 10 to 50 / 50). The fraction containing compound was evaporated to dryness to afford Int-42 (257 mg, 0.507 mmol, 91%).Table II. Intermediates used towards the compounds of the invention.SM = Starting Material, Mtd = Method, MS Mes’d = Measured mass, NA = not measuredMSInt# Structure Name SM Mtd MW Mes’d 4-methyl-3- (methylsulfonyl)-N-((4- Int-2(3-(4,4,5,5-tetraethyl- + [M-H]+Int-1 C 562.5l,3,2-dioxaborolan-2- CAS# 563.3 yl)phenyl)pyridin-2- 2247367-07-1yl)methyl)benzamideN-((4-(3- Int-3 [M-H]+Int-2 bromophenyl)pyridin-2- + Al 459.4 459.2 yl)methyl)-4-methyl-3 - CAS# 461.2MS Int# Structure Name SM Mtd MW Mes’d (methylsulfonyl)benzami 591-18-4oO de°^ \O / 4-methyl-3- J* vIZo= / (methylsulfonyl)-N-((4- Int-4(4,4,5,5-tetraethyl-l,3,2- + [M-H]+Int-3 „ 0 0 ° \ / C 486.4dioxaborolan-2- CAS# 487.3 1 oOT O- yl)pyridin-2- 2247367-07-1zOT -nyl)methyl)benzamideCAS#N-((4-bromopyridin-2- 0 0 51522-22-6 [M-H]+yl)methyl)-4-methyl-3 - Int-4 + D 383.3 383.1(methylsulfonyl)benzamiCAS# 385.1 de865156-50-9N-((4-(4-methoxy-3- (4,4,5,5-tetramethyl- Int-6l,3,2-dioxaborolan-2- + [M-H]+Int-5 yl)phenyl)pyridin-2- C 536.5CAS# 537.3 yl)methyl)-4-methyl-3 - 73183-34-3 (methylsulfonyl)benzamideN-((4-(3-bromo-4- Int-3methoxyphenyl)pyridin- [M-H]+n0Ax0 +Int-6 2-yl)methyl)-4-methyl-3- Al 489.4 489.1CAS#JUHu (methylsulfonyl)benzami 491.0182056-39-9deN-((4-(3-bromo-4- Int-3fluorophenyl)pyridin-2- [M-H]++Int-7 yl)methyl)-4-methyl-3 - A2 477.4 477.2CAS#(methylsulfonyl)benzami 479.1811842-30-5deCAS# [M-H] N-*.+2-(2-chloropyridin-4-yl)- Int-8CIX| / ^yXc / - 131418-12-7 E 194.6 195.05 -methyloxazole196.9 N-((4-(3- Int-10bromophenyl)pyridin-2- [M-H]++Int-9 yl)methyl)-2,3-dihydro- Al 487.4 487.1CAS#5H- 489.0591-18-4benzo[e] [l,4]oxathiepine-MS Int# Structure Name SM Mtd MW Mes’d 8-carboxamide 1,1- If dioxideN-((4-(4,4,5,5-tetraethyl- l,3,2-dioxaborolan-2- Int-11yl)pyridin-2-yl)methyl)- + [M-H]+Int-100n0 / 2,3-dihydro-5H- C 514.2CAS# 515.3 benzo[e] [l,4]oxathiepine- 2247367-07-1CD 8-carboxamide 1,1- dioxideN-((4-bromopyridin-2- CAS#° n ° yl)methyl)-2,3-dihydro- 2771132-16-0 [M-H]+5H- Int-11 + D 411.3 411.1 benzo[e] [l,4]oxathiepine- CAS# 413.1 8-carboxamide 1,1- 865156-50-9dioxideN-((4-(3- Int-13bromophenyl)pyridin-2- [M-H]++Int-12 yl)methyl)-3- Al 489.4 489.2CAS#((methoxymethyl)sulfony 491.1591-18-4l)-4-methylbenzamide3- ((methoxymethyl)sulfonyInt-14l)-4-methyl-N-((4- + [M-H]+Int-13 y n 0y0ny °'V\ / (4,4,5,5-tetraethyl-l,3,2- C 516.5CAS# 517.6 dioxaborolan-2- 2247367-07-1yl)pyridin-2- yl)methyl)benzamideCAS#N-((4-bromopyridin-2- 1490760-54-7 [M-H]+oj yl)methyl)-3- In - 45Ht 1 + D 413.3 413.1((methoxymethyl)sulfonyCAS# 415.1 l)-4-methylbenzamide865156-50-9CAS# [M-H]+2-(6-bromopyridin-2-yl)- Int-15 Br N JLr / — 1445679-31-1 E 239.0 239.0XJ 5 -methyloxazole241.0 CAS#5-ethyl-2-(3- [M-H]+Int-16 XX 1594701-58-2 E 299.1iodophenyl)oxazole 300.0MS Int# Structure Name SM Mtd MW Mes’d Int-18[M-H] % \+Int-17 CO 2-(3-bromophenyl)-5- +0 Ex 264.1 264.0 cyclopropyloxazole CAS#O 266.0126403-68-7O4 CAS#O 885274-35-12-(3-bromophenyl)-5- [M-H]+Int-18 + Ex 350.0iodooxazole 349.9 Y CAS#352.0 516-12-1F OH3-((l,l-difluoro-2- [M-H]- Int-19 Ck / '•^S COOH hydroxyethyl)sulfonyl)-4- Int-20 Ex 280.2279.2 methylbenzoic acid3-((l,l-difluoro-2- [M-H]- Int-20 hydroxyethyl)thio)-4- Int-21 Ex 248.2247.1 methylbenzoic acidCAS#FF 1 3 -((2 -ethoxy- 1,1- 200720-35-0N— COOEt [M-H]- Int-21 s'^ ^^ .COOH difluoro-2-oxoethyl)thio)- + Ex 290.2% 289.0 m m 4-methylbenzoic acid CAS#667-27-6(4-(6-fluoro-3’-(5- Int-23methy loxazol-2-y 1)- [1,1'- + [M-H]+Int-22 bipheny 1] -3 -y l)py ridin-2- F 359.4CAS # 360.4 yl)methanamine7647-01-0hydrochloridetert-butyl ((4-(6-fluoro-3'- Int-24(5-methyloxazol-2-yl)- +[M-H]+Int-23 nrFjry.BocH [l,l'-biphenyl]-3- CAS# B 459.5 460.4 yl)pyridin-2- 1092114-39-0yl)methyl)carbamateInt-25F tert-butyl ((4-(3-bromo-4- [M-H]++Int-24 fluorophenyl)pyridin-2- Al 381.3 381.2BocHN^Sf^zY^Br CAS#N yl)methyl)carbamate 383.2811842-30-5tert-butyl ((4-(4, 4,5,5- CAS#[M-H]+Int-25 tetraethyl-1,3,2- 1060813-12-8 C 390.3391.5 dioxaborolan-2- +MS Int# Structure Name SM Mtd MW Mes’d yl)pyridin-2- CAS#To yl)methyl)carbamate 2247367-07-1-3-((2- O o v \ / ' z — — hydroxyethyl)sulfonyl)-4- CAS# [M-H]- Int-26 ° — 2= Ex 244.3methylbenzoic acid 1895543-43-7 243.1 oTEA salts(4-(3’-(5-methyloxazol-2- Int-28yl)-[l,l'-biphenyl]-3- + [M-H]+Int-27 yl)pyridin-2- F 341.4CAS # 342.1 yl)methanamine7647-01-0hydrochloridetert-butyl ((4-(3'-(5- Int-29methy loxazol-2-y 1)- [ 1 , T- + [M-H] Int-28 XI A>~+B 441.5 bipheny 1] -3 -y l)py ridin-2- CAS# 442.3 yl)methyl)carbamate 1092114-39-0Int-25tert-butyl ((4-(3- [M-H]++Int-29 XIBocHN'^r-x%r / ^ / XBr bromophenyl)pyridin-2- Al 363.3 363.3CAS#N yl)methyl)carbamate 365.3591-18-4HO(RS) 1 O O 3-((l-fluoro-2- [M-H]- Int-30 hydroxyethyl)sulfonyl)-4- Int-31 Ex 262.3261.1 methylbenzoic acidXo^nHO2-((5-bromo-2- 1 ° No Int-31 F^^' Br methylphenyl)sulfonyl)- Int-32 Ex 297.1LCMS2-fluoroethan- 1 -olethyl 2-((5-bromo-2- [M-H]- ^°Y°oInt-32 Br methylphenyl)sulfonyl)- Int-33 Ex 339.2 337.0- 2-fluoroacetate 339.0MS Int# Structure Name SM Mtd MW Mes’d CAS#69321-55-7^0 ethyl 2-((5-bromo-2- + No Int-33 methylphenyl)thio)-2- Ex 307.2S ZA .. Br CAS# LCMS fluoroacetateXJ 401-55-8ON-((4-(3-bromo-4- Y methoxyphenyl)pyridin- Int-102-yl)methyl)-2,3-dihydro- [M-H]++Int-34 5H- Al 517.4 517.3CAS#benzo[e] [l,4]oxathiepine- 519.3182056-39-98-carboxamidc 1,1- dioxide(4-(3-(4-(5-methyloxazol- Int-362-yl)pyridin-2- + [M-H]+Int-35 yl)phenyl)pyridin-2- F 342.4CAS # 343.2 <3 yl)methanamine7647-01-0hydrochloridetert-butyl ((4-(3-(4-(5- methyloxazol-2- Int-8[M-H]+Int-36 JCL X>- yl)pyridin-2- + B 442.5443.2 yl)phenyl)pyridin-2- Int-29yl)methyl)carbamateCAS#2-(3-bromophenyl)-5- 31938-07-5278.1 Int-37 (cyclopropylmethyl)oxaz + Ex 278.1280.1 XX ole CAS#54322-65-5(4-(3-(6-(5-methyloxazol- Int-39YA. .NA 2-yl)pyridin-2- Int-38 LJ1 N XJ- + [M-H]+yl)phenyl)pyridin-2- F 342.4V U CAS # 343.1 yl)methanamine7647-01-0hydrochloridetert-butyl ((4-(3-(6-(5- methyloxazol-2- Int-15[M-H]+Int_39 yl)pyridin-2- + B 442.5443.2 yl)phenyl)pyridin-2- Int-29yl)methyl)carbamateMS Int# Structure Name SM Mtd MW Mes’d (4-(2- Y 'o (aminomethyl)pyridin-4- Int-41+ [M-H]+yl)-2-(4-(5-methyloxazol- Int-40 O w fV ry_ F 372.4H2NU OVI 2-yl)pyridin-2- CAS # 373.27647-01-0 yl)phenyl)methanolhydrochlorideW tert-butyl ((4-(4-(((tert- Ybutyldimethylsilyl)oxy)mInt-42 ethyl)-3-(4-(5- [M-H]++ Int-41 methyloxazol-2- B 586.8587.3 yl)pyridin-2- Int-8yl)phenyl)pyridin-2- yl)methyl)carbamatetert-butyl ((4-(3-bromo-4- Int-43[M-H]+(((tert- +Int-42 butyldimethylsilyl)oxy)m Ex 507.5 507.3XV CAS#ethyl)phenyl)pyridin-2- 509.318162-48-6yl)methyl)carbamatetert-butyl ((4-(3-bromo-4- Int-25 OH [M-H]++ (hydroxymethyl)phenyl)pInt-43 A2 393.3 393.1 JCJL yridin-2- CAS# BocHN / ''^395.1 1261648-93-4 yl)methyl)carbamate(4-(3-(4-(l-methyl-lH- Int-45pyrazol-4-yl)pyridin-2- + [M-H]+Int-44 yl)phenyl)pyridin-2- F 341.4342.2 CAS #yl)methanamine7647-01-0hydrochloridetert-butyl ((4-(3-(4-(l- Int-46methyl-lH-pyrazol-4- + [M-H]+Int-45 yl)pyridin-2- Al 441.5442.3 CAS#yl)phenyl)pyridin-2- 1434058-71-5yl)methyl)carbamatetert-butyl ((4-(3-(4, 4,5,5- Int-29tetraethyl-1,3,2- + [M-H]+Int-46 dioxaborolan-2- 466.4 C467.5 CAS# V yl)phenyl)pyridin-2- 2247367-07-1yl)methyl)carbamateEx= compound not synthetized according a general method, procedure has been described.Table III. Illustrative compounds of the invention.SM = Starting Material, Mtd = Method, MS Mes’d = Measured massEx= compound not synthetized according a general method, procedure has been described.Cpd MtStr Oucture Name SM MW MS Mes’d # d4-methyl-N-((4-(4’-(l- Int-1Wmethyl-lH-l,2,4-triazol-3- +oCpd- yl)-[l,l’-biphenyl]-3- CAS# 537. [M+H]+538.Al1 yl)pyridin-2-yl)methyl)-3 - 1184174 6 2 (methylsulfonyl)benzamid -04-6e4-methyl-N-((4-(3'-(3- Int-1methyl-l,2,4-oxadiazol-5- +Cpd-0 0°'V yl)-[l,l'-biphenyl]-3- CAS# 538. [M+H]+Al2 ycny-yc yl)pyridin-2-yl)methyl)-3 - 160377- 6 538.9 (methylsulfonyl)benzamid 58-2e4-methyl-N-((4-(3'-(5- Int-1methyl-l,3,4-oxadiazol-2- +Cpd- °0 N'V~ yl)-[l,l'-biphenyl]-3- 538. [M+H]+CAS# Al3 yl)pyridin-2-yl)methyl)-3 - 6 540.441491- (methylsulfonyl)benzamid53-6e4-methyl-N-((4-(3'-(5- Int-1methyl-1 ,2,4-oxadiazol-3 - +Cpd- o 0 N-° yl)-[l,l'-biphenyl]-3- 538. [M+H]+JL 1 ^1 JL CAS# Al4 arXOT yl)pyridin-2-yl)methyl)-3 - 6 539.2160377- (methylsulfonyl)benzamid57-1e4-methyl-3- Int-1(methylsulfonyl)-N-((4-(3'- +Cpd- 523. [M+H]+y A XI (oxazol-2-yl)-[l,l'- CAS# Al5 6 524.2 bipheny 1] -3 -y l)py ridin-2- 885274- yl)methyl)benzamide 35-1Cpd Mt Structure Name SM MW MS Mes’d # dN-((4-(4-methoxy-3-(4-(l- / Qmethyl-lH-pyrazol-4- Int-5+C IZ yl)pyridin-2- pd- 4 567. [M+H]+yl)phenyl)pyridin-2- CAS# A26 o o 7 568.2ZA yl)methyl)-4-methyl-3 - 1434058ZAA ZZ z o= (methylsulfonyl)benzamid -71-50<° o s=O' / Q ' _ eo Oz1 N-((4-(4-methoxy-3-(5-(l- methyl-lH-pyrazol-4- Int-5yl)pyridin-2- +Cpd- 567. [M+H]+yl)phenyl)pyridin-2- CAS# A27 7 568.3 yl)methyl)-4-methyl-3 - 1038392 (methylsulfonyl)benzamid -68-5e1 1 N-((4-(4-methoxy-3-(6-(l- 6 o methyl-lH-pyrazol-4- Int-5ip- ° yl)pyridin-2- +Cpd- op ° 567. [M+H]O O+yl)phenyl)pyridin-2- CAS# A28 7 568.2 yl)methyl)-4-methyl-3 - 1492848ZI ZI P p p(methylsulfonyl)benzamid -05-1e / / / N>b' ■ iN-((4-(3-([3,4'-bipyridin]- Int-52'-yl)-4- +Cpd- methoxyphenyl)pyridin-2- 564. [M+H]+CAS# A29 yl)methyl)-4-methyl-3 - 7 565.31159817 (methylsulfonyl)benzamid-79-4eN-((4-(3-([3,3'-bipyridin]- Int-56-yl)-4- +Cpd- methoxyphenyl)pyridin-2- 564. [M+H]+CAS# A210 yl)methyl)-4-methyl-3 - 7 565.31088410 (methylsulfonyl)benzamid-80-3eN-((4-(6-methoxy-3’- Int-5(oxazol-2-yl)-[l,l’- +Cpd- bipheny 1] -3 -y l)py ridin-2- 553. [M+H]+CAS# A211 yl)methyl)-4-methyl-3 - 7 554.3885274- (methylsulfonyl)benzamid35-1eCpd MtStructure Name SM MW MS Mes’d # d4-methyl-N-((4-(3'-(4- / Of Int-1methy loxazol-2-y 1)- [1,1'- +Cpd- 2 Pl 1'V bipheny 1] -3 -y l)py ridin-2- 537. [M+H]+CAS# A212 yl)methyl)-3- 6 538.3 o 1368720(methylsulfonyl)benzamidZA -81-3eX° / 4-methyl-N-((4-(3'-(5- a Int-1methy loxazol-2-y 1)- [1,1'- +Cpd- bipheny 1] -3 -y l)py ridin-2- 537. [M+H]+CAS# A213 yl)methyl)-3- 6 538.31368720 (methylsulfonyl)benzamid-81-3eN-((4-(3-([3,4'-bipyridin]- Int-56-yl)-4- +Cpd- o 0 methoxyphenyl)pyridin-2- 564. [M+H]+1 X-IT UK CAS# A24 AX\zQ yl)methyl)-4-methyl-3 - 7 565.31142197 (methylsulfonyl)benzamid(7 ~ -30-5eN-((4-(3-([3,4'-bipyridin]- Int-1ZI6-yl)phenyl)pyridin-2- +Cpd- 534. [M+H]+X X vu yl)methyl)-4-methyl-3 - CAS# A215 l^j!l 6 535.2(methylsulfonyl)benzamid 1142197e -30-5N-((4-(3-(5-(4H-l,2,4- Int-5triazol-4-yl)pyridin-2-yl)- +Cpd- 4-methoxyphenyl)pyridin- 554. [M+H]+CAS# A216 2-yl)methyl)-4-methyl-3- 6 555.21394374 (methylsulfonyl)benzamid-27-6eN-((4-(6-methoxy-3’-(5- Int-5methy loxazol-2-y 1)- [1,1 - +Cpd- oP A XI x>- bipheny 1] -3 -y l)py ridin-2- 567. [M+H]+CAS# Al17d'lX 'XXCT yl)methyl)-4-methyl-3 - 7 568.41368720 (methylsulfonyl)benzamid-81-3eCpd MtStructure Name SM MW MS Mes’d # dN-((4-(6-fluoro-3'-(5- Int-7methy loxazol-2-y 1)- [1,1'- +Cpd- bipheny 1] -3 -y l)py ridin-2- CAS# 555. [M+H]+B18 ^y^'Xr^O^ yl)methyl)-4-methyl-3 - 1092114 6 556.2(methylsulfonyl)benzamid -39-0e4-methyl-N-((4-(3-(4-(5- methyloxazol-2-yl)pyridin- Int-1Cpd- 2-yl)phenyl)pyridin-2- 538. [M+H]++ A219 yl)methyl)-3- 6 539.4Int-8 (methylsulfonyl)benzamideN-((4-(3'-(5-methyloxazol- Int-92-yl)-[l,l'-biphenyl]-3- +Cpd- yl)pyridin-2-yl)methyl)- 565. [M+H]+CAS# B20 2,3-dihydro-5H- 6 566.21368720benzo[e] [l,4]oxathiepine- -81-38-carboxamide 1,1-dioxide3- Int-12 ((methoxymethyl)sulfonyl)+Cpd- -4-methyl-N-((4-(3'-(5- 567. [M+H]+CAS# B21 methy loxazol-2-y 1)- [1,1'- 7 568.41092114bipheny 1] -3 -y l)py ridin-2- -39-0yl)methyl)benzamide4-methyl-N-((4-(3-(6-(5- methyloxazol-2-yl)pyridin- Int-1Cpd- 2-yl)phenyl)pyridin-2- + 538. [M+H]+A222 yl)methyl)-3- Int-15 6 539.4(methylsulfonyl)benzamideN-((4-(3'-(5-ethyloxazol-2- yl)-[l,l'-biphenyl]-3- Int-1Cpd- yl)pyridin-2-yl)methyl)-4- + 551. [M+H]+Al23 methyl-3- Int-16 7 552.3(methylsulfonyl)benzamideCpd MtStructure Name SM MW MS Mes’d # dN-((4-(3’-(5- o cyclopropyloxazol-2-yl)- W Int-1[l,l’-biphenyl]-3- Cpd- + 563. [M+H]+yl)pyridin-2-yl)methyl)-4- Al24 0 Int-17 7 564.2 methyl-3- O(methylsulfonyl)benzamidpeY 3-((l,l-difluoro-2- hydroxyethyl)sulfonyl)-N- ((4-(6-fluoro-3’-(5- Int-19Cpd- 621. [M+H]+methy loxazol-2-y 1)- [1,1'- + D25 6 622.2 bipheny 1] -3 -y l)py ridin-2- Int-22yl)methyl)-4- methylbenzamideN-((4-(6-fluoro-3'-(5- A methy loxazol-2-y 1)- [1,1'- Int-26Cpd- p bipheny 1] -3 -y l)py ridin-2- 585. [M+H]++ D26 yl)methyl)-3-((2- 7 586.2Q Int-22hydroxyethyl)sulfonyl)-4- methylbenzamide6-fluoro-N-((4-(3'-(5- methy loxazol-2-y 1)- [1,1 - CAS#bipheny 1] -3 -y l)py ridin-2- 2771132Cpd- 583. [M+H]+yl)methyl)-2,3-dihydro- -60-4 D27 6 584.25H- +benzo[e] [l,4]oxathiepine- Int-278-carboxamide 1,1-dioxide(R)-4,9-difluoro-N-((4-(3- (4-(5-methyloxazol-2- CAS#yl)pyridin-2- 3008582Cpd- yl)phenyl)pyridin-2- 602. [M+H]+-46-2 D28 yl)methyl)-3,4-dihydro- 6 603.3+2H- Int-27benzo[b] [l,4]oxathiepine- 7-carboxamide 5,5-dioxideCpd MtStructure Name SM MW MS Mes’d # d(R)-9-chloro-4-fluoro-N- ((4-(3-(4-(5-methyloxazol- CAS#2-yl)pyridin-2- 3008582 [M+H]+Cpd- yl)phenyl)pyridin-2- 619.o -64-4 D 619.3 29 yl)methyl)-3,4-dihydro- 1O + 621.32H- C Int-27 benzo[b][l,4]oxathiepine- Y 7-carboxamide 5,5-dioxide3-((l-fluoro-2- hydroxyethyl)sulfonyl)-N- ((4-(6-fluoro-3’-(5- Int-30Cpd- 603. [M+H]+methy loxazol-2-y 1)- [1,1'- + D30 6 604.3 bipheny 1] -3 -y l)py ridin-2- Int-22yl)methyl)-4- methylbenzamide(R)-2,6-difluoro-N-((4-(3- (4-(5-methyloxazol-2- Int-35yl)pyridin-2- Q +Cpd- yl)phenyl)pyridin-2- 602. [M+H]+CAS# D32 yl)methyl)-2,3-dihydro- 6 603.330085825H- -33-7benzo[e] [l,4]oxathiepine- 8-carboxamide 1,1-dioxideN-((4-(3'-(5- (cyclopropylmethyl)oxazol-2-y 1)- [ 1 , 1 ’-biphenyl] -3 - Int-1Cpd- 577. [M+H]+yl)pyridin-2-yl)methyl)-4- + Al33 7 578.2 methyl-3- Int-37 (methylsulfonyl)benzamide(R)-4,9-difluoro-N-((4-(3- (6-(5-methyloxazol-2- Int-38yl)pyridin-2- +Cpd- yl)phenyl)pyridin-2- 602. [M+H]+CAS# D34 yl)methyl)-3,4-dihydro- 6 603.230085822H- -46-2benzo[b] [l,4]oxathiepine- 7-carboxamide 5,5-dioxideCpd MtStructure Name SM MW MS Mes’d # d(R)-9-chloro-4-fluoro-N- ((4-(3-(6-(5-methyloxazol- Int-382-yl)pyridin-2- + [M+H]+Cpd- yl)phenyl)pyridin-2- 619.o CAS# D 619.1 35 yl)methyl)-3,4-dihydro- 1o 3008582 621.12H- o -64-4 benzo[b][l,4]oxathiepine- Y 7-carboxamide 5,5-dioxide3-chloro-5- Int-35 ((difluoromethyl)sulfonyl)- + [M+H]+Cpd- N-((4-(3-(4-(5- 595.CAS# D 595.3 36 methyloxazol-2-yl)pyridin- 02592405 597.2 2-yl)phenyl)pyridin-2- -50-8yl)methyl)benzamide3-chloro-5- Int-38 ((difluoromethyl)sulfonyl)- + [M+H]+Cpd- N-((4-(3-(6-(5- 595.CAS# D 595.3 37 methyloxazol-2-yl)pyridin- 02592405 597.3 2-yl)phenyl)pyridin-2- -50-8yl)methyl)benzamide(R)-9-chloro-4-fluoro-N- ((4-(4-(hydroxymethyl)-3 - (4-(5-methyloxazol-2- Int-40yl)pyridin-2- + [M+H]+Cpd- 649.yl)phenyl)pyridin-2- CAS# D 649.3 38 1yl)methyl)-3,4-dihydro- 3008582 651.3 2H- -64-4 benzo[b][l,4]oxathiepine- 7-carboxamide 5,5-dioxide(R)-9-chloro-4-fluoro-N- ((4-(3-(4-(l -methyl- 1H- Int-44pyrazol-4-yl)pyridin-2- + [M+H]+Cpd- yl)phenyl)pyridin-2- 618.CAS# D 618.3 39 yl)methyl)-3,4-dihydro- 13008582 620.3 2H- -64-4benzo[b] [l,4]oxathiepine- 7-carboxamide 5,5-dioxideEx= compound not synthetized according a general method, procedure has been described.Table IV. NMR data of illustrative compounds of the invention.Cpd# Analytical data (NMR, SFC if applicable, optical data if applicable)Cpd- 'H NMR (400 MHz, MeOD-d,) 58.58 - 8.51 (m, 2H), 8.43 (d, 1H), 8.13 - 8.04 (m, 4H), 7.95 (t, 1H), 1 7.79 - 7.62 (m, 6H), 7.60 - 7.50 (m, 2H), 4.77 (s, 2H), 3.99 (d, 3H), 3.14 (s, 3H), 2.74 (s, 3H).Cpd- 'H NMR (400 MHz, DMSO-dj) 59.36 (t, 1H), 8.61 (d, 1H), 8.44 (d, 1H), 8.37 (t, 1H), 8.17 - 8.04 (m, 2 4H), 7.88 - 7.70 (m, 5H), 7.65 (t, 1H), 7.57 (d, 1H), 4.69 (d, 2H), 3.23 (s, 3H), 2.69 (s, 3H), 2.44 (s, 3H).Cpd- 'H NMR (400 MHz, DMSO-dj) 5 9.36 (t, 1H), 8.62 (dd, 1H), 8.45 (d, 1H), 8.26 (t, 1H), 8.18 - 8.11 3 (m, 2H), 8.08 - 7.96 (m, 3H), 7.86 - 7.76 (m, 3H), 7.76 - 7.61 (m, 3H), 7.57 (d, 1H), 4.69 (d, 2H), 3.24 (s, 3H), 2.69 (s, 3H), 2.60 (s, 3H).Cpd- 'H NMR (400 MHz, DMSO-dj) 59.36 (t, 1H), 8.61 (d, 1H), 8.45 (d, 1H), 8.28 (t, 1H), 8.14 (dd, 1H), 4 8.06 - 7.97 (m, 3H), 7.85 - 7.60 (m, 6H), 7.57 (d, 1H), 4.69 (d, 2H), 3.24 (s, 3H), 2.69 (d, 6H). Cpd- 'H NMR (400 MHz, DMSO-dj) 5 9.36 (t, 1H), 8.61 (d, 1H), 8.46 (d, 1H), 8.31 - 8.23 (m, 2H), 8.15 5 (dd, 1H), 8.08 - 7.98 (m, 2H), 7.91 (ddd, 1H), 7.86 - 7.70 (m, 4H), 7.65 (td, 2H), 7.57 (d, 1H), 7.43 (d, 1H), 4.69 (d, 2H), 3.24 (s, 3H), 2.69 (s, 3H).Cpd-1H NMR (400 MHz, CDC13) 58.67 (dd, 1H), 8.58 (d, 1H), 8.50 (d, 1H), 8.09 (dd, 2H), 7.91 - 7.88 (m, 6 2H), 7.79 - 7.76 (m, 1H), 7.72 - 7.67 (m, 2H), 7.59 - 7.55 (m, 1H), 7.53 - 7.49 (m, 1H), 7.46 (d, 1H), 7.32 (dd, 1H), 7.14 (d, 1H), 4.82 (d, 2H), 3.99 (s, 3H), 3.95 (s, 3H), 3.12 (s, 3H), 2.78 (s, 3H).Cpd- 'H NMR (400 MHz, CDCI3) 5 8.86 (d, 1H), 8.58 (d, 1H), 8.50 (d, 1H), 8.16 (d, 1H), 8.09 (dd, 1H), 7 7.89 (dd, 1H), 7.84 - 7.83 (m, 1H), 7.80 (dd, 1H), 7.76 - 7.71 (m, 2H), 7.69 (dd, 1H), 7.59 - 7.57 (m, 1H), 7.51 (dd, 1H), 7.46 (d, 1H), 7.13 (d, 1H), 4.82 (d, 2H), 3.99 (s, 3H), 3.95 (s, 3H), 3.12 (s, 3H), 2.77 (s, 3H).Cpd- 'H NMR (400 MHz, DMSO-fifc) 59.38 (t, 1H), 8.56 (d, 1H), 8.42 (d, 1H), 8.32 (s, 1H), 8.17 - 8.09 (m, 8 2H), 8.04 (s, 1H), 7.86 - 7.76 (m, 2H), 7.73 - 7.56 (m, 4H), 7.52 (d, 1H), 7.31 (d, 1H), 4.66 (d, 2H), 3.90 (s, 3H), 3.89 (s, 3H), 3.23 (s, 3H), 2.68 (s, 3H).Cpd- 'H NMR (500 MHz, CDCI3) 58.96 (dd, 1H), 8.83 (dd, 1H), 8.71 (dd, 1H), 8.59 (d, 1H), 8.50 (d, 1H), 9 8.19 (d, 1H), 8.12 - 8.11 (m, 1H), 8.11 - 8.07 (m, 1H), 7.99 (dt, 1H), 7.72 (dd, 1H), 7.71 - 7.67 (m, 1H), 7.59 (t, 1H), 7.52 (dd, 1H), 7.49 - 7.43 (m, 3H), 7.16 (d, 1H), 4.82 (d, 2H), 3.96 (s, 3H), 3.12 (s, 3H), 2.78 (s, 3H).Cpd-1H NMR (400 MHz, DMSO-t / 6) 5 9.39 (t, 1H), 9.04 (ddd, 2H), 8.65 (dd, 1H), 8.56 (d, 1H), 8.44 (d, 10 1H), 8.22 (ddt, 3H), 8.14 (dd, 1H), 8.05 (dd, 1H), 7.86 (dd, 1H), 7.68 (d, 1H), 7.65 -7.52 (m, 3H), 7.34 (d, 1H), 4.66 (d, 2H), 3.94 (s, 3H), 3.24 (s, 3H), 2.69 (s, 3H).Cpd- 'H NMR (500 MHz, CDCI3) 58.59 (d, 1H), 8.51 - 8.48 (m, 1H), 8.26 - 8.23 (m, 1H), 8.12 - 8.04 (m, 11 2H), 7.73 (s, 1H), 7.70 - 7.64 (m, 4H), 7.57 - 7.50 (m, 2H), 7.49 - 7.43 (m, 2H), 7.14 - 7.09 (m, 1H), 4.82 (d, 2H), 3.90 (s, 3H), 3.11 (s, 3H), 2.77 (s, 3H).Cpd- 'H NMR (500 MHz, CDCI3) 58.65 (d, 1H), 8.52 - 8.49 (m, 1H), 8.32 - 8.28 (m, 1H), 8.12 - 8.03 (m, 12 2H), 7.90 - 7.87 (m, 1H), 7.76 - 7.68 (m, 3H), 7.66 - 7.63 (m, 1H), 7.61 - 7.51 (m, 4H), 7.48 - 7.44 (m, 2H), 4.86 (d, 2H), 3.12 (s, 3H), 2.78 (s, 3H), 2.27 (s, 3H).Cpd# Analytical data (NMR, SFC if applicable, optical data if applicable)Cpd- 'H NMR (500 MHz, CDC13) 58.65 (d, 1H), 8.52 - 8.49 (m, 1H), 8.30 - 8.27 (m, 1H), 8.10 (dd, 1H), 13 8.04 - 8.00 (m, 1H), 7.91 - 7.88 (m, 1H), 7.76 - 7.62 (m, 4H), 7.61 - 7.51 (m, 4H), 7.46 (d, 1H), 6.89 - 6.86 (m, 1H), 4.86 (d, 2H), 3.12 (s, 3H), 2.78 (s, 3H), 2.43 (s, 3H).Cpd- 'H NMR (500 MHz, DMSO-tfc) 59.36 (t, 1H), 9.14 - 9.11 (m, 1H), 8.73 - 8.69 (m, 2H), 8.56 (d, 1H), 14 8.46 - 8.44 (m, 1H), 8.28 (dd, 1H), 8.22 (d, 1H), 8.14 (dd, 1H), 8.07 (d, 1H), 7.88 - 7.84 (m, 3H), 7.67 (s, 1H), 7.63 - 7.57 (m, 2H), 7.35 (d, 1H), 4.66 (d, 2H), 3.94 (s, 3H), 3.24 (s, 3H), 2.69 (s, 3H). Cpd- 'H NMR (500 MHz, DMSO-fifc) 59.38 (t, 1H), 9.15 (d, 1H), 8.72 - 8.70 (m, 2H), 8.63 (d, 1H), 8.52 (t, 15 1H), 8.46 (d, 1H), 8.37 (dd, 1H), 8.28 - 8.25 (m, 2H), 8.15 (dd, 1H), 7.88 - 7.84 (m, 3H), 7.78 - 7.77 (m, 1H), 7.73 (dd, 1H), 7.69 (t, 1H), 7.59 (d, 1H), 4.70 (d, 2H), 3.25 (s, 3H), 2.70 (s, 3H)Cpd-1H NMR (500 MHz, DMSO-fifc) 5 9.36 (t, 1H), 9.22 (s, 2H), 9.05 (d, 1H), 8.56 (d, 1H), 8.44 (d, 1H), 16 8.20 (dd, 1H), 8.13 (dd, 2H), 8.08 (d, 1H), 7.87 (dd, 1H), 7.68 - 7.66 (m, 1H), 7.61 (dd, 1H), 7.59 (d, 1H), 7.35 (d, 1H), 4.65 (d, 2H), 3.93 (s, 3H), 3.24 (s, 3H), 2.69 (s, 3H)Cpd- 'H NMR (400 MHz, DMSO-fifc) 59.34 (t, 1H), 8.54 (d, 1H), 8.43 (d, 1H), 8.13 (dd, 1H), 8.06 (t, 1H), 17 7.91 (dt, 1H), 7.81 (dd, 1H), 7.72 (dd, 2H), 7.68 - 7.62 (m, 2H), 7.58 (t, 2H), 7.30 (d, 1H), 7.01 (d, 1H), 4.64 (d, 2H), 3.85 (s, 3H), 3.24 (s, 3H), 2.69 (s, 3H), 2.39 (s, 3H).Cpd- 'H NMR (500 MHz, DMSO-tfc) 59.28 (t, 1H), 8.59 (d, 1H), 8.44 (d, 1H), 8.16 - 8.10 (m, 2H), 8.00 (d, 18 1H), 7.95 (dd, 1H), 7.88 - 7.81 (m, 1H), 7.79 - 7.73 (m, 2H), 7.71 (dd, 1H), 7.66 (t, 1H), 7.56 (d, 1H), 7.51 (dd, 1H), 7.02 (s, 1H), 4.67 (d, 2H), 3.23 (s, 3H), 2.69 (s, 3H), 2.40 (s, 3H).19F NMR (471 MHz, DMSO-tfc) 5 -118.0 (s, IF).Cpd-1H NMR (400 MHz, DMSO-tfc) 59.40 (t, 1H), 8.84 (dd, 1H), 8.66 - 8.60 (m, 1H), 8.48 (t, 1H), 8.46 - 19 8.42 (m, 2H), 8.24 (dt, 1H), 8.15 (dd, 1H), 7.86 (ddd, 2H), 7.77 (d, 1H), 7.73 (dd, 1H), 7.68 (t, 1H), 7.58 (d, 1H), 7.18 (d, 1H), 4.69 (d, 2H), 3.25 (s, 3H), 2.69 (s, 3H), 2.45 (d, 3H).Cpd- 'H NMR (400 MHz, CDCI3) 5 8.66 (d, 1H), 8.55 (d, 1H), 8.29 (t, 1H), 8.17 (dd, 1H), 8.02 (dt, 1H), 20 7.91 - 7.88 (m, 1H), 7.81 - 7.77 (m, 1H), 7.74 (dt, 1H), 7.70 (dt, 1H), 7.67 - 7.63 (m, 1H), 7.62 - 7.55 (m, 3H), 7.55 - 7.52 (m, 1H), 7.49 (d, 1H), 6.88 (d, 1H), 5.04 (s, 2H), 4.87 (d, 2H), 4.41 - 4.36 (m, 2H), 3.44 - 3.39 (m, 2H), 2.43 (d, 3H).Cpd- 'H NMR (400 MHz, CDCI3) 5 8.64 (d, 1H), 8.48 (d, 1H), 8.28 (t, 1H), 8.10 (dd, 1H), 8.02 (dt, 1H), 21 7.89 (t, 1H), 7.79 - 7.72 (m, 2H), 7.72 - 7.63 (m, 2H), 7.63 - 7.61 (m, 1H), 7.60 - 7.52 (m, 3H), 7.45 (d, 1H), 6.88 (d, 1H), 4.85 (d, 2H), 4.59 (s, 2H), 3.66 (s, 3H), 2.76 (s, 3H), 2.43 (d, 3H).Cpd-1H NMR (400 MHz, DMSO-fifc) 59.41 - 9.35 (m, 1H), 8.64 (d, 1H), 8.47 - 8.41 (m, 2H), 8.27 (d, 1H), 22 8.21 (d, 1H), 8.17 - 8.11 (m, 1H), 8.12 - 8.01 (m, 2H), 7.89 - 7.83 (m, 1H), 7.78 (s, 1H), 7.76 - 7.66 (m, 2H), 7.57 (d, 1H), 7.11 (d, 1H), 4.69 (d, 2H), 3.24 (s, 3H), 2.69 (s, 3H), 2.44 - 2.43 (m, 3H). Cpd- 'H NMR (400 MHz, DMSO-fifc) 59.37 (t, 1H), 8.62 (d, 1H), 8.44 (d, 1H), 8.23 (d, 1H), 8.14 (dd, 1H), 23 8.04 (s, 1H), 7.97 (d, 1H), 7.89 (d, 1H), 7.85 - 7.73 (m, 4H), 7.65 (td, 2H), 7.57 (d, 1H), 7.05 (s, 1H), 4.68 (d, 2H), 3.24 (s, 3H), 2.77 (q, 2H), 2.69 (s, 3H), 1.25 (t, 3H).Cpd- 'H NMR (400 MHz, DMSO-fifc) 59.31 (t, 1H), 8.58 - 8.52 (m, 1H), 8.38 (d, 1H), 8.14 (t, 1H), 8.08 (dd, 24 1H), 7.98 (t, 1H), 7.89 (dt, 1H), 7.84 - 7.79 (m, 1H), 7.78 - 7.71 (m, 3H), 7.68 (dd, 1H), 7.58 (q, 2H), 7.51 (d, 1H), 6.98 (d, 1H), 4.62 (d, 2H), 3.18 (s, 3H), 2.63 (s, 3H), 2.05 - 1.97 (m, 1H), 0.96 - 0.90 (m, 2H), 0.82 - 0.77 (m, 2H).Cpd# Analytical data (NMR, SFC if applicable, optical data if applicable)Cpd- 'H NMR (500 MHz, DMSO-fifc) 59.45 (t, 1H), 8.60 (d, 1H), 8.47 (d, 1H), 8.29 (dd, 1H), 8.14 (q, 1H), 25 8.02 - 7.94 (m, 2H), 7.86 (ddd, 1H), 7.80 - 7.75 (m, 2H), 7.73 (dd, 1H), 7.67 (q, 2H), 7.52 (dd, 1H), 7.03 (q, 1H), 6.10 (s, 1H), 4.67 (d, 2H), 4.10 (t, 2H), 2.69 (s, 3H), 2.40 (d, 3H).Cpd- 'H NMR (500 MHz, DMSO-fifc) 59.34 (t, 1H), 8.60 (d, 1H), 8.41 (d, 1H), 8.17 - 8.10 (m, 2H), 8.03 - 26 7.95 (m, 2H), 7.86 (ddd, 1H), 7.78 (q, 2H), 7.73 (dd, 1H), 7.67 (t, 1H), 7.58 - 7.50 (m, 2H), 7.04 (q, 1H), 4.83 (t, 1H), 4.67 (d, 2H), 3.70 (q, 2H), 3.50 (t, 2H), 2.68 (s, 3H), 2.41 (d, 3H).19F NMR (471 MHz, DMSO-tfc) 5 -118.0 (s, IF).Cpd- 'H NMR (400 MHz, DMSO-fifc) 59.57 (t, 1H), 8.63 (d, 1H), 8.36 (d, 1H), 8.25 - 8.21 (m, 1H), 8.16 - 27 8.11 (m, 1H), 8.08 - 8.04 (m, 1H), 8.00 - 7.95 (m, 1H), 7.93 - 7.87 (m, 1H), 7.86 - 7.79 (m, 3H), 7.76 (dd, 1H), 7.69 - 7.63 (m, 2H), 7.04 (d, 1H), 5.01 (s, 2H), 4.70 (d, 2H), 4.25 - 4.18 (m, 2H), 3.78 - 3.71 (m, 2H), 2.42 (d, 3H).Cpd- 'H NMR (500 MHz, DMSO-tfc) 5 9.42 (t, 1H), 8.77 (dd, 1H), 8.56 (d, 1H), 8.41 (t, 1H), 8.36 (t, 1H), 28 8.23 (dd, 1H), 8.22 - 8.13 (m, 2H), 7.84 - 7.75 (m, 2H), 7.71 (d, 1H), 7.66 (dd, 1H), 7.62 (t, 1H), 7.10 (q, 1H), 6.16 (ddd, 1H), 4.63 (d, 2H), 4.52 (dt, 1H), 4.07 (t, 1H), 2.80 - 2.64 (m, 1H), 2.55 - 2.47 (m, 1H), 2.38 (d, 3H).19F NMR (471 MHz, DMSO-tfc) 5 -127.6 (s, IF), -186.8 (s, IF).[a]D20°c= -37,88 ° (589 nm, c 0,15 w / v %, DMF, 20 °C)SFC (Chiralpak OJ-3 4.6x100 mm, Mobile phase: CO2 / (MeOH + 0,3%iPrNH2) 95 / 5)): rt = 3.43, 100% eeCpd- 1H NMR (500 MHz, DMSO-fifc) 59.55 (t, 1H), 8.85 (d, 1H), 8.64 (d, 1H), 8.49 (d, 2H), 8.45 - 8.42 (m, 29 1H), 8.41 (d, 1H), 8.24 (dt, 1H), 7.88 (dt, 1H), 7.85 (dd, 1H), 7.80 (d, 1H), 7.74 (dd, 1H), 7.69 (t, 1H), 7.18 (d, 1H), 6.24 (ddd, 1H), 4.71 (d, 2H), 4.60 (dt, 1H), 4.08 (t, 1H), 2.90 - 2.73 (m, 1H), 2.62 - 2.54 (m, 1H), 2.46 (d, 3H).19F NMR (471 MHz, DMSO-tfc) 5 -186.7 (s, IF).[a]D20°c= -38,72 ° (589 nm, c 0,06 w / v %, DMF, 20°C)SFC (Chiralpak IH-3 4.6x100 mm, Mobile phase: CO2 / (MeOH + 0,3%iPrNH2) 55 / 45): rtl = 1.29, rt2 = 1.59, 99.5% ee (second eluted)Cpd- 'H NMR (500 MHz, DMSO-fifc) 59.33 (t, 1H), 8.60 (d, 1H), 8.43 (d, 1H), 8.20 (dd, 1H), 8.15 (q, 1H), 30 8.03 - 7.94 (m, 2H), 7.85 (ddd, 1H), 7.76 (dd, 2H), 7.71 (dd, 1H), 7.66 (t, 1H), 7.61 (d, 1H), 7.51 (dd, 1H), 7.02 (t, 1H), 5.71 (ddd, 1H), 5.49 (s, 1H), 4.68 (d, 2H), 4.03 (dd, 1H), 3.88 - 3.77 (m, 1H), 2.69 (s, 3H), 2.40 (d, 3H).19F NMR (471 MHz, DMSO-tfc) 5 -118.0 (s, IF), -185.1 (s, IF).Cpd# Analytical data (NMR, SFC if applicable, optical data if applicable)Cpd-1H NMR (500 MHz, DMSO-fifc) 59.57 (t, 1H), 8.84 (d, 1H), 8.64 (d, 1H), 8.49 (t, 1H), 8.46 - 8.39 (m, 32 2H), 8.28 - 8.18 (m, 2H), 7.88 (dt, 1H), 7.85 (dd, 1H), 7.81 (d, 1H), 7.73 (dd, 1H), 7.69 (t, 1H), 7.16 (d, 1H), 6.25 - 6.12 (m, 1H), 5.23 (d, 1H), 4.89 (dd, 1H), 4.72 (d, 2H), 4.49 - 4.34 (m, 2H), 2.45 (d, 3H).19F NMR (471 MHz, DMSO-tfc) 5 -127.6 (s, IF), -186.8 (s, IF).[a]D20= -24,89 ° (589 nm, c 0,19 w / v %, DMF, 20°C).SFC (Chiralpak IH-3 4.6x100 mm, Mobile phase: CO2 / (MeOH + 0,3%iPrNH2) 55 / 45): rt = 1.32, 100% eeCpd- 'H NMR (500 MHz, DMSO-fifc) 59.33 (t, 1H), 8.62 (d, 1H), 8.45 (d, 1H), 8.23 (d, 1H), 8.14 (dd, 1H), 33 8.04 (d, 1H), 7.97 (dt, 1H), 7.88 (dt, 1H), 7.83 - 7.77 (m, 3H), 7.74 (dd, 1H), 7.65 (td, 2H), 7.57 (d, 1H), 7.09 (d, 1H), 4.69 (d, 2H), 3.24 (s, 3H), 2.69 (d, 5H), 1.12 - 1.03 (m, 1H), 0.56 - 0.51 (m, 2H), 0.29 - 0.23 (m, 2H).Cpd- 'H NMR (500 MHz, DMSO-fifc) 59.50 (t, 1H), 8.65 (d, 1H), 8.45 (t, 1H), 8.31 (d, 1H), 8.29 - 8.25 (m, 34 2H), 8.21 (dd, 1H), 8.09 (t, 1H), 8.05 (dd, 1H), 7.88 (dt, 1H), 7.81 (d, 1H), 7.75 - 7.70 (m, 2H), 7.15 - 7.06 (m, 1H), 6.30 - 6.18 (m, 1H), 4.71 (d, 2H), 4.60 (dt, 1H), 4.14 (t, 1H), 2.88 - 2.73 (m, 1H), 2.62 - 2.58 (m, 1H), 2.45 (d, 3H).19F NMR (471 MHz, DMSO-tfc) 5 -127.6 (d, IF), -186.9 (t, IF)[a]D20= -36,23 ° (589 nm, c 0,15 w / v %, DMF, 20°C)SFC (Chiralpak IH-3 4.6x100 mm, Mobile phase: CO2 / (MeOH + 0,3%iPrNH2) 55 / 45): rt =1.18, 100% eeCpd-1H NMR (500 MHz, DMSO-tfc) 59.55 (t, 1H), 8.67 (d, 1H), 8.48 (dd, 2H), 8.41 (d, 1H), 8.29 (dt, 1H), 35 8.21 (dd, 1H), 8.13 - 8.03 (m, 2H), 7.93 -7.86 (m, 2H), 7.84 - 7.78 (m, 1H), 7.72 (t, 1H), 7.10 (d, 1H), 6.23 (ddd, 1H), 4.73 (d, 2H), 4.60 (dt, 1H), 4.07 (t, 1H), 2.81 (dt, 1H), 2.61 - 2.54 (m, 1H), 2.44 (d, 3H).19F NMR (471 MHz, DMSO-tfc) 5 -186.5 - -186.9 (m, IF).[ot]D20= -39,8 ° (589 nm, c 0,17 w / v %, DMF, 20°C)SFC (Chiralpak IH-3 4.6x100 mm, Mobile phase: CO2 / (MeOH + 0,3%iPrNH2) 55 / 45): rtl =1.19, rt2 =1.46, 99.3% ee (second eluted)Cpd-1H NMR (500 MHz, DMSO-fifc) 5 9.63 (t, 1H), 8.84 (d, 1H), 8.64 (d, 1H), 8.53 (t, 1H), 8.49 (d, 1H), 36 8.47 - 8.42 (m, 2H), 8.24 (d, 1H), 8.18 (t, 1H), 7.88 (dd, 1H), 7.85 (dd, 1H), 7.82 (d, 1H), 7.74 (dd, 1H), 7.69 (t, 1H), 7.41 (t, 1H), 7.17 (d, 1H), 4.72 (d, 2H), 2.45 (d, 3H).19F NMR (471 MHz, DMSO-tfc) 5 -124.1 (s, IF), -124.2 (s, IF).Cpd-1H NMR (500 MHz, DMSO-fifc) 5 9.63 (t, 1H), 8.66 (d, 1H), 8.54 (t, 1H), 8.46 (d, 2H), 8.28 (d, 1H), 37 8.24 - 8.17 (m, 2H), 8.11 - 8.03 (m, 2H), 7.89 (d, 1H), 7.84 (d, 1H), 7.77 - 7.69 (m, 2H), 7.41 (t, 1H), 7.11 (d, 1H), 4.73 (d, 2H), 2.45 (d, 3H).19F NMR (471 MHz, DMSO-tfc) 5 -124.2 (s, 2F).Cpd# Analytical data (NMR, SFC if applicable, optical data if applicable) Cpd-1H NMR (400 MHz, DMSO-fifc) 59.53 (t, 1H), 8.83 (dd, 1H), 8.60 (d, 1H), 8.47 (d, 1H), 8.39 (d, 1H), 38 8.14 (t, 1H), 7.94 -7.86 (m, 3H), 7.82 - 7.75 (m, 2H), 7.73 (dd, 1H), 7.17 (d, 1H), 6.35 - 6.16 (m, 1H), 5.36 (t, 1H), 4.67 (d, 2H), 4.66 - 4.55 (m, 3H), 4.07 (t, 1H), 2.81 (dt, 1H), 2.59 (s, 1H), 2.43 (d, 3H).[a]D20= -40.75 ° (589 nm, c 0,19 w / v %, DMF, 20°C)SFC (Chiralpak IH-3 4.6x100 mm, Mobile phase: CO2 / (MeOH + 0,3%iPrNH2) 55 / 45): rt = 2.49, 100% eeCpd-1H NMR (500 MHz, DMSO-fifc) 5 9.53 (t, 1H), 8.63 (d, 1H), 8.60 (d, 1H), 8.50 (s, 2H), 8.48 (d, 1H), 39 8.41 (d, 1H), 8.29 - 8.23 (m, 2H), 8.20 (s, 1H), 7.83 (d, 1H), 7.78 (s, 1H), 7.73 (dd, 1H), 7.66 (t, 1H), 7.56 (dd, 1H), 6.23 (ddd, 1H), 4.70 (d, 2H), 4.59 (dt, 1H), 4.08 (t, 1H), 3.91 (s, 3H), 2.81 (m, 1H), 2.62 - 2.56 (m, 1H).19F NMR (471 MHz, DMSO-tfc) 5 -186.7 (s, IF).[a]D20= -34,34 ° (589 nm, c 0,2 w / v %, DMF, 20°C)SFC (Chiralpak IH-3 4.6x100 mm, Mobile phase: CO2 / (MeOH + 0,3%iPrNH2) 55 / 45): rtl =1.61, rt2 = 2.00, 99.3% ee (second eluted)BIOLOGICAL EXAMPLESExample 2. In vitro assays2.1. Biochemical assays2.1.1. ADP-Glo™ SMARCA2 / 4 Assays2.1.1.1. Overview
[0358] The ADP-Glo™ assay is a luminescent technology assay which measures the ADP formed from a helicase reaction. In this specific study, the helicase reactions consisted of the metabolism of ATP to ADP using pCMV-dR8.91 plasmid as a substrate by SWI / SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2 (635-1331, N-ter FLAG, Active Motif, Cat# 81439) or SMARCA4 (658-1328, N-ter FLAG, Active Motif, Cat# 81440). In a second step the ATPase reactions are terminated, and all the remaining ATP is depleted. In a final step the ADP is converted into ATP and this newly synthesized ATP is measured by using a luciferase / luciferin reaction. The generated light is measured using an EnVision plate reader, wherein the luminescent signal obtained positively correlates with the helicase activity.2.1.1.2. Protocol with compound pre-incubation
[0359] The test compounds were prepared as a 10-point dilution series with 1 / 5 dilution steps in 100% DMSO starting from 2 mM highest concentration, diluted 1 / 20 in water and 1 pL was transferred to the assay plates (Revvity Inc., Cat# 6007290).
[0360] The enzyme-substrate mixture was prepared by adding the enzyme and the substrate to the assay buffer (final concentration 25 mM Hepes pH7.5, 0.25 mM EGTA, 5% glycerol, 0.005% Tween 20, 5 mM MgCl2and 1 mM DTT).
[0361] 2 pL enzyme-substrate mixture was added to the assay plates, resulting in a final enzyme concentration of 0.625 nM (SMARCA2) and 1.25 nM (SMARCA4) and a final substrate concentration of 2 nM (SMARCA2 assay) and 1 nM (SMARCA4 assay).
[0362] The reaction was started by adding 2 pL of ATP (diluted in the assay buffer, (final concentration 10 pM)) on the assay plates. Plates were centrifuged for a few seconds at 300xg, followed by an incubation at RT for 120 min.
[0363] The reactions were stopped, and the unconsumed ATP was depleted by adding 5 pL ADP-Glo Reagent (Promega, Cat# V912B) to the reaction. The plates were centrifuged for a few seconds at 300xg and incubated at RT for 40 min (ATP depletion).
[0364] The ADP was converted to ATP and luciferase and luciferin was introduced to detect ATP by adding 10 pL Kinase Detection Reagent (Promega, Cat# V913B + V914B) to the reaction. The plates were centrifuged for a few seconds at 300xg and incubated at RT for 30 min (ADP detection).
[0365] Luminescence was measured on an EnVision plate reader (Revvity Inc.).2.1.1.3. Assay variant with high ATP concentration
[0366] Besides the standard ADP-Glo™ assay, an assay variant with high ATP concentration was developed, this to mimic the ATP concentration in the intra-cellular environment. In this high ATP variant, an ATP concentration of 1 mM and an enzyme concentration of 7.5 nM was used. The incubation time with luciferin and luciferase (ADP detection step) was increased to 60 min.Table V. Conditions for human SMARCA helicase ADP-Glo™ assaysEnzyme, Substrate, Incubation ATP Assay buffer[Enzyme] [Substrate] time25 mM Hepes10 pM ATP (or 1 pH7.5, 0.25 mMSMARCA2 (Active pCMV-dR8.91mM ATP for EGTA, 5%Motif, Cat# 81439), plasmid (Gentaur,high ATP assay) glycerol, 0.005% 120 min 0.625 nM (7.5 nM for Cat# PVT2323), 2(Promega, Cat# Tween 20, 5 mMhigh ATP assay) nMV915B) MgCl2and 1 mMDTTEnzyme, Substrate, Incubation ATP Assay buffer[Enzyme] [Substrate] time25 mM Hepes10 pM ATP (or 1 pH7.5, 0.25 mMSMARCA4 (Active pCMV-dR8.91mM ATP for EGTA, 5%Motif, Cat# 81440), plasmid (Gentaur,high ATP assay) glycerol, 0.005% 120 min 1.25 nM (7.5 nM for Cat# PVT2323), 1(Promega, Cat# Tween 20, 5 mMhigh ATP assay) nMV915B) MgCE and 1 mMDTT2.1.1.4. Data analysis and Results
[0367] Raw data were generated following the read-out performed on the EnVision plate reader, plotted to generate concentration response curves to calculate percentage inhibition (PIN) and IC50 for each SMARCA homologue.Table VI. SMARCA2 & SMARCA4 ADP-Glo™ assay IC50 of illustrative compounds of the invention.* > 500 - 20000 nM** > 100 - 500 nM*** > 50 - 100 nM**** 0.01 - 50 nMNA not measuredCpd# SMARCA2 SMARCA4 Cpd- 13 * * * * * * * *Cpd-1 * * * * Cpd-14 * * * * **Cpd-2 * * * * * * * * Cpd- 15 * * * * * * *Cpd-3 * * * * * * * * Cpd- 16 * * * * **Cpd-4 * * * * * * * Cpd- 17 * * * * * * * *Cpd-5 * * * * * * * * Cpd- 18 * * * * * * * *Cpd-6 * * * * * * * * Cpd- 19 * * * * * * * *Cpd-7 * * * * ** Cpd-20 * * * * * * * *Cpd-8 * * * * ** Cpd-21 * * * * * * * *Cpd-9 * * * * * * * * Cpd-22 * * * * * * * *Cpd- 10 * * * * * * * * Cpd-23 * * * * * * * *Cpd-11 * * * * * * * * Cpd-24 * * * * * * * *Cpd- 12 * * * * ** Cpd-25 * * * * **Cpd-26 * * * * * * * * Cpd-34 * * * * * * * *Cpd-27 * * * * * * * * Cpd-35 * * * * * * * *Cpd-28 * * * * * * * * Cpd-36 * * * * * * * *Cpd-29 * * * * * * * * Cpd-37 * * * * * * * *Cpd-30 * * * * * * * * Cpd-38 * * * * * * * *Cpd-32 * * * * * * * * Cpd-39 * * * * * * * *Cpd-3 * * * * **32.2. Cellular assays2.2.1. KRT80-Based Target Engagement Assay2.2.1.1. Overview
[0368] Keratin, type II cytoskeletal 80 (KRT80) is a gene that is transcriptionally regulated downstream of SMARCA2 and is known to be a biomarker for SMARCA2 inhibition in SMARCA4 deficient cells, such as A549. The KRT80 mRNA transcription assay aims at measuring the reduction of KRT80 gene expression levels in A549 cells upon treatment with possible SMARCA2 inhibitors using quantitative Polymerase Chain Reaction (qPCR) as a readout. For normalization purposes, glucuronidase beta (B2M) mRNA levels are measured within the same cDNA sample.2.2.1.2. Protocols
[0001] The test compounds are prepared as a 10-point 1 / 5 dilution series in 100% DMSO starting from 10 mM.
[0002] A549 cells (ATCC, Cat# CCL-185) are seeded (7000 cells in 45 pL per well) in DMEM assay medium supplemented with 2% heat-inactivated fetal bovine serum (FBS) and 1% Penicillin-Streptomycin (P / S) in 384-well cell plates. The plates are briefly centrifuged at 300xg and stored at RT for 15-30 min to allow cells to distribute evenly in the wells.
[0003] Compounds and controls are diluted 1 / 10 in assay medium and 5 pL transferred to the cell plates. The plates containing cells and compounds are briefly centrifuged at 300xg and incubated at 37 °C, 5% CO2 for 15-18 h.
[0004] The supernatant is then removed, and the cells washed once with cold PBS (4 °C) using a Blue®Washer device (BlueCatBio GmbH).
[0005] Then the cells are lysed by adding 25 pL of Cells-to-Ct lysis buffer (Thermo Fisher Scientific Inc., Cat# 4391851C). The plates are incubated on an orbital shaker for 5 min. 2.5 pL of Cells-to-Ct STOP solution is added on top of the lysis buffer and the plates incubated 2 min on the orbital shaker.
[0006] Plates are put on ice if the RT-PCR is performed the same day. If the RT-PCR is performed later, plates are sealed with an aluminum seal and kept at -80 °C and later thawed on an orbital shaker (30 min at 500 rpm) and put on ice until the RT-PCR.
[0007] A PCR plate is filled with 20 pL of reverse transcription mix containing 50% Fast Advanced reverse transcription buffer, 5% Fast Advanced reverse transcription enzyme mix (Thermo Fisher Scientific Inc., Cat# A39110), and 20% nuclease-free water (Qiagen GmbH, Cat# 129117).
[0008] 5 pL of the cell lysate is added on top of the reverse transcription mix in the PCR plate and the plate is sealed.
[0009] RT-PCR is performed in a thermal cycler to generate cDNA: samples are incubated for 30 min at 37 °C, 5 min at 95 °C followed by cooling to 4 °C. Sample plates are then kept on ice or frozen at -20 °C for later use.
[0010] A PCR plate is filled with 6 pL of a mix (60% of the total reaction volume) containing 50% of TaqMAN Fast Universal PCR Master Mix (Thermo Fisher Scientific Inc., Cat# 4444557), 1.7% of TaqMAN KRT80 gene expression assay (Thermo Fisher Scientific Inc., Cat# 4351368) (250 nM final), 1.7% of TaqMAN B2M expression assay (Thermo Fisher Scientific Inc., Cat# 4448491) (250 nM final) and 6.6% of nuclease-free water (Qiagen GmbH, Cat# 129117).
[0011] With a liquid handler, 4 pL of the cDNA (40% of the total reaction volume) is added on top of the qPCR mix. The PCR plate is sealed, briefly centrifuged, and the qPCR is performed using the following program: 20 s at 95 °C, 40 cycles of 1 s at 95 °C and 20 s at 60 °C.
[0012] Raw data are generated by the ViiA7 Real-Time PCR System and the cycle threshold (Ct) calculations are done by the ViiATM 7 software (Thermo Fisher Scientific Inc.) for both genes, KRT80 and B2M. These data are imported into the Phaedra software (Open Analytics NV) for automated calculation of Delta Ct (DCt) and Normalized Relative Quantities (NRQ). Based on the control wells, data are converted to percentage of inhibition (PIN) and concentration-response curves generated. From those curves, IC50 values were determined, all using Phaedra.2.2.2. SMARCA2 / 4 Selectivity Assay (HT1080 SMARCA2 / 4 KO Cells, Multiplexed qPCR KRT802.2.2.1. Overview
[0013] Keratin, type II cytoskeletal 80 (KRT80) is a gene transcriptionally regulated downstream of both SMARCA2 and SMARCA4. Its expression is reduced upon inhibition of either target and therefore serves as a pharmacodynamic biomarker for SMARCA2 / 4 inhibition. The SMARCA2 / 4 selectivity assay uses HT1080 SMARCA2 knockout (KO) cells to assess SMARCA4 inhibition, and HT1080 SMARCA4 KO cells to assess SMARCA2 inhibition, enabling the evaluation of compound selectivity. Quantitative Polymerase Chain Reaction (qPCR) is used to detect changes in KRT80 mRNA expression. TATA-Box Binding Protein (TBP) is measured in the same lysate as a housekeeping gene using a multiplexed readout.2.2.2.2. ProtocolsTest compounds are prepared as a 10-point 1 / 5 dilution series in 100% DMSO, starting from a 2 mM top concentration (final assay concentration: 6.67 pM @ 0.33% DMSO).HT1080 SMARCA2 KO and SMARCA4 KO cells are seeded separately (10,000 cells in 45 pL per well) in EMEM assay medium supplemented with 2% heat-inactivated fetal bovine serum (FBS) and 1% Penicillin-Streptomycin (P / S) in 384-well cell plates. Plates are briefly centrifuged at 1000 RPM and left at room temperature (RT) for 30-45 min to allow even cell distribution.Compounds and controls are diluted 1 / 30 in assay medium and 5 pL is transferred to the assay plates (duplicates per cell line on separate plates). Plates are briefly centrifuged again and incubated at 37 °C, 5% CO2 for 15-18 hours.After incubation, supernatants are removed, and cells are washed once with cold PBS (4 °C) using a Blue®Washer device (BlueCatBio GmbH).Cells are lysed by adding 25 pL of Cells-to-Ct lysis buffer (Thermo Fisher Scientific Inc.) followed by 5 min incubation on an orbital shaker. 2.5 pL of Cells-to-Ct STOP solution is added and plates are incubated another 2 min on the shaker.Plates are placed on ice if RT-PCR is performed the same day. For delayed analysis, plates are sealed and stored at -80 °C. Prior to reverse transcription, plates are thawed on an orbital shaker (30 min at 500 rpm) and kept on ice.A PCR plate is prepared with 18 pL of reverse transcription mix per well containing 70% Fast Advanced RT buffer, 7% Fast Advanced RT enzyme mix (Thermo Fisher Scientific Inc.), and 23% nuclease-free water (Qiagen GmbH).7 pL of lysate is added to the PCR plate, which is then sealed. RT-PCR is performed with the following program: 60 min at 37 °C, 5 min at 95 °C, followed by cooling to 4 °C. The cDNA is stored on ice or at -20 °C until qPCR analysis.A new PCR plate is filled with 6 pL of qPCR mix containing 83.3% TaqMAN Fast Advanced Master Mix (Thermo Fisher Scientific Inc.), 2.6% TaqMAN KRT80 gene expression assay (Thermo Fisher Scientific Inc., Cat# Hs01372365_ml), 2.6% TaqMAN TBP expression assay (Thermo Fisher Scientific Inc., Cat# Hs00427620_ml), and 11.1% nuclease-free water (Qiagen GmbH).With a liquid handler, 4 pL of cDNA is added to the qPCR mix. The PCR plate is sealed, briefly centrifuged, and stored at 4 °C if not immediately run. qPCR is performed using the following program: 20 s at 95 °C, followed by 40 cycles of 1 s at 95 °C and 20 s at 60 °C.Raw data are generated using the ViiA7 or QuantStudio Real-Time PCR systems. Ct values for both genes (KRT80 and TBP) are calculated by their respective software. Data are then imported into Phaedra software (Open Analytics NV) for automated calculation of Delta Ct (ACt), Normalized Relative Quantities (NRQ) and scaled NRQ. Based on the control wells, data are converted to Percentage of Inhibition (PIN) and concentration-response curves are generated. From those curves, IC50 values are determined, all using Phaedra software.2.2.3. Cell Death Based Ph en otypic Assay2.2.3.1. Overview
[0014] SK-MEL-5 (ATCC, Cat# HTB-70) is a SMARCA4 mutant melanoma cell line which is highly dependent on SMARCA2 to grow. The SK-MEL-5 proliferation assay aims at measuring the effect of possible SMARCA2 inhibitors on the proliferation of the SK-MEL-5 cells by using an ATPlite™ readout (Revvity, Inc.). ATP is a marker for cell viability because it is present in all metabolically active cells. SMARCA2 inhibitors are able to decrease SK-MEL-5 cell proliferation and thus the amount of ATP, which results in a decrease in ATPlite™ luminescent signal.2.2.3.2. Protocols
[0015] The test compounds were prepared as 8-point serial dilutions with 1 / 4 dilution steps in 100% DMSO starting from 10 mM highest concentration (final highest concentration 30 pM) in 384 well plates.
[0016] Four days prior to the start of the assay, SK-MEL-5 cells were thawed and seeded in T175 flasks, 2.0 xlO6cells per flask, in 25 mL culture medium (EMEM containing 10% heat inactivated Fetal Bovine Serum (FBS) and 1% Penicillin - Streptomycin (P / S)). After 24 h incubation at 37 °C, 5% CO2, the medium was refreshed, and the cells were further incubated in an incubator at 37 °C and 5% CO2 for 72 h
[0017] SK-MEL-5 cells were harvested using 0.25% Trypsin-EDTA and counted. 2000 cells were seeded in only the inner wells of a 384 well cell plate, in 70 pL assay medium (EMEM containing 2% heat inactivated FBS and 1% P / S) per well. The outer wells were filled with 70 pL of phosphate-buffered saline. The plates were briefly centrifuged at 300xg and stored at RT for 15-30 min to allow cells to distribute evenly in the wells.
[0018] Compounds and controls were diluted 1 / 22 in assay medium and 5 pL was transferred to the cell plates. The plates with cells and compound were briefly centrifuged at 300xg and incubated at 37 °C, 5% CO2 for 96 h.
[0019] After 96 h incubation, the plates were centrifuged for 1 min at 300xg and 50 pL supernatant was removed from the wells. 25 pL ATPlite™ reagent (Revvity, Cat# 6016739) was added to the wells containing cells and compounds. The plates were briefly centrifuged at 300xg and were incubated at RT for 10 min.
[0020] Readout of the luminescent signal was performed on a plate reader, e.g., EnVision (Revvity, Inc.).
[0021] Raw data were generated by the plate reader (e.g., EnVision). These raw data were imported into the Phaedra software (Open Analytics NV) for automated calculation of results based on the control wells and the creation of the concentration response curves from which IC50 values were derived.2.2.3.3. Results & Outcome
[0022] The data obtained when subjecting illustrative compounds of the invention are described in the table below.Table VII. SK-MEL-5 cell death assay results of illustrative compounds of the invention.* > 1000 - 20000 nM** > 500 - 1000 nM* * * > 100 - 500 nM* * * * 0.01 - 100 nMCpd# SK-MEL-5 Cpd-20 * * * * Cpd-1 * Cpd-21 * * * * Cpd-2 * * * Cpd-22 * * * Cpd-3 * * * Cpd-23 * * * Cpd-4 * * * Cpd-24 * * * Cpd-5 * * * Cpd-25 * * * Cpd-6 * * * Cpd-26 * * * * Cpd-7 ** Cpd-27 * * * * Cpd-8 * Cpd-28 * * * * Cpd-9 * * * * Cpd-29 * * * * Cpd- 10 ** Cpd-30 * * * * Cpd-11 * * * Cpd-32 * * * * Cpd- 12 * * * Cpd-33 * * *Cpd- 13 * * * * Cpd-34 * * * * Cpd-14 ** Cpd-35 * * * * Cpd- 15 ** Cpd-36 * * *Cpd- 16 * Cpd-37 * * *Cpd- 17 * * * * Cpd-38 * * * * Cpd- 18 * * * * Cpd-39 * * * *Cpd- 19 * * * *Example 3. Pharmacokinetic, ADME and Toxicity Assays3.1. Thermodynamic solubility
[0023] The thermodynamic solubility is determined in Fasted State Simulated Gastric Fluid (FaSSGF, pH 1.6), Fed State Simulated Intestine Fluid (FeSSIF v2, pH 5.8), Fasted State Simulated Intestine Fluid (FaSSIF v2, pH 6.5) and phosphate buffer (pH7.4).
[0024] Approximately 1 mg of each compound is weighed into a 12 mL clear glass screw cap vial and 1 mL of medium is added (final concentration about 1 mg / mL). The sample is placed in a thermodynamic water bath at 37 °C and 120 rpm of orbital shaking for 24 h.
[0025] For HPLC / DAD analysis the sample is filtered through a 0.2 pm PTFE filter mounted onto syringe and then analysed neat and accurately diluted 10 and 100 times.
[0026] The same batch of test compound is used as a standard, assigning the purity of 100%, in order to prepare the calibration curve. Test compound stock solution is prepared at a concentration of 1 mg / mL in DMSO and diluted to cover the calibration range from 0.0001 - 0.1 mg / mL.
[0027] The samples are analysed on HPLC system with a flow rate of 0.5 mL / min. Solvent A is 10 mM ammonium carbonate at pH 10 and solvent B is acetonitrile. The sample is going through a XB ridge C18 2.7 pM (2.1 x 50 mm) column, from Waters. The solvent gradient has a total run time of 12 min and ranges from 10% B to 90% B.
[0028] Peak areas are analysed and are plotted against the standard curve to obtain the solubility of the compound.
[0029] Solubility values are reported in pM or pg / mL.3.2. Aqueous Solubility
[0030] This protocol describes determination of kinetic solubility by turbidimetry.
[0031] Turbidimetric solubility allows rapid determination of solubility using small amounts of compound. Briefly, compound’s DMSO solutions (prepared at specific concentrations) are spiked into aqueous buffer and turbidity is measured using VIS spectrophotometry at 620 nm. Sulfaphenazole and a-naphtoflavone are used as assay controls.
[0032] 10 mM DMSO stock solution is diluted in DMSO (in 96-well V-bottom polypropylene microplates) to a concentration of 1 mM.
[0033] 3 pL of compound ’s / control’s dilution in DMSO in triplicates are added to appropriate wells containing 297 pL of 100 mM PBS solution to the final concentration of 10 pM (1% DMSO; Table 3.; done in 96-well flat bottom microplates)
[0034] The plate is incubated by gently shaking (200-300 rpm) for 45 min at 37 °C and left at RT (without shaking) for 15 min (total incubation time = 1 h).
[0035] The plate absorbance at 620 nm is read on a Microplate reader (Tecan, Infinite F500 or Spark).
[0036] Calculation of solubility range data and resulting curves is made by Excel tools software.
[0037] The absorbance is proportionally increased with concentration of insoluble particles. Compound / control samples are compared to a solvent control in aqueous buffer (DMSO 1% final concentration), where significant increase of sample absorbance is considered when its absorbance is 3-fold standard deviation of average DMSO absorbance.
[0038] Results are accepted depending on solubility values obtained for assay controls:a-naphtoflavone: <10 pMsulfaphenazole: >10 pM
[0039] Results are expressed as an average of three replicas (<10 pM or >10 pM) for one concentration set-up.3.3. Plasma Protein Binding (Equilibrium Dialysis)
[0040] The binding of the test compound to plasma proteins is tested by equilibrium dialysis using a Teflon unit from HTDialysis, performed on a Freedom EVO liquid handling unit.
[0041] Prior to the start of the experiment, dialysis membranes (Dialysis membranes MW cut-off 12-14kDa - HTDialysis - Cat# 1101) are soaked in deionised water for 60 min, transferred and left overnight in 20% ethanol. On the day of experiment, compound and control stock solutions are diluted, spiked into plasma in order to achieve a final concentration of 5 pM (0.5% DMSO).
[0042] Immediately after assembly of the Teflon unit, a volume of 100 pL of plasma (spiked with compound / control) is placed on one side of the well and 100 pL of blank PPB buffer (60 mM Na2HPC>4, 14 mM KH2PO4, 70 mM NaCl) is added to the other side, respectively, with each compound assayed in duplicate. The test compound is incubated for 4 h at 37 °C with gentle shaking. Thereafter, an aliquot is taken from each side of the well and matrix matched (mix of equal volumes of spiked plasma with blank PPB buffer and samples from buffer compartment with blank plasma). In order to estimate the recovery an aliquot is also taken at t=0 min from spiked plasma solutions and matrix matched as described above.
[0043] Matrix matched samples are further mixed with six volumes of STOP solution (acetonitrile: methanol, 2: 1 v / v with an internal standard (IS)). After brief mixing and centrifugation (at 4500 rpm for 30 min, at +4°C), the supernatant is transferred into new plates and analysed and quantified by LC-MS / MS.
[0044] The percentage bound (PPB) is determined using the following equation:
[0045] PPB = [(Cplasma-Cbuffer) / Cplasma]*100
[0046] Cplasma = Peak area of the compound in the plasma / Peak area of the IS in the plasma
[0047] Cbuffer = Peak area of the compound in the buffer / Peak area of the IS in the buffer
[0048] The recovery is a control, it allows to be sure that the compound has not a non-specific binding to the plates or it is not stable in the plasma in these conditions.
[0049] % recovery = [(Buffer+Plasma) / Recovery]* 100
[0050] Buffer = (ratio of the peak area of the compound / peak area of IS) in Buffer compartment after 4 h
[0051] Plasma = (ratio of the peak area of the compound / peak area of IS) in Plasma compartment after 4 h
[0052] Recovery = ratio at TO of the peak area of the compound in the well recovery / peak area of the IS in the well recovery3.4. Aldehyde oxidase stability
[0053] An in vitro metabolic stability in human and rat liver S9 (human: 20-donor pool, mixed gender (Coming, Cat# 452961) and rat: pooled, male Sprague-Dawley (Coming, Cat# 452591)) is done in order to investigate the test compound as substrate of aldehyde oxidase. A 10 mM DMSO stock solution of the test compound is first diluted in DMSO (40 fold) to obtain a 250 pM working solution. Incubation mixtures are prepared by adding liver S9 suspension (final protein concentration of 2 mg / mL) to 50 mM potassium phosphate buffer, pH 7.4. Hydralazine (Sigma, Cat# H1753) (selective inhibitor of aldehyde oxidase; final concentration of 100 pM) or miliQ water are added for incubations with and without addition of selectiveinhibitor, respectively. After pre-warming for 5 min at 37 °C, the reaction is initiated by addition of test compound to the incubation mixture (final concentration in the incubation mixture of 1 pM, 0.4%DMSO). After 0, 3, 6, 12, 18 and 30 min of incubation, the reaction (aliquot of 100 pL) is terminated with 300 pL of acetonitrile: methanol (2: 1) mixture with 1% acetic acid and the analytical internal standard. Samples are mixed, centrifuged and the supernatant analysed by LC-MS / MS (Table 2 and Table 3). Phthalazine (Aldrich, Cat# P38706) is included as a positive control.
[0054] S9 stability, expressed as the percentage of remaining parent compound, is calculated from the peak area ratio of compound and internal standard following different incubation times compared to the same ratio at the t=0 min (100%). The half-life (tl / 2) is calculated in GraphPadPrism software from % remaining vs. time regression using non-linear regression fit (one phase exponential decay) with following constrain parameters: Span=100, Plateau=0, K=no constraint).
[0055] In vitro intrinsic clearance (CLint) is calculated from the half-life value using following equation: CLint[pL / min / mg] = (ln2 / tl / 2)*(mL per incubation / mg S9 protein)3.5. Liver microsomal stability
[0056] The test compound is diluted from DMSO stock solution to obtain a final concentration of 1 pM in the final incubation mix (final DMSO 0.03%). A NADPH generating system (Cofactor solution) is prepared by adding to a 50 mM PBS pH 7.4 buffer, NADP (Sigma, N0505), G6P (Sigma, G6526), MgCLxOILO (Sigma, M2670) and G6P DH (Sigma, G637) to obtain in the final incubation mix NADP at 0.5 mM , G6P at 5 mM , MgC12.6H2O at 0.5 mM and G6P DH at 1.5 U / mL. Liver microsomes (Coming; Discovery Life Sciences) solution is prepared from 20 mg / mL stock concentration to obtain a final concentration in the incubation mix of 0.5 mg / mL.
[0057] Test compounds are incubated at 37 °C with and without cofactors and reaction is started by adding cofactors or buffer (for negative control) to incubation mix. Time points are taken at 0, 10, 25 and 40 min. At the desired incubation time point, a STOP solution (acetonitrile: methanol, 2:1 v / v) is added at a ratio 3: 1 to the incubation mix. Samples are then centrifuged (at 4500 rpm, at 4 °C, for 30 min). The supernatant is then analyzed using a LC-MS / MS method.
[0058] Metabolic stability, expressed as the percentage of remaining parent compound, is calculated from the ratio of peak area of the remaining compound and peak area of the internal standard after different time of incubation compared to the same ratio at the t=0 min (100%):
[0059] % remaining = (peak area ratios of test compound vs IS at appointed time) / (peak area ratios of test compound vs IS at 0 min) x 100
[0060] The half-life (ti / 2) is calculated in GraphPad Prism software from % remaining vs. time regression using non-linear regression fit (one phase exponential decay with following constrain parameters: Span=100, Plateau=0, K=no constraint).
[0061] In vitro intrinsic clearance (CLmt) is calculated from half-life using following equation:
[0062] CLmt = [pL / min / mg] = 0.693 / ti / 2 / min ' (mL of incubation / mg protein) x 10003.6. Hepatocyte stability
[0063] The test compound is diluted from DMSO stock solution to obtain a final concentration of 1 pM in the final incubation mix. The test compound is incubated in dog, monkey, human, mouse and rat hepatocytes (BioIVT, mouse Cat. No. M005052, rat Cat. No. M00005, dog, Cat. No. M00205, monkey Cat. No. M00305, human Cat. No. X008001) (final concentration: 0.5x106 cells / mL), resuspended in Krebs-Henseleit modified buffer for 3 h (except in human - 90 min) at 37 °C. Aliquots are taken at different time points and the reaction is terminated by addition of 3 volumes of STOP solution (acetonitrile: methanol = 2:1 with an internal standard). Aliquots were then centrifuged (at 4500 rpm, at 4 °C, for 30 min). The supernatant is then analysed using a LC-MS / MS method.
[0064] Metabolic stability, expressed as the percentage of remaining parent compound, is calculated from the ratio of peak area of the remaining compound and peak area of the internal standard after different time of incubation compared to the same ratio at the t=0 min (100%).
[0065] The half-life (t 1 / 2) is calculated in GraphPadPrism software from % remaining vs. time regression using non-linear regression fit (one phase exponential decay) with following constrain parameters: Span=100, Plateau=0, K=no constraint)
[0066] In vitro intrinsic clearance (CLint) is calculated from half-life using the following equation:
[0067] CLint|pL / min / l 0"cclls| = (ln2 / tl / 2)*(mL per incubation / #cells per incubation)3.7. Caco2 Permeability
[0068] Bi-directional Caco-2 assays are performed as described below. Cells are seeded at 1 x 105 cells / cm2 in 96-well HTS Transwell plates (Coming). Permeability assays are performed with the cells at days 21-25 post-seeding.
[0069] This assay is performed in both the apical (A) to basolateral (B) A-B or B-A direction. Compounds and the references (propranolol, labetalol, ranitidine, colchicine) are prepared at 10 pM in HBSS-MES (pH 6.5) or HBSS-HEPES (pH 7.4) with a final DMSO concentration of 1 % (v / v). The working solution is then centrifuged and the supernatant is added to the donor side.
[0070] The assay plate is incubated at 37 °C for 60 min or 40 min for the A-B or B-A assay, respectively. Samples are aliquoted from the donor side at time zero and the end point, and from the receiver side at the end point.
[0071] In addition, Lucifer yellow (LY), a membrane integrity marker, is co-incubated with the test compound at the start of the experiment to assess integrity of the cell layers. As LY cannot freely permeate lipophilic barriers, a high Papp of the Lucifer yellow (measured by fluorescence) indicates poor formation of the cell monolayer.
[0072] Moreover, the Transepithelial electrical resistance (TEER) of each Multiscreen™ well is also evaluated prior to the initiation of the assay so as to evaluate monolayer integrity.
[0073] Reference compounds namely, Propranolol (highly permeable), Labetalol (moderately permeable), Ranitidine (poorly permeable), and Colchicine (P-glycoprotein substrate) are included in this assay. Samples are analysed by LC / MS-MS.
[0074] Apparent permeability (Papp) values are calculated from the relationship:
[0075] Papp = [compound] acceptor final ' Vacceptor / ([COmpOUnd] donor initial ' Vdonor) / Tmc' Vdonor / Surface area ' 60 ' IO-6cm / s
[0076] V = chamber volume
[0077] Tine = incubation time.
[0078] Surface area = 0.33cm2
[0079] The Efflux ratios, as an indication of active efflux from the apical cell surface, are calculated using the ratio of Papp B>A / Papp A>B.
[0080] The following assay acceptance criteria are used: If at least 3 out of 4 control molecules are in these ranges determined by the historical data, the assay is validated.
[0081] Lucifer yellow permeability: <0.5 10-6 cm / s
[0082] Colchicine: Papp (A>B) value < 1 (xlO-6 cm / s) with Efflux ratio >4
[0083] Labetalol: Papp (A>B) value < 6 (xlO-6 cm / s)
[0084] Propranolol: Papp (A>B) value < 25 (xlO-6 cm / s)
[0085] Ranitidine: Papp (A>B) value < 2 (xlO-6 cm / s)3.8. MDCKII-MDR1 Permeability
[0086] MDCKII-MDR1 cells are Madin-Darby canine kidney epithelial cells, over-expressing human multi -drug resistance (MDR1) gene, coding for P-glycoprotein (P-gp). Cells are obtained from Netherlands Cancer Institute and used after a 3-4 day cell culture in 24-well Millicell cell culture insert plates (Millipore, PSRP010R5). Bi-directional MDCKII-MDR1 permeability assay is performed as described below.
[0087] 3x105 cells / mL (1.2x105 cells / well) are seeded in plating medium consisting of DMEM + 1% Glutamax-100 + 1% Antibiotic / Antimycotic + 10% FBS (Biowest, S 1810). Cells are left in CO2 incubator for 3-4 days. The medium is changed 24 h after seeding and on the day of experiment.
[0088] Test and reference compounds (amprenavir and propranolol) are prepared in Dulbecco’s phosphate buffer saline (D-PBS, pH7.4) and added to either the apical (400 pL) or basolateral (800 pL) chambers of the Millicell cell culture insert plates assembly at a final concentration of 10 pM (0.5 pM in case of amprenavir) with a final DMSO concentration of 1%
[0089] 100 pM Lucifer Yellow (Sigma) is added to the all-donor buffer solutions, in order to assess integrity of the cell monolayers by monitoring Lucifer Yellow permeation. Lucifer yellow is a fluorescent marker for the paracellular pathway, and it is used as an internal control in every monolayer to verify tight junction integrity during the assay.
[0090] After a 1 h incubation at 37 °C while shaking at an orbital shaker at 150 rpm, 75 pL aliquots are taken from both apical (A) and basal (B) chambers and added to 225 pL acetonitrile: water solution (2:1)containing analytical internal standard (10 ng / mL warfarin) in a 96 well plate. Aliquoting is also performed at the beginning of the experiment from donor solutions to obtain initial (Co) concentration.
[0091] Concentration of compound in the samples is measured by high performance liquid-chromatography / mass spectroscopy (LC-MS / MS).
[0092] Lucifer yellow is measured with a Fluoroscan Ascent FL Thermo Scientific (Ex 485 nm and Em 530 nm) in a 96 well plate containing 150 pL of liquid from all receiver wells (basolateral or apical side).
[0093] The apparent permeability coefficient (Papp) is calculated according to the following equation: Papp = (dQ / dT)*(l / C0)*(l / A)
[0094] where dQ / dT = permeability rate
[0095] CO = initial concentration in donor compartment
[0096] A = surface area of the cell monolayer (0.11 cm2)
[0097] ‘ ‘Concentration” is the ratio between compound and internal standard peak areas.
[0098] The Papp value has a dimension of a rate (xlO-6 cm / sec).
[0099] Permeability values are classified as follows: low permeability: <2xl0-6cm / sec, moderate permeability: 2-10x 10'6cm / sec, high permeability: >10* 10'6cm / sec.
[0100] The Efflux ratio, as an indication of active efflux from the apical cell surface, is calculated using following equation: Efflux ratio = Papp (B2A) / Papp (A2B).
[0101] A compound is considered to be a possible P-gp substrate when the efflux ratio is > 2.
[0102] Mass balance (MB) is calculated from equation: MB = (Md+Mr) / Mo, where Md = mass of drug in donor compartment at time 60 min, Mr = mass of drug in receiver compartment at time 60 min, Mo = mass of drug in donor compartment at time 0 min, Mass of drug = Analyte / IS ratio * volume of compartment (75 pL or 250 pL).
[0103] Mass balance results should be evaluated as follows: Mass balance between 80-120%: acceptable, Mass balance between 50-80% and 120-135% should be interpreted with caution, Mass balance <50% and >135% should be discarded.
[0104] Results are accepted based on obtained data: Lucifer yellow: all Papp values should be <3x10-6 cm / sec, Amprenavir: low permeability (PappA2B <2x10-6 cm / sec), efflux ratio >2, Diclofenac: high permeability (PappA2B >10x10-6 cm / sec), efflux ratio <23.9. Pharmacokinetic study in rodents3.9.1. Animals
[0105] Wistar-Han rats (male, 200-225g) are obtained from Janvier (France).
[0106] CD-I Mice (male, 25 -30g) are obtained from Janvier (France).
[0107] Animals are acclimatized for at least 7 days before treatment and are kept on a 12 h light / dark cycle (0700 - 1900). Temperature is maintained at approximately 22 °C, and food and water are provided ad libitum.3.9.2. Pharmacokinetic study
[0108] Compounds are formulated in DMSO / 10% hydroxylpropyl-P-cyclodextrine (5 / 95) for the intravenous route and in a suitable solution for the oral route. Test compounds are orally dosed as a single oesophageal gavage at 5 mg / kg under a dosing volume of 10 mL / kg (group of 3 animals) and intravenously dosed as a bolus via the caudal vein at 0.5 mg / kg under a dosing volume of 5 mL / kg. (groups of 2 animals). Blood samples are collected at the retro-orbital sinus with EDTA as anti-coagulant at the following time points: 0.05, 1, 3, 6 and 24 h (intravenous route), and 0.25, 1, 3, 6, and 24 h (oral route). Whole blood samples are centrifuged at 5000 rpm for 10 min and the resulting plasma samples are stored at -20 °C pending analysis.3.9.3. Quantification of compound levels in plasma
[0109] Plasma concentrations of each test compound are determined by an LC-MS / MS method in which the mass spectrometer is operated in positive or negative electrospray mode.3.9.4. Determin ation of ph armacokin etic parameters
[0110] Pharmacokinetic parameters are calculated for each individual animal and for each analyte by noncompartmental analysis.3.10. Liability for QT prolongation[oni] Potential for QT prolongation is assessed in the hERG manual patch clamp assay.3.10.1. Manual patch clamp assay
[0112] Single CHO cells are used for recording hERG currents at near physiological temperature (34-35 °C) using the whole-cell patch-clamp technique with an Axopatch 700A amplifier / pClamp software (Molecular Devices, Sunnyvale CA).
[0113] Electrodes (5-7 MQ resistance) are prepared from GC 150-10 glass capillary tubes (Harvard Apparatus, Cambridge, UK) and filled with intracellular solution (in mM: KC1 120; Na2ATP 4; HEPES 10; EGTA 10; MgCh 1.75; CaCl25.374, pH 7.2 adjusted with KOH).
[0114] The patch-clamp recording chamber is perfused with control extracellular solution (in mM: NaCl 145; KC14; MgC12 1; HEPES, 10; glucose 10; CaCl22 at pH 7.4 adjusted with NaOH).
[0115] With the formation of a gigaohm seal, the cell membrane is ruptured to establish the whole-cell configuration. The minimum acceptable seal resistance is 1 gigaohm, and access resistance no greater than 20pF.
[0116] The cell membrane is then voltage-clamped at a holding potential of -80 mV and depolarised to +20 mV for 2 sec followed by a negative pulse at -40 mV for 1.6 sec, before returning to -80 mV at a frequency of 0.1 Hz.
[0117] Once the hERG current is stable, the perfusion is switched to extracellular solution containing test compounds starting from the lowest concentration. Each concentration on the 4pt concentration-response curve is tested for 4 min to achieve steady state.3.10.2. Automated patch clamp
[0118] Electrophysiological recordings are made from a Chinese Hamster Ovary cell line stably expressing the full-length ion channel. Single cell ionic currents are measured in whole-cell configuration at RT (21-23 °C) using a QPatch II (Sophion Bioscience).
[0119] The internal solution for hERG contains (mM): 120 KC1, 20 KF, 10EGTA, 10 HEPES and is buffered to pH 7.3.
[0120] The external solution (HEPES -buffered saline, HBPS) contains (mM): 138 NaCl, 4.5 KC1, 1.8 CaCE, 1.0 MgCE. 10 HEPES, 10 glucose, buffered to pH 7.4.
[0121] Cells are clamped at a holding potential of -80 mV before a step to +20 mV for 500 ms, and then -40 mV for 500 ms. The test pulse is applied every 10 seconds. Currents are measured from the -40 mV step and referenced to the holding current.
[0122] Compounds are incubated for 120 seconds to allow stabilization of the parameters. Concentrationresponse curves are generated by cumulative addition of compound with concentrations low to high.FINAL REMARKS
[0123] It will be appreciated by those skilled in the art that the foregoing descriptions are exemplary and explanatory in nature, and intended to illustrate the invention and its preferred embodiments. Through routine experimentation, an artisan will recognize apparent modifications and variations that may be made without departing from the spirit of the invention. All such modifications coming within the scope of the appended claims are intended to be included therein. Thus, the invention is intended to be defined not by the above description, but by the following claims and their equivalents.
[0124] All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication are specifically and individually indicated to be incorporated by reference herein as though fully set forth.
[0125] It should be understood that factors such as the differential cell penetration capacity of the various compounds can contribute to discrepancies between the activity of the compounds in the in vitro biochemical and cellular assays.
[0126] At least some of the chemical names of compound of the invention as given and set forth in this application, may have been generated on an automated basis by use of a commercially available chemical naming software program, and have not been independently verified. Representative programs performing this function include the Lexichem naming tool sold by OpenEye Scientific Software, Inc. and the Autonom Software tool sold by MDL, Inc. In the instance where the indicated chemical name and the depicted structure differ, the depicted structure will control.REFERENCESBundgaard H. 1985. Design of prodrugs, Elsevier.Clark K et al. 2012. Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc. Natl. Acad. Sci. U. S. A. 109, 16986— 16991.Ehrenhofer-Wolfer K et al. 2019. SMARCA2 -deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines. Sci. Rep. 9, 11661.Kadoch C et al. 2013. Proteomic and bioinformatic analysis of mammalian SWI / SNF complexes identifies extensive roles in human malignancy. Nat. Genet. 45, 592-601.Ozanne J, Prescott AR, Clark K. 2015. The clinically approved drugs dasatinib and bosutinib induce antiinflammatory macrophages by inhibiting the salt-inducible kinases. Biochem. J. 465, 271-279. Remington JP, Gennaro AR. 1985. Remington ’s Pharmaceutical Sciences, Mack.Stahl PH, Wermuth CG. 2011. Pharmaceutical Salts: Properties, Selection, and Use, 2nd Revised Edition Wiley,Sundberg TB et al. 2014. Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells. Proc. Natl. Acad. Sci. U. S. A. Ill, 12468-12473.Wilson BG et al. 2014. Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation. Mol. Cell. Biol. 34, 1136-1144.Wuts PGM, Greene TW. 2006. Greene ’s Protective Groups in Organic Synthesis, 4th Edition \ Wiley.
Claims
CLAIMS1. A compound or a pharmaceutically acceptable salt thereof, according to Formula I:O R4a p4b Cy2Iwherein,A is 6-10 membered monocyclic or bicyclic aryl, or 5-10 membered monocyclic or bicyclic heteroaryl comprising one, two or three heteroatoms independently selected from N, O, and S;R< N0 0 OY is independently selected from' ' , ' ' andRyand Rzare each independently hydrogen or C1-3 alkyl;X is N or CH;R1is Ci -e alkyl, C1-3 alkoxy(Ci-3)alkyl, 3-6 membered monocyclic cycloalkyl, 4-6 membered monocyclic heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S, -NH2, -NH(CI.3 alkyl), -N(CI-3alkyl)2, -NHC(=O)(CI.3alkyl), -N(CI-3alkyl)C(=O)(Ci-3alkyl), or hydroxy(Ci.4)alkyl, wherein said cycloalkyl, heterocycloalkyl, alkyl and alkoxy groups are optionally substituted with one or more halogen, C1-6 alkoxy, -NIL. -NH(CI-3 alkyl), -N(CI-3 alkyl)2;n is 0, 1, or 2;each R2is independently selected from halogen and Ci-e alkyl, which alkyl is optionally substituted with halo or C1-4 alkoxy;or R1and one R2together with the atoms onto which they are attached form a fused 5-8 membered monocyclic cycloalkyl, or a fused 5-8 membered monocyclic heterocycloalkyl comprising Y in formula I and zero, one, or two additional heteroatoms independently selected from N, O, and S, wherein the cycloalkyl or heterocycloalkyl is optionally substituted with one or more independently selected halogens (preferably fluoro) or C1-4 alkyl;R3is hydrogen or C1-6 alkyl;R4aand R4bare each independently hydrogen or C1-6 alkyl optionally substituted with one or more independently selected halo or C1-4 alkoxy;or R4aand R4b, together with the carbon to which they are attached, form a C3-6 cycloalkyl or 4-6 membered heterocycloalkyl comprising one or two heteroatoms independently selected from N, O, and S, which cycloalkyl or heterocycloalkyl is optionally substituted with one or more halo or C1-4 alkoxy;Li is a bond or C1-4 alkyl;B is phenyl or 5-6 membered monocyclic heteroaryl comprising one, two, three or four heteroatoms independently selected from N, O, and S;Cyi is phenyl or 5-6 membered monocyclic heteroaryl comprising one, two, three or four heteroatoms independently selected from N, O, and S, each of which is optionally substituted with one or more independently selected halo,Cy2 is a 5-6-membered monocyclic heteroaryl comprising one, two, three or four heteroatoms independently selected from N, O, and S, which heteroaryl is optionally substituted with one or more independently selected -L2-R5groups;L2 is a bond or Ci-e alkyl;Each R5is independently selected from- -OH,- -CN,- -P(O)(Ci.4alkyl)2,- halo,- -S(=O)2-Ci.4 alkyl,- -NR8aR8b,- -CONR9aR9b,- -CO2R9a,- C1-4 alkyl optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9aor Ci -4 alkoxy,- C1-4 alkoxy optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9a, C1-4 alkoxy, or C3-6 cycloalkyl, and- C3-6 cycloalkyl, which cycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1.4 alkyl, C1.4 alkoxy, , -S(=O)2Ci.4alkyl, -C(=O)Ci.4alkyl, or -CO2R9a, - 4-8 membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, C1-4 alkoxy, -S(=O)2Ci-4 alkyl, -C(=O)Ci-4 alkyl, or -CO2R9a;R6is hydrogen, halo, or C1-6 alkyl;The subscript m is 0, 1 or 2;Each R7is independently selected from- -OH,- -CN,- -P(O)(Ci.4alkyl)2,- halo,- -S(=O)2-Ci.4 alkyl,- -NR8aR8b,- -CONR9aR9b,- -CO2R9a,- Ci-4 alkyl optionally substituted with one or more independently selected halo, -OH, -CN, -CO2R9aor Ci -4 alkoxy,- Ci-4 alkoxy optionally substituted with one or more independently selected halo, -OH, -CN, or C1-4 alkoxy,- C3-6 cycloalkyl, which cycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy, and- 4-8 membered monocyclic or spirocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy;each R8ais independently hydrogen or C1-4 alkyl;each R8bis independently hydrogen, C1-4 alkyl or -C(O)Ci.2alkyl;each R9ais independently selected from hydrogen and C1-4 alkyl;R9bis hydrogen, C1-4 alkyl or C1-4 alkoxy, orR9aand R9btogether with the atoms onto which they are attached form a 4-7 membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, Ci -4 alkyl.
2. The compound, or a pharmaceutically acceptable salt and / or solvate thereof, according to claim 1, wherein R3is H.
3. The compound according to claim 1 or claim 2, wherein the compound is according to Formula III:^Y,Ni [R7]mR:(III)wherein A, Y, B, Cyi, Cy2, R1, R2, R3, R4a, R4b, R6, R7, m and n are as defined for formula (I), or a pharmaceutically acceptable salt and / or solvate thereof.
4. The compound, or a pharmaceutically acceptable salt and / or solvate thereof, according to any one ofclaims 1-3, wherein Bism, wherein m is 0, 1, 2, 3, or 4.
5. The compound, or a pharmaceutically acceptable salt and / or solvate thereof, according to any one ofclaims 1-4, wherein Bis is 0, 1, 2, or 3.
6. The compound, or a pharmaceutically acceptable salt and / or solvate thereof, according to any one of O Oclaims 1-5, wherein Yis7. The compound, or a pharmaceutically acceptable salt and / or solvate thereof, according to any one ofclaims 1-6, whereinis selected from:substituted with 1 R2a, wherein R2ais selected from halogen (preferably fluoro) and C1-4 alkyl.The compound, or a pharmaceutically acceptable salt and / or solvate thereof, according to any one of claims8. The compound, or a pharmaceutically acceptable salt and / or solvate thereof, according to any one of Nclaims 1 to 5, wherein Yis9. The compound, or a pharmaceutically acceptable salt and / or solvate thereof, according to any one ofclaims 1 to 5 or 9, wherein is selected from:0 Oand10. The compound according to claim 1, wherein the compound of Formula I is a compound according to Formula XII, XlVa, or XlVb:(XlVb)or a pharmaceutically acceptable salt and / or solvate thereof,whereinnl is 0 or 1;n2 is 0, 1, 2, 3, or 4; andR2ais selected from halogen (preferably fluoro) and Ci- 4 alkyl.
11. The compound, or a pharmaceutically acceptable salt and / or solvate thereof, according to any one of claims 1 to 10, wherein R7is selected from:- -CN,halo,Ci-4 alkoxy optionally substituted with one or more independently selected halo, -OH, -CN, or C1.4 alkoxy, and4-8 membered monocyclic or spirocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more independently selected oxo, halo, -OH, -CN, C1-4 alkyl, or C1-4 alkoxy.optionally wherein R7is C1-2 alkoxy optionally substituted with one or more independently selected - OH or Ci -2 alkoxy.
12. The compound, or a pharmaceutically acceptable salt and / or solvate thereof, according to any one of claims 1 to 11, wherein Cyi is:
13. The compound, or a pharmaceutically acceptable salt and / or solvate thereof, according to any one of claims 1 to 12, wherein Cy2 is:p5b p5b14. A compound selected from Table III of the description, or a pharmaceutically acceptable salt and / or solvate thereof.
15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound, a pharmaceutically acceptable salt, a solvate, or a solvate of a pharmaceutically acceptable salt thereof according to any one of claims 1-14.
16. A compound, a pharmaceutically acceptable salt, a solvate, or a solvate of a pharmaceutically acceptable salt thereof, according to any one of claims 1-14, or a pharmaceutical composition according to claim 16 for use in medicine.
17. A compound, a pharmaceutically acceptable salt, a solvate, or a solvate of a pharmaceutically acceptable salt thereof, according to any one of claims 1-14, or a pharmaceutical composition according to claim 15 for use in the prophylaxis and / or treatment of proliferative diseases.
18. A compound, or a pharmaceutically acceptable salt and / or solvate thereof, according to any one of claims 1-14, or a pharmaceutical composition according to claim 15, for use in the prophylaxis and / or treatment of a disease, disorder or condition that is selected from metastatic tumours (such as but not limited to, melanoma, lymphoma, leukaemia, fibrosarcoma, rhabdomyosarcoma, and mastocytoma) and types of tissue carcinoma (such as but not limited to, colorectal cancer, prostate cancer, small cell lung cancer and non-small cell lung cancer, breast cancer, pancreatic cancer, bladder cancer, renalcancer, gastric cancer, glioblastoma, primary liver cancer, ovarian cancer, prostate cancer and uterine leiomyosarcoma), acute lymphoblastic leukemia, acute myeloidleukemia, adrenocortical carcinoma, anal cancer, appendix cancer, astrocytomas, atypical teratoid / rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer (osteosarcoma and malignant fibrous histiocytoma), brain stem glioma, brain tumors, brain and spinal cord tumors, breast cancer, bronchial tumors, Burkitt lymphoma, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T -Cell lymphoma, embryonal tumors, endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, ewing sarcoma family of tumors, eye cancer, retinoblastoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), gastrointestinal stromal cell tumor, germ cell tumor, glioma, hairy cell leukemia, head and neck cancer, hepatocellular (liver) cancer, hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumors (endocrine pancreas), Kaposi sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, Burkitt lymphoma, cutaneous T-cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, lymphoma, Waldenstrom macroglobulinemia, medulloblastoma, medulloepithelioma, melanoma, mesothelioma, mouth cancer, chronic myelogenous leukemia, myeloid leukemia, multiple myeloma, asopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, oral cancer, oropharyngeal cancer, osteosarcoma, malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, papillomatosis, parathyroid cancer, penile cancer, pharyngeal cancer, pineal parenchymal tumors of intermediate differentiation, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm / multiple myeloma, pleuropulmonary blastoma, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell (kidney) cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, Ewing sarcoma family of tumors, sarcoma, kaposi, Sezary syndrome, skin cancer, small cell Lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach (gastric) cancer, supratentorial primitive neuroectodermal tumors, T -cell lymphoma, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom macroglobulinemia, Wilms tumor, a neoplastic disease of the blood and blood forming organs, including but not limited to: acute myeloid leukaemia (AML), and acute lymphoblastic leukemia (ALL) and chronic lymphoblastic leukaemia (CLL), breast cancer (e.g. invasive ductal cancer, invasive lobular cancer), lung cancer (e.g. non-small-cell lung cancer, lung adenocarcinoma, squamous cell lung cancer and small-cell lung cancer), urothelial cancer, bladder cancer (e.g. urothelial bladder cancer, nonmuscle invasive bladder cancer, muscle invasive bladder cancer), upper tract cancer (e.g. urothelial upper tract cancer), urethral cancer, gastric cancer, pancreatic cancer, prostate cancer, colorectal cancer,multiple myeloma, liver cancer, melanoma (e.g. cutaneous melanoma), head and neck cancer (e.g. oral cancer), thyroid cancer, renal cancer (e.g. renal pelvis cancer), glioblastoma, endometrial cancer, cervical cancer, ovarian cancer, and testicular cancer.
